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Preface  
Scientists are people who keep their juvenile desire to give an explanation to all and keeping 
discovering always something new. Since I was a child I have been very curious about 
everything wishing to find out explanations and solutions. However, just after my degree in 
Materials Engineering I chose to start working for companies even though always covering 
positions as a researcher. Then, following my real nature, after almost 9 years I left a permanent 
position accepting a temporary one to join a multidisciplinary group which deals with one of the 
most fascinating fields regarding bio-interfaces. Specifically, I was involved in the development 
of new smart nano-capsules for nano-biotechnologies. In my opinion, nothing is comparable to a 
job that allows discovering something useful for humankind and I am proud of my choice. 
The objective of this work was to provide biodegradable nanocapsules produced layer-by-layer 
on oil based templates, demonstrating therefore nanoemulsion capability, once properly 
optimized, to be used at the same manner of solid templates but with unparalleled advantages 
compared to them. Indeed, they do not need to be removed after capsule preparation, they can 
embed high payloads of active substances and drugs and may then be exploited in a variety of 
bio-technology fields such as nano-food, nutraceutics, cosmetics, cosmeceutics, and, above all, 
nanomedicine including drug delivery and imaging for diagnostics.  
In synthesis, the first chapter of the thesis is an overview on nanotechnologies mainly applied 
to nanomedicine but also to fields like food and cosmetics. The second chapter deals with 
preparation and characterization of monodisperse and biodegradable oil in water nanoemulsions 
characterized by a tunable stability over time. A third chapter follows regarding the development 
of monodisperse biodegradable nanocapsules by using previous oil in water nanoemulsions as 
template. This chapter includes nanocapsules made of polymer multi-layers and a chemical part 
for the stabilization of the polymer multi-layer. Finally, there are also some preliminary results 
on the preparation of hybrid polymer silica shell nanocapsules always around nanoemulsions in 
the Appendix.  
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Chapter I: Nano-bio-technologies 
1.1. Introduction 
Nano-bio-technologies represent today one of the most investigated and challenging topics of 
scientific research both at an academic and industrial level. This study involves a body of 
knowledge ranging from pharmaceutics, biology, chemistry and material science. It comprises 
several important fields such as nanomedicine, including drug delivery and diagnostics, nano-
food, nutraceutics, cosmetics. 
According to the National Nanotechnology Initiative (2006), “Nanotechnology is the 
understanding and control of matter at dimensions of roughly 1 to 100 nanometers, where unique 
phenomena enable novel applications. Encompassing nanoscale science, engineering and 
technology, nanotechnology involves imaging, measuring, modeling, and manipulating matter at 
this length scale.” Consequently, interest and activities in this research area have greatly 
increased over the past years. The potential benefits of nanotechnology have been recognized by 
many industries, and commercial products are already being manufactured, such as in the 
microelectronics, aerospace, pharmaceutical industries, food industries, cosmetics and so on [1]. 
One of the possible contributions of nanotechnology, in the case of nanomedicine, would be in 
building biocompatible multifunctional nanocarriers (NCs) able to navigate within living 
organisms releasing their cargo at the site of interest by means of active or passive stimuli. Such 
carrier systems are used to improve cargo stability, to sustain and control their release rates, to 
increase the bioavailability of cargo substances, and to target them to specific sites within the 
body. A system which combines all these functionalities into one structure has still not been well 
developed. The requirements of such a system can be conceptually divided into several steps. 
First, the cargo (in general bioactive molecules) has to be encapsulated. This not only allows for 
high local concentration inside the carrier, but also for protection of the cargo molecules against 
cytotoxic damage and enzymatic degradation. Next, the cargo has to be delivered to the target 
cells while sparing the surrounding cells by exploiting an internal or an external trigger.  
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NCs should be limited in size to cross for example the pores of tumor capillaries. The upper 
limit for an ideal vehicle size should not exceed about 200 nm. Secondly, due to their nature, the 
capsules tend towards protein adsorption, potentially leading to capsule aggregation in the blood 
capillaries [2]. Of course NCs design will be depending on the kind of administration route, 
which is mostly via intraveneous injection but it can be also via oral, skin or other routes. 
In contrast, applications of nanotechnology within the food industry are rather limited. 
However, achievements and discoveries in nanotechnology are beginning to impact the food 
industry and associated industries; this affects important aspects such as food safety, synthesis of 
new food products and ingredients, on demand and interactive food. Building on the concept of 
“on demand” food, for example, the idea of interactive food is to allow consumers to modify 
food depending on their own nutritional needs or tastes. The concept is that thousands of 
nanocapsules containing flavour or color enhancers or added nutritional elements (such as 
vitamins), would remain dormant in the food and only be released when triggered by the 
consumer. Moreover, food science and the food industry face the enormous challenge of making 
food both healthy and tasty. Because of the pressures of life in modern society, many consumers 
tend to choose food rich in fats and carbohydrates increasing the number of obesity and diabetes 
cases. The challenge for the food industry is to make healthy food a logical choice for the 
consumer. This logical choice can be realized by manipulating the complex structure and 
proprieties of food [3]. One way could be to reduce the volume in nanometer size preserving 
always, with the same surfaces, the same organoleptic proprieties. In general, when a functional 
food aids in the prevention and/or treatment of disease(s)/disorder(s) as well as deficiency 
conditions like anemia it is called a “nutraceutical” [4]. Examples of nutraceuticals include 
fortified dairy products (milk as such is a nutrient and its product casein is a pharmaceutical) and 
citrus fruits (orange juice is nutrient and its constituent ascorbic acid is a pharmaceutical). In this 
case, the use of nanotechnology for instance nanoemulsions and polymer micelles-based delivery 
systems can boost the bioavailability of nutrients such as phytochemicals [5]. 
Nanotechnology has also applications in the cosmetic industry. The functions of whitening, 
anti-aging and so on variously are expected for cosmetics. Therefore development of drug 
delivery systems (DDS) for cosmetics is highly desired, since a clearer effect can be obtained by 
delivering an active ingredient, for example, into the skin in this way. Examples of NCs for drug 
delivery, also used in cosmetic industry are nano-encapsulation vesicular delivery systems, 
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nanoemulsions and nanocrystals, liposomes and niosomes, micelles, polymeric nanocapsules, 
solid lipid NCs and nanostructured lipid carriers, carbon nanotubes and fullerenes, and 
dendrimers. The primary advantages of using nanoparticles (NPs)-based formulations in 
cosmetic products are to improve the stability of various cosmetic ingredients (like unsaturated 
fatty acids, vitamins), enhance penetration of certain ingredients (such as vitamins), increase the 
efficacy and tolerance of ultraviolet (UV) filters on the skin surface and make the product more 
aesthetically pleasing (e.g., in mineral sunscreens, making the particles of the active mineral 
smaller allows them to be applied without leaving a noticeable white cast). However, concerns 
have been raised regarding the potential dangers which may occur as a consequence of NPs 
contact with human skin. This has initiated an integrated approach including advanced physico-
chemical characterization of different types of NCs to understand their stability and mechanisms 
by which they penetrate intact skin. Some physico-chemical characteristics which may be 
important in understanding how far a nanoparticle may penetrate the skin include particle 
morphology and size, size distribution, surface chemistry, surface coating, surface charge, 
specific surface area, pore density, porosity, water solubility, agglomeration and aggregation [6, 
7]. The direction also in this case is towards completely biodegradable materials.  
 
1.2. Drug delivery 
1.2.1. Introduction to drug delivery 
The effectiveness of most of the present drugs is limited by their poor solubility in water, 
strong side effects due to the combination of high drug toxicity and non controlled bio-
distribution, and clearance by the extremely aggressive immune defense system of human body. 
Indeed, the host immune system is based on the reticulo-endothelial system (RES), which 
includes kidney, liver, spleen and lymph nodes causing clearance of external bodies [8]. Each of 
them acts in response to certain size range. 
In the last three decades nanotechnology has attracted a huge interest in healthcare due to the 
possibility to vehicle whatever drug, carry and deliver it directly on the site of disease by means 
of biocompatible NCs [9]. NCs not only improve the solubility of drugs but also protect them 
 from the attack of the immune defenses
in order to strongly reduce clearance thus enhancing
the way for a much more effective
molecules which is expensive and time consuming. 
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NCs circulating in the blood due to their small size can accumulate in the tumor tissue more than 
in the healthy tissue [10]. This Enhanced Permeabilit
sizes below 200nm which are possible with NCs
described later. Moreover, NCs can promote an active tar
specific receptors again making drug delivery specific to the site of disease [
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in NCs depending on the physical and chemical properties of their reservoir can be delivered 
with desired pharmacokinetic profiles respect to the free drugs. Moreover, biomolecules acting 
as pro-drugs, for instance hyaluronidase [18] can be embedded into NCs to enhance drug 
penetration of physiological barriers [8].  
1.2.2. Side effects in drug delivery 
One major limitation in the use of the actual chemotherapeutics is their toxicity that indeed is 
needed to kill tumor cells but they reach and kill also healthy cells. This is due to the fact that 
actual chemotherapeutics are mainly delivered as free drugs therefore they can reach any tissue. 
Moreover, to be able to reach in a proper concentration target tissue they are needed high doses 
of them in the blood. Furthermore, many widely used conventional chemotherapeutics, such as 
taxanes, include synthetic solvents (for example, castor oil and polysorbate 80) that directly 
contribute to adverse effects [17]. Another example of powerful drug is the Doxorubicin, an 
anthracycline antibiotic used in the treatment of a wide range of cancers such as some leukemias 
and Hodgkin’s lymphoma, as well as cancers of the bladder, breast, stomach, lung ovaries, 
thyroid, soft tissue sarcoma and others. Apart from inhibiting some essential activities for the life 
of the cell, leading it to death as for most of the drugs used for treatment of cancer diseases, 
Doxorubicin presents a severe cardiotoxicity [19]. Therefore there is an increasing need to design 
suitable DDS in order to guarantee not only the efficacy of pharmacological therapy but also 
avoid or minimize all the unpleasant side effects and indeed there are already some NCs based 
therapeutics, FDA (Food and Drug Administration) approved for clinical uses, such as pegylated 
liposomal doxorubicin, liposomal daunorubicin, albumin-bound paclitaxel [17]. For instance, a 
PEG-ylated (polyethylene glycol coated) liposome-encapsulated form of Doxorubicin (Doxil® or 
Caelyx®) was developed by Ben Venue Laboratories for Johnson & Johnson to treat some 
serious skin cancers such as Kaposi’s sarcoma and other AIDS-related cancers. This particular 
drug delivery system and the utilization of PEG coating results in preferential concentration of 
Doxil® in skin, thus increasing the therapeutic effects of the drug and reducing the cardiotoxicity 
of the therapeutic agent compared to un-encapsulated doxorubicin. It was also approved for 
treatment of ovarian cancer and multiple myeloma [20, 21]. However, although less toxic than 
conventional therapies these agents are still associated with adverse effects, such as stomatitis 
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and palmar-plantar erythrodysesthesia for PEG-ylated liposomal doxorubicin and sensory 
neuropathy and nausea for albumin-bound paclitaxel. Moreover, despite the much higher cost 
than conventional drugs, the increase in overall survival is modest in many cases [17]. Therefore, 
a better understanding of the barriers that prevent efficacy and uniform delivery of DDS just into 
tumors is needed to develop strategies to really enhance no-side effects and effective treatments. 
1.2.2. Clearance in drug delivery 
The fate of a drug in vivo administration is determined by a combination of several processes: 
for example drugs administrated intravenously are subjected to distribution, metabolism, and 
elimination, while drugs administrated via the extravascular route are subjected to absorption, 
distribution, and metabolism as well as elimination. However, regardless of the administration 
rout involved, there is always a response from the body to drug clearance. The entity of this 
clearance depends on several features like drug chemical structure but also size and shape of 
DDS. During the last few decades, much work has been directed toward the development of 
delivery systems which will allow the fate of drugs within the patient to be controlled by 
modifying the above features.  
One of the first attempts to modify the way a therapeutic is administered was the process of 
chemically bonding a drug molecule, a protein, a peptide or antibody fragments to PEG 
molecules through a particular chemical bond that is degradable in a physiological environment. 
The main advantage of the PEG-ylation is that PEG disguises the agent from the host's immune 
system (reduced immunogenicity) [22] and increases the hydrodynamic size of the agent 
prolonging its circulatory time by reducing renal clearance. The frequency of the drug intake can, 
therefore, be diminished, without lowering the efficiency and, potentially, the toxicity can be 
reduced [23]. Furthermore, PEG-ylation can provide water solubility to hydrophobic molecules 
and can alter the absorption and distribution patterns. Finally it can cause changes in binding 
affinity of the therapeutic moiety to the cell receptors [24, 25]. PEG is not biodegradable or 
resorbable by the body but has the advantage of being biocompatible and extremely hydrophilic 
[26]. Some successful examples of this application are already available and many others are 
being tested and put on the market [27, 28]. 
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In the case of drugs loaded into NCs the advantage is that one strategy of enhanced circulation 
time can be applied to several kinds of drugs. Also in the case of NCs PEGylation is commonly 
used as strategy for this mean. For example PEG has first been used to improve circulation time 
of micelles and liposomes then serving as classic example during the development of any kind of 
NCs [12]. In particular, stabilization and protection induced by PEG is due to the minimization 
of the opsonization promoted by the immune defense system. Opsonization is a plasma protein 
deposition process that allows mononuclear phagocytic systems (MPS) present in the liver and 
spleen and to a lesser extent, in the bone marrow, to remove the carriers from circulation [11]. In 
other words there is a deposition of macromolecules called opsonins (fibronectins, 
immunoglobulins and complement proteins, circulating in blood vessels) onto the foreign bodies 
and opsonins are recognized by receptors expressed on the cell membrane of phagocytes [29].  
There are cases of materials which do not need a PEG-ylation to survive in the blood for 
enough time; NCs made of hyaluronic acid is an example [10]. 
Size and particle surface features both play an importante role in the blood opsonization 
processes and clearance kinetics [29-31]. For example, Daunosome and Myocet are clinically 
used liposomes with sizes of 80-90 nm without PEG coating that have been reported to exhibit 
enhanced circulation times, although to a lesser degree than PEG-ylated liposomes such as 
Doxil/Caelyx [12]. Indeed, it has been seen that after administration of NCs of different sizes, 
myeloprolipherative diseases (MPD) cells present in the liver (Kupffer cells) and the spleen 
contain NCs of 150-300 nm whereas MPD cells present in the bone marrow contain NCs of 30-
150 nm. Therefore, at least to reduce the main clearance that is the one induced by the liver it is 
required a size below 150 nm. From the other side it has to be taken also into account that very 
small particles (<20-30nm) are instead eliminated by renal excretion.  
Moreover, very small sizes (at least between 30 and 100 nm) means large surface area. This 
may pose problems in terms of interaction and aggregation of these nanoparticles in biological 
systems, which subsequently determines the increase of the final particle size and, hence, 
clearance. For instance, dendrimers with a size of approximately 10 nm are well known to 
flocculate in biological media [32].  
Lipid based nanosystems, instead, can interact with lipoproteins, leading to a dramatic size 
change; this happens for examples with micelles. The size of the particle, therefore, is not the 
only important factor to consider, as anticipated; also the surface properties of the NCs, in 
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particular surface charge density play an important role. Charged NCs are ingested faster than 
uncharged ones, and positively charged NCs are found to be ingested more than negatively 
charged ones. Atomic force microscopy measurements of adhesive forces between NCs and cell 
membranes show that the uptake of polyelectrolyte NCs strongly correlates with the adhesion of 
capsules to the outer cell membrane [33]. Furthermore, the surface charge of the nanocapsules 
can affect the smooth execution of cell functions, interacting with the membrane potential. It is 
therefore necessary to consider the surface charge of the polyelectrolyte nanocapsules [2].Again, 
PEG-ylation can be a solution to allow surface charge density control and avoid fast clearance by 
opsonization [8]. It is worth noticing that PEG does not completely solve but slows the carrier 
recognition by the phagocitic cells and the second one is that PEG chains could hide, for 
example, some antibodies with which the carrier was functionalized for targeting. Therefore, 
there are strategies which allow PEG separation from NCs in presence of a certain environment 
like a specific pH.  
Another route to elude the RES could be based on the choice of certain NC shape [34]. Indeed, 
it has been demonstrated how the internalization process can depend on the shape of the NCs. 
The internalization process includes a variety of pathways: clathrin-dependent, independent and 
dipendent receptor-mediated endocytosis, pinocytosis. Among these, the most effective 
mechanism for the uptake of NCs is the receptor-mediated endocytosis (RME) where molecules 
(ligands) distribuited over the NCs surface bind to counter-molucules (receptors) expressed over 
the cell membrane, which eventually bends to invaginat the foreign carrier. The receptors 
together with the bond NCs enter the cell by membrane invagination (Figure 1.2).  
 
 
Figure 1.2. A schematic illustration of receptor-mediate endocytosis (RME). 
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Some experiments in vitro show how shapes different from spherical can induce even zero 
internalization based on the contact angle between particle and cell [35].  
In the internalization process, also the elastic deformation of the cytoskeleton of the cell plays a 
role and can be considered as important as the specific ligand-receptor binding [33]. In addition, 
it is frequently observed that nanocapsules are deformed upon the incorporation process due to 
the mechanical stress caused in the intracellular space. Therefore, mechanical properties of the 
NCs can also impact the internalization mechanism. From the RES elusion point of view one 
could be interested in a rigid NC whereas from the internalization of NC into target cells it could 
be more interesting to have highly deformable NCs like nanocapsules.  
1.2.4. Delivery at site of disease  
Drug biodistribution plays a key role in treatment efficacy. Indeed, the ideal situation would 
imply the presence of drug just at the site of disease in order to be able to kill all the tumor cells 
and keep alive the healthy ones all around the body (Figure 1.3). 
One of the major advantages offered by the use of NCs is the possibility to get closer and closer 
to that ideal case through passive targeting of drugs to the site of action or by active targeting of 
the drug [9]. 
 
Figure 1.3. Schematic representation of different mechanisms by which NCs can deliver drugs to tumors. 
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Passive targeting exploits the anatomical differences between normal and diseased tissues to 
deliver the drugs to the required site due to EPR effect. Indeed, the integrity of the endothelial 
barrier in tumor tissue is perturbed by inflammatory processes or by tumor growth, the latter 
being a consequence of dysregulated angiogenesis [29]. The explanation here is that tumor 
tissues, in order to grow quickly, stimulate more the production of blood vessels that are 
abnormal in form and architecture because they are made of poorly-aligned defective endothelial 
cells with wide fenestrations, lacking a smooth muscle layer or innervation with a wide lumen 
and other heavily impaired functionalities. Therefore, circulating NPs can accumulate more in 
the tumor tissue than in the normal one. Actually even in lesser extent this effect is also observed 
at the site on inflammation. The only difference between them is the duration of retention period; 
in the case of inflammation retention time is shorter because the lymphatic drainage system is 
still operative differently from cancer. Retention time in cancer can last a few weeks whereas in 
inflamed tissue the retention can last few days. Blood vessels fenestrations which allow EPR 
depend on the kind of tumor and stadium and they are typically in the range of 200-780 nm [11]. 
Therefore in terms of EPR NCs size should not exceed 200 nm, preferable below 150 nm to 
better escape MPD cells and higher than 30 nm to avoid renal excretion. EPR is a universal 
phenomenon in solid tumors with the exception of hypovascular tumors, such as prostate or 
pancreatic cancers [8]. Although the EPR effect helps retain NCs in the tumor, NCs must first 
remain in circulation long enough to reach and extravasate the site of a tumor following one of 
the routes described in the previous paragraph about clearance. One of the examples is Doxil 
which has shown good drug retention resulting 6 times more effective than free doxorubicin [9]. 
Another example is the cisplatin loaded glycol chitosan NCs successfully accumulated by tumor 
tissues in tumor-bearing mice because of the prolonged circulation, this time induced by the 
hydrophilicity of the glycol groups, and EPR effect.   
Combined with the above described EPR effect - passive mechanism exploiting tumor 
fenestrations - it is possible to enhance the specificity of the treatment by mean of an active 
targeting of the drug or the NCs loading drug. Active targeting requires the conjugation of 
receptor specific ligands that can promote site specific targeting and it is also size dependent 
[36]. The success of drug targeting depends on the selection of the targeting moiety, which 
should be abundant have high affinity and specificity of binding to cell surface receptors. The 
active targeting can be achieved by molecular recognition of the diseased cells by various 
Chapter I: Nano-bio-technologies 
 
11 
 
signature molecules over-expressed at the diseased site either via the ligand-receptor, antigen-
antibody interactions or by targeting through aptamers. In this way the therapeutic agent can be 
actively targeted by conjugating the carrier with a cell or tissue specific ligand, thereby allowing 
a preferential accumulation of the drug at the diseased site. Examples of active targeting include 
ligands, such as the arginine-glycine-aspartic acod (RGD) peptide, epidermal growth factor 
receptor (EGFR), biotin, folate, transferrin (Tf) [8]. For instance, PEG-ylated gold NCs have 
been decorated with various amounts of Tf and the results suggest that targeted NCs can provide 
greater intracellular delivery of therapeutic agents to the cancer cells within solid tumors than 
their non-targeted analogs [9]. Other examples as said are the aptamers, which are DNA or RNA 
oligonucleotide sequences that selectively bind to their target with high affinity and specificity. 
They can target tissues and have an accumulation and a therapeutic effect by their own as shown 
by injecting in vivo an RNA TTA1 aptamer [37] or by modifying NCs like shown with 
paclitaxel-polylactide nanoconjugates which showed an enhanced targeting to cancer cells [9]. 
1.2.3. Drug resistance in drug delivery 
Drug behavior is described by parameters such as volume of distribution (Vd), half-lives from 
plasma and clearance from the body [13]. These parameters are important to determine overall 
drug disposition which might relate to toxicity towards certain body organs but they give limited 
information about access to target tumor cells. An average concentration of drug that is higher in 
the tumor than in normal tissues is not enough if tissue penetration is poor. To be effective 
anticancer drugs must penetrate tissue efficiently, reaching all the cancer cells and in a 
concentration sufficient to exert a therapeutic effect as the survival of one cell could form the 
focus of tumor recurrence, at distances as far as 200µm [14]. In the reality the distribution of 
many anticancer drugs in tumor tissue is incomplete for several reasons [13]. For examples in the 
case of basic drugs like doxorubicin, epirubicin, mitoxantrone, they are sequestered in acidic 
endosomes of cells that are proximal to the vasculature and this retention does not allow drug to 
move from one cell to another following the typical penetration mechanism of lipid soluble drugs 
(Figure 1.4) [13, 14]. 
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Figure 1.4. Distribution of doxorubicin in vivo (blue) in relation to tumor blood vessels (red) and inner part of 
tumor (green). 
Moreover, in tumor one reason for ineffective drug penetration are the disorganized vascular 
network and the absence of functional limphatics causing an increased IFP which reduces drug 
convection towards the tissue and thereby inhibits drug distribution. Moreover, the composition 
and the structure of the extracellular matrix (ECM) of the tumor tissue is different typically more 
adhesive thus slowing down the movement of molecules within tumor. Furthermore, poor 
vascular organization leads to low concentration of oxygen in the inner part of the tumor (almost 
0 at around 100µm from blood vessels) with the increase of metabolism and its products such as 
lactic and carbonic acids which lower the extracellular pH [14]. Hypoxic cells leaving in this part 
of the tumor behave completely different from peri-vascular cells and they are more resistant to 
conventional chemotherapy [13]. For these kinds of cells they have been developed new drugs 
so-called pro-drugs which are reduced under hypoxic conditions to an active form that is 
cytotoxic. The design of an effective pro-drug is complicated because as it diffuses from blood 
vessels to the hypoxic region the decrease of O2 determines an increase of the metabolism of 
such molecule and there is a risk that no drug will remain to further diffuse in the tissue. On the 
other hand too little metabolism could reduce the efficacy of drug itself in killing tumor cells 
while traveling distal from blood vessels.  
The resistance to drugs from cells is a major obstacle in successfully treating malignant 
diseases [8]. This phenomenon contributes to treatment failure in over 90% of patients with 
metastatic disease. Drug resistance can be intrinsic (gene mutation, gene amplification or 
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epigenetic) or acquired through exposure to chemotherapeutic agents. Tumor microenvironment 
can lead to drug resistance like in the case of hypoxic cells. One of the main modalities for drug 
resistance is that cells present a high expression of the ATP-binding cassette (ABC) transporters 
such as permeability-glycoproteins (P-gp) leading to a subsequent efflux of anticancer drugs 
from the cancer cell cytoplasm. Indeed, tumor cells often use glycolysis – the conversion of 
glucose into lactate to produce ATP- to obtain the energy they need to survive and proliferate 
rather than oxidative metabolism that leads to the production of CO2 and carbonic acid [14]. 
Nanotechnology provides an innovative and promising alternative to conventional small-
molecule chemotherapeutics like drugs or pro-drugs [8]. Indeed, NCs can be taken up by non-
specific endocytosis and cross the cellular membrane in an ‘invisible’ form that prevents drugs 
from being recognized by efflux pumps (Figure 1.5).  
 
 
Figure 1.5. Model of the internalization process for free drugs and drugs in NCs. 
Free drugs can be internalized by normal cells and just a small amount can diffuse out of the 
cell (Figure 1.5.A). In the case of drug resistant cells for free drugs, due to the P-gp present on 
the cell membrane, there is a more difficult internalization and an efflux of the drug from the 
cytoplasm towards the outside (Figure 1.5.B). When drug is vehicled by NCs these DDS can 
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enter eluding P-gp and after degradation release all drug in the cell (Figure 1.5.D). Of course 
compared to the case of normal tumor cells (Figure 1.5.C), some drug will diffuse from the 
cytoplasm out of the cell membrane through the usual efflux mechanism but the amount of drug 
reaching nucleus can be significantly high and enough to kill cell.  
Also the issue of some drugs to be sequestered in acidic organelles of cells that are proximal to 
the vasculature can be faced by the use of NCs [16]. However, once using NCs it has to be 
considered that they should be small enough to deeply penetrate tumor tissue, possibly not higher 
than 10nm, as well as properly modified on the surface to move freely in the ECM without 
binding with it. At the same time it is known how such a small size is not optimal in terms of 
clearance due to the excretion from the kidney. Therefore a multistage DDS is maybe the optimal 
strategy as shown just as model by using PEGylated quantum dots of 10nm in size embedded in 
a gelatin NCs of 100nm also PEGylated on their surface.   
Another important consideration regarding NCs penetration is that neutral and hydrophilic NCs 
[16, 17] diffuse faster and distribute more homogeneously inside the tumor interstitial space than 
cationic and anionic NCs because the latter form aggregates with negatively (for example, 
hyaluronan) and positively (for example, collagen) matrix molecules [17]. Of course the 
enzymatic activity in the ECM environment sooner or later can rescue the mobility of the NCs 
but the penetration and delivery time is a key parameter to avoid the exposure of cells to 
sublethal concentration of drug. Indeed, in these conditions they can develop drug resistance as it 
was shown. Another determinant of interstitial transport is the sulfated glycosaminoglycan 
content. These thin and elongated fibers not only carry a highly negative charge but they also 
significantly increase the viscosity of the interstitial fluid. For what concern the binding with the 
ECM particularly collagen and glycosaminoglycanit, to degrade these components the use of co-
drugs like degrading bacteria, enzymes or even hormones like relaxin which modify the structure 
of collagen fibers has been proposed. However, agents that modify the ECM or its interaction 
with tumor cells might increase the probability of metastatic spread, so that their clinical 
applicability is unclear [14]. 
As far as concerns the shape, studies have shown that macromolecules with linear and semi-
flexible configurations diffuse more efficiently than rigid spherical NCs [17].  
Another strategy which could be implemented independently on the kind of DDS is based on 
the normalization of the tumor vasculature by using antiangiogenic agents which can restore the 
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balance between proa-angiogenic and antiangiogenic factors and reverse the vasculature to a 
more normal phenotype (Figure 1.6).  
 
 
Figure 1.6. Model of normalization. 
However, vessel normalization is transient, and thus, anticancer agents or NCs containing drugs 
should be given during the normalization window or just before normalization in order to exploit 
the EPR especially in the case of DDS based on the use of NCs. 
1.2.4. NCs in nanomedicine 
Despite the numerous strengths, discoveries and results cancer continues to be one of the 
biggest plagues of our time. Only in Europe there are predictions of deaths due to cancer for the 
2013 approaching 1.5 million of people [38]. The hope is in the nanotechnologies applied to drug 
delivery but also to the diagnostics. Indeed, the EPR effect is observed even during the early 
stages of carcinogenesis (for example dyspasia and hyperplasia), thus NCs could be also used to 
detect very small lesions for surgical removal [17].  
In terms of drug delivery, as already said the use of NCs to vehicle and deliver drugs is opening 
new therapeutic opportunities thanks to a series of advantages [9] like increase the aqueous 
solubility of drugs, protect drug from degradation, produce a prolonged release of the drug, 
improve the bioavailability of the drug, provide a targeted delivery of the drug, decrease the 
toxic side effects of the drug, offer appropriate form for all routes of administration, allow rapid-
formulation development. Moreover, in terms of bioavailability as already described in the 
Chapter I: Nano-bio-technologies 
 
16 
 
previous paragraph it can allow internalizing drugs in drug resistant cells [8]. Moreover, they can 
carry multiple drugs and/or imaging agents and owing to their high surface area to volume ratio 
it is possible to achieve high ligand density on the surface for targeting purposes [12]. Several 
kinds of NCs have been developed up to now belonging to different classes like lipid lased 
nanocarriers (for example, liposomes, micelles, oil in water emulsions, solid lipid nanoparticles), 
organic NCs (for example, dendrimers, carbon based nanomaterials, viral capsides, 
nanostructures made of biological building blocks like proteins), polymer NCs (for examples, 
nanoparticles, nanocapsules, polymersomes, polymer micelles), inorganic NCs (for example, 
ceramic, magnetic and metal based nanoparticles as well as nanoshells).  
1.2.4.1. Lipid based carriers:  
Lipid-based carriers have attractive biological properties, including biocompatibility, 
biodegradability, isolation of drugs from the surrounding environment, and the ability to entrap 
both hydrophobic and hydrophilic drugs. Main kinds of lipid based carriers are liposomes, 
phospholipids micelles, oil in water emulsions and solid lipid NPs (Figure 1.7).  
 
Liposomes: Liposomes are concentric bilayered structures made of amphipathic phospholipids. 
Their diameters range between a few and thousand nanometers. Depending on the number of 
bilayers, three main kinds of liposomes are distinguished: small unilamellar vesicles (SUVs; 20-
100 nm), large unilamellar vesicles (LUVs; 100-500 nm), both usually used as protective 
capsules and giant unilamellar vesicles (GUVs; 0.5-100 µm), generally studied as oversimplified 
models of biological cells. Liposome formulations are particularly attractive, as they may carry 
lipid-soluble drugs intercalated in the lipid bilayer and, at the same time, water-soluble drugs in 
the aqueous core [39]. The liposome surface is amenable to modification with targeting ligands 
and polymers [40]. There are several examples of drugs already available on the market made in 
liposomial forms, among all the already cited liposomial doxorubicin Doxil®, but also 
AmBisome® (liposomial Amphotericin B used for fungal infections). Main limitations in the use 
of liposomes include the high production cost (PEG-ylation, optimization of drug encapsulation 
and so on), fast oxidation of some phospholipids and side effects like in the case of the palmar 
plantar erythrodysestesia due to uncontrolled extravasation [12]. 
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Lipid Micelles: These drug carriers are formed in solution as aggregates in which the 
amphiphilic component molecules are generally arranged in a spheroidal structure with 
hydrophobic cores shielded from the water by a mantle of hydrophilic groups. Micelles are 
widely used to increase solubility and bioavailability of poorly soluble drugs [41]. For instance 
they have shown improved bioavailability of protopanaxadiol by mixing phospholipid micelles 
with Labrasol® in rats. Moreover, phospholipid micelles can be used to vehicle peptide based 
drugs as an important class of therapeutic agents which development into commercial products is 
often hampered due to their inherent physico-chemical and biological instabilities [42]. Despite 
their simplicity, this feature represent also the main limitation in being really effective for the 
tumor which requires the development of more and more complex and multifunctional systems. 
Moreover, for what concernes the administration route, the experience with micelles as well as 
with liposomes is that they can never be administered orally because they are readily disrupted 
by intestinal detergents such as bile salts and are subject to degradation by intestinal 
phospholipases, releasing prematurely the carrier-entrapped drug in the gastro intestinal (GI) 
fluid [43].  
   
Oil in water Nanoemulsions: Nanoemulsions (NEs) are biodegradable, biocompatible, easy to 
produce and used as carriers for lipophilic drugs which are prone to hydrolysis [45]. They are 
employed as a sustained release delivery system for depot formation via subcutaneous injection. 
They enhance gastrointestinal absorption and reduce inter- and intra-subject variability for 
various drugs. Due to their very large interfacial area, they exhibit excellent drug release profile. 
NEs have been studied and developed for parenteral, oral, ocular, pulmonary and dermal 
deliveries. They have also been tested as multifunctional platform for both imaging and 
anticancer therapy. [46]. Stability against sedimentation is attained based on the nano size of the 
droplets because the sedimentation rate due to gravity is less than Brownian movement and 
diffusion. NEs are metastable and can be destabilized by Ostwald ripening whereby the small 
droplets dissolve and their mass is taken up by the large droplets. When this happens, the 
nanoemulsion becomes opaque and creaming will occur. There are some methods to improve 
emulsions stabilities which will be described in the following chapter as well as their 
applications in more detail.  
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Solid Lipid Nanoparticles (SLN): SLN are a new pharmaceutical delivery system developed at 
the beginning of the 1990, made of solid lipids which remain solid at room temperature [47]. The 
use of physiological lipids, the avoidance of organic solvents and the high pressure 
homogenization as an established production method represent some of the advantages of these 
systems. SLNs have good tolerability as they are prepared from physiological lipids and are 
especially useful in ocular drug delivery as they can enhance the corneal absorption and improve 
the ocular bioavailability of drugs. They also allowed a targeting effect on the brain [9]. 
Moreover, DNA modified SLNs have shown a high gene expression especially in vivo, thus 
representing great potential for targeted gene delivery. Furthermore, they have been developed 
and investigated for parenteral, pulmonary and dermal application routes. To avoid clearance 
from the RES also in this case it has been proposed to obtain stealth NCs by PEG-ylation. SLNs 
have another advantage of allowing autoclave sterilization, a necessary step towards formulation 
of ocular preparations [47].  
  
 
Figure 1.7. Schemes of the main lipid based NCs like micelles, liposomes, and liquid or solid lipid NCs. 
1.2.4.2. Organic NPs  
Organic NPs include dendrimers, viral capsids, carbon-based nanomaterials, like fullerenes and 
carbon nanotubes, and nanostructures made from biological building blocks such as proteins like 
Abraxane which is an FDA approved albumin-bound paclitaxel nanoparticle formulation [12] 
(Figure 1.8). 
  
Dendrimers: Dendrimers derive their name from the Greek word dendra, meaning reminiscent 
of a tree [9]. These are highly branched macromolecules with controlled near monodisperse 
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three-dimensional architecture emanating from a central core [40]. Macromolecule’s growth 
starts from a central core molecule and growth occurs in an outward direction by a series of 
sequential reactions. Hence, precise control over size can be achieved by the extent of sequential 
reactions, starting from a few nanometers up to 100 nm. This class of compounds is interesting 
because the number of branching increases in a geometric progression with each unit step of 
growth. As a result, the shape and molecular rigidity changes as the molecular weight of such 
compounds increases. As a rule, this is accompanied by a change of physicochemical properties 
of the dendrimers such as the characteristic viscosity, solubility, density, etc. Cavities in the core 
structure and folding of the branches create cages and channels. The surface groups of 
dendrimers are amenable to modification and can be tailored for specific applications. 
Therapeutic and diagnostic agents are usually attached to surface groups on dendrimers by 
covalent bonding [40, 9] or through reversible ionic interactions [48]. Promising results in vivo 
by using dendrimer methotrexate conjugates on animal tumor reduction have been the motivation 
for further pre-clinical development, thus a variety of dendrimers are now under investigation for 
cancer treatments [12]. In addition, low solution viscosities make them useful as injectable 
sealants for corneal wounds [9]. Dendrimers have also revealed their potential in transdermal 
drug delivery enhancing bioavailability of indomethacin by using poly(amido amine) (PAMAM) 
as dendrimer. Furthermore the use of dendrimers as potential gene-delivery is also currently 
under investigation. One limitation is the need of many repetitive steps for synthesis and 
therefore the high cost which poses a challenge for large-scale production [12].  
 
Fullerenes and Carbon Nanotubes: Fullerenes are particular molecules composed entirely of 
carbon in the form of a hollow sphere or ellipsoid with the wall composed of one atom thick 
sheets of carbon and diameter of few nanometers. Recent studies have demonstrated that they 
can be drug carriers by bounding the surface to a drug with covalent or non covalent bonds [49]. 
Furthermore, because fullerenes are strong anti-oxidants, they have been used as neuroprotective 
and anti-inflammatory agents. Therefore, they could be used to treat various diseases. However, 
one limitation is in their manipulation difficulty.  
Carbon nanotubes (CNs) belong to the same structural family as fullerenes and consist of 
graphite sheets rolled up into a tubular form. These structures can be obtained either as single or 
multi-walled nanotubes. The diameter and the length of single-walled nanotubes may vary 
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between 0.5–3.0 nm and 20–1000 nm, respectively. The corresponding lengths are 1.5–100 nm 
and 1–50 µm, respectively. CNs can apparently cross the cell membrane as ‘nanoneedles’, 
without perturbing or disrupting the membrane and localize into cytosol and mitochondria even 
though the mechanisms are purely understood. A number of CN derivatives, are under trial for 
the treatment of Parkinson’s diseases and nervous system ischemia and, in many cases, it has 
been shown that structure and features of the carrier can be involved by their own in disease 
treatment [50]. They have been tested in vivo on animal model as anticancer drug carrier as well 
as carriers of immunoactive compounds, proteins, and genes and finally for photothermal cancer 
therapy considering their capability to be heated by near infrared (NIR) [51].  
However, detailed understanding of the pharmacological and toxicological properties of carbon 
nanomaterials, as well as a balanced evaluation of their risks and benefits to human health, is 
required before they can be recommended for routine clinical use [52]. Factors that influence the 
safety of and kinetics of drug release from nanomaterials include their shape, length, and 
dispersability, as well as the presence of metal contaminants.  
 
 
Figure 1.8. Schemes of the main organic NCs like dendrimers, fullerene, single and multiwalled carbon 
nanotubes.  
1.2.4.3. Polymer NCs 
Polymers are the most commonly explored materials for constructing NPs-based drug carriers 
[12]; one of the earliest reports of their use for cancer therapy dates back to 1979. Then, over the 
past few decades, researchers have had considerable interest in developing biodegradable 
polymer NCs [9]. They can be mainly divided in nanospheres, nanocapsules, micelles and 
polymersomes (Figure 1.9).  
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Nanosphere: They have a matrix like structure, where active compounds can be absorbed on 
their surface, entrapped or dissolved in the matrix [9]. They can be made from synthetic 
polymers, including poly(lactic acid) (PLA), and poly(lactic co-glycolic acid) (PLGA) or from 
natural polymers such as chitosan, collagen and so on [12] and they can be used to encapsulate 
drugs without chemical modification differently from polymer-drugs conjugates. The drug can 
be released in a controlled manner through surface or bulk erosion, diffusion through the 
polymer matrix, swelling followed by diffusion or in response to the local environment. As with 
liposomes, technology also allows precision surface modification of nanospheres with polymeric 
and biological materials for specific applications or targeting to the desired locations in the body 
[40]. Recently, NPs formulated from PLGA were investigated as drug delivery system for 
photodynamic therapy by carrying zinc (II) phthalocyanine (ZnPc) showing tumor regression in 
vivo compared to animal treatment with free ZnPc. PLGA NPs have also been tested in vivo 
loaded with drug and chemosensitizer as treatment against drug resistance [9]. Other examples 
involving chitosan conjugated with folic acid showed capability to reduce production of P-gp as 
a way to overcome tumor drug resistance. PLGA NPs modified in surface with chitosan have 
been used as drug carrier for brain delivery. Several multifunctional NPs are now in various 
stages of pre-clinical and clinical development. There are, however, a few examples of polymeric 
NPs that show near-homogeneous size distribution. 
 
Nanocapsules: Nanocapsules have a polymeric shell and an inner core with the active 
substance usually dissolved in the core but it can also be adsorbed on the shell [9]. The cavity 
can contain the active substance in liquid or solid or as a molecular dispersion [26]. Moreover, 
the reservoir can be lipophilic or hydrophilic according to the preparation methods. In the case of 
nanocapsules the polymeric shell plays a predominant role in protecting the active substances 
incorporated and probably in the release profile. Shell thickness value can vary from a few to 
tens of nanometers, depending on the production method. Nanocapsules can be employed as 
confined protective shell for enzymes, as transfection vectors in gene therapy, as dye dispersants, 
as carriers in heterogenous catalysis, imaging and most of all as drug carriers [45]. They can 
protect drugs from degradation, reduce systemic toxicity, provide controlled release and mask 
unpleasant taste. In particular, biodegradable materials allow sustained release within the target 
site over a period of days or even weeks whereas just biocompatible polymers can be destroyed 
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by external stimuli allowing a fast drug release. Loading capability depends on the preparation 
method but is usually very high considering the entire inner compartment involved [26]. 
Therefore, nanocapsules, prepared with biodegradable polymers, have received more and more 
attention and have been regarded as one of the most promising drug delivery systems. Main 
limitations are related to the preparation procedures which can be time consuming, not 
consolidated, not optimized to control size and shell thickness, not capabille to embed drug at 
very high efficiencies or not suitable to use really natural polymers. Main topic of this thesis was 
to afford most of the general issues and build up nanocapsules controlled in size, polydispersion 
index (PDI), shell thickness and made of natural polymers with vegetal oil as core to allow high 
loading capabilities for lipophilic active substances. 
 
Polymer micelles: Polymer micelles represent a class of micelles that are formed of block 
copolymers consisting of hydrophilic and hydrophobic blocks [9, 40, 43]. Like other micelles 
they are composed of a core of hydrophobic blocks stabilized by a corona of hydrophilic 
polymer chains. The hydrophilic block is typically PEG with a molecular weight from 1 to 15 
kDa. These NCs provides a set of advantages like high drug-loading capacity and long 
circulation times due to the hydrophilic corona and small size under 100 nm in diameter. In 
addition they can be made target specific by the chemical attachment of a targeting moiety to 
their surface. Hydrophobic drugs or contrast agents may be trapped physically within the 
hydrophobic cores or can be linked covalently to component molecules of the micelle. The 
polymer used are biodegradable, bioresorbable and biocompatible. Among the polymer used to 
construct copolymers there are polyglycolic acid (PGA), polycaprolactone (PCL), PLA and 
many others. There are some promising in vivo tests for polymeric micelles loading doxorubicin 
towards drug resistant ovarian cancer [44]. They can incorporate paclitaxel, tamoxifen, 
camphothesin, porphyrine and vitamins [9]. They can be made thermo or pH sensitive by using 
poly(N-isopropylacrylamide) (PNIPAM) and functionalized for active targeting. However, the 
targeting ability of polymer micelles is limited due low drug incorporation stability which cause 
the loaded drug to be released before getting to the site of action [45]. Consequently, 
manipulation of the production parameters and the design of the inner core are under 
investigation to improve drug loading and drug incorporation stability. 
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Polymersomes: Tri-block copolymers made of a hydrophobic center block and two 
hydrophilic end block blocks under proper condition can form unilamellar polymer vesicles 
named polymersomes [53, 12]. During the self-assembly process in aqueous solution, the 
hydrophobic components of amphiphilic copolymers attract each other to form a membrane to 
minimize the contact with water and tend to enclose into a hollow structure, while the 
hydrophilic parts are expressed on both the inside and outside of the membrane, forming the 
hydrophilic shells. Therefore, polymersomes have architecture similar to that of liposomes, but 
being composed of synthetic polymer amphiphiles which make them more robust. Like 
liposomes they are able to stably load a broad range of active molecules (e.g. fluorescent 
molecules, anti-cancer drugs, genes or proteins etc.) into either hydrophilic or hydrophobic 
compartments. Typically, the membrane of this polymersome is composed of aliphatic 
biodegradable polyester such as PLA or PCL, whereas the corona is a hydrophilic block, such as 
PEG. In addition to PEG, hydrophilic block polymers such as poly(2-methacryloyloxyethyl 
phosphorylcholine) (PMPC) and poly(ethylethylene phosphate) (PEEP), which impart excellent 
biocompatibility, have also been combined with PLA or PCL to form biocompatible and 
degradable polymersomes. In vivo tests show promising results for these kinds of drug delivery 
systems. They have also been tested as theranostic NCs for magnetic resonance (MR) Imaging 
and magneto-chemotherapy [54]. Specific disadvantages of polymersomes like of polymer 
micelles are the difficulty of polymer synthesis, the immature drug-incorporation technology, 
slow extravasation and possible chronic liver toxicity due to slow metabolic process which is 
indeed also related to other synthetic polymer NPs at least the ones not made of natural polymers 
[55]. However, by working on the biodegradability of the synthetic polymers used a widespread 
of polymeric micelles and polymersomes could be expected in the field of drug delivery. 
 
 
Figure 1.9. Schemes of the main polymer NCs like nanospheres, nanocapsules, polymer micelles, polymersomes. 
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1.2.4.4. Inorganic NPs 
Inorganic NPs are useful for drug delivery as well as gene therapy by carrying a huge amount 
of molecules on their high developed surface, due to the small size. They can also be used by 
their own to care tumor by hyperthermia through local heating by external stimuli mainly photo 
but also radio frequency (RF) in some cases. Moreover, they usually are exploited as tracers for 
imaging allowing a theranostic approach and they can be combined with some of the previous 
systems especially the polymer ones to combine their properties with the ones of the other NCs. 
 
Ceramic NPs and nanocapsules: The use of ceramic particles for drug delivery, especially 
biomacromolecular therapeutics, is emerging as a new area [9]. Silica, alumina and titania are 
examples of highly biocompatible ceramic NPs. Because of their possible ultra-low size (down 
to 50 nm) and porous nature they are becoming important drug delivery vehicles. Indeed, this 
size makes them more effective in evading the uptake by the RES, as already described. In 
addition they do not show swelling or changes in porosity with pH. Therefore, they can protect 
different bio-macromolecules, such as enzymes, against denaturation induced by changes in the 
external pH and temperature. Further their surfaces can be easily functionalized for conjugation 
to target-specific ligands such as monoclonal antibodies. Most of the studie regard silica, 
showing how, properly doped, can be used for drug or gene delivery. Other oxides like ceria 
(CeO2) and yttria (Y2O3) have shown that they may act as antioxidant, block reactive oxygen 
species (ROS) production and cause a low level of ROS production. In this way they can 
promote survival of cells under oxidative stress leading to protection of cells from death. 
Inorganic nanocapsules especially the ones made of silica are also gaining a huge interest both in 
the field of diagnostic and theranostic as it will be described in the Appendix. 
 
Magnetic NPs: Magnetic NPs (MNPs) are being widely used for biotechnological and 
biomedical applications [9]. Magnetic iron oxides are the most used but they have hydrophobic 
surfaces, therefore, they have to be coated by synthetic and natural polymers like dextran, PEG, 
poly(vinylpyrrolidone) (PVP) streptavidin, poly-lysine (PLL), polyethylene imide (PEI) and so 
on to avoid aggregation. MNPs with surface bound drugs can be injected into the vascular 
system and captured at the tumor site via a locally applied magnetic field. Drug is then released 
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typically by means of a change of the pH. Magnetite (Fe3O4) is generally preferred to maghemite 
(Fe2O3) because they are highly biocompatible and they are super-paramagnetic therefore no 
permanent magnetization there exist each other inducing aggregation. They can be used not only 
for guided drug delivery but also for magnetic resonance imaging (MRI). For instance they were 
combined with fluorescence labeled dendrimers to track - in a precise way by multimodal 
imaging - the fate of these dendrimers once injected in vivo showing capability of dendrimers 
smaller than 11.7-11.9 nm to cross blood brain barriers (BBB) and reach malignant glioma cells. 
Various magnetizable nanophases (magnetite, maghemite, Co, etc.) can be incorporated into 
different biocompatible and nontoxic polymers, such as PLGA, PLA, dextran, chitosan. Then 
they can carry therapeutic agents in the bulk of the polymer and be guided by external magnetic 
field. Recently, PEI modified MNPs have been used as a potential vascular drug/gene carrier to 
brain tumors. MNPs are also promising for multi-functional chemotherapeutic application that 
combines drug release and magnetic hyperthermia therapy. 
  
Metal based NPs: Metal NPs have the advantage to be extremely small, down to 50nm and 
thus the large surface area provides the ability to carry a relatively high dose of drugs. Gold NPs 
are the most commonly used [9]. Indeed, it is easy to synthesize them in a range of sizes, in a 
cheap and reproducible way. Moreover, due to their negative charge they can be easily 
functionalized by various biomolecules and they are considered biocompatible and nontoxic. 
Gold NPs have a variety of drug-delivery applications. For instance, they have been used to 
deliver insulin via efficient transmucosal delivery. They have been useful in improving 
anticancer delivery in vitro of oxaliplatin. They have shown an important role in efficient drug 
delivery and biomarking of drug-resistant tumor cells. In addition, they present a surface 
plasmon resonance (SPR) effect which can be used for imaging as well as for photothermal 
therapy. Indeed, they can be heated by NIR light destroying targeted tumor cells by hyperthermia 
[12]. Silver NPs have also been considered and used in drug delivery for their positive effects 
through their antimicrobial properties, reduction in wound inflammation and modulation of 
fibrogenic cytokines [9]. 
  
Nanoshell: These systems with sizes typically ranging from 100 to 200nm are typically 
composed by a silica core and a metallic outer layer mainly made of gold [12]. They can be used 
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for theranostic. Indeed, their absorbing nanoshells are suitable for hyperthermia-based 
therapeutics by heating up the surrounding cancer tissue, whereas the scattering properties of the 
nanoshells make them useful as contrast agents for imaging applications. The advantage to use 
nanoshells is that by adjusting the core and shell thickness, nanoshells can be designed to absorb 
and scatter light at a desired wavelength [56].  
Despite the advantages of inorganic NPs full attention must be given to safety and toxicological 
issues by studying empty non-drug-loaded NPs to understand possible side effects induced by 
the carrier itself. For instance cationic NPs including Au have been shown to cause hemolysis 
and blood clotting and usually anionic particles are rather non-toxic. Moreover, metal NPs like 
gold, once entrapped in acidic environment of cell organelles, can deliver high concentrations of 
ions which can induce gene-toxicity [57]. For silica NPs it has been found an increasing toxicity 
with doses and exposure times due to higher and higher ROS levels and glutathione levels 
corresponding to an increased oxidative stress [9]. Even in the case of Fe3O4, which is the only 
clinical approved metal oxide NPs, considered biocompatible and biodegradable, there are some 
concerns about its possible side effects especially to high doses such as inflammation, generation 
of reactive oxygen species (ROS), genotoxicity, and so on [58]. 
1.2.5. Evolution of NCs over the last decades 
To face the complexity of the tumor there has been a continuous evolution of the NCs adding 
more and more complex features. The easiest NCs are the ones that just exploit the localization 
at the tumor site by escaping the vascular compartment through EPR mechanism. Of course even 
in this case they need at least one modification in most of the cases to guaranty a long circulation 
time. 
However, much interest has been expressed over the last two decades in adding biological 
targeting capabilities to liposomes and many other NCs. Therefore, NCs surface can be 
conjugated with targeting moieties, including antibodies, ligands, aptamers and small peptides. 
Targeting has been directed to tumor cell surface markers and to molecules expressed in the 
tumor microenvironment and on the tumor-associated vascular endothelium. A major difficulty 
encountered with surface-bound biorecognition moieties is that they are typically much shorter 
than the polymer molecules used to elude the RES. Thus, they tend to be hidden inside the highly 
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flexible polymer shield, resulting in a decrease in targeting efficacy. To avoid this problem, the 
targeting moiety can be attached at the distal end of the polymer chain. Actually, two or more 
different moieties can be attached on the same NC for a more effective active targeting. Then 
NCs can embed different drugs providing local co-concentrations of synergistic therapeutic 
agents, or a combination of therapeutic and imaging moieties, in order to visualize the 
biodistribution of the active principle and to potentially monitor or alter the therapeutic course in 
real time.  
Apart from the functionalization for a specific target there was also the need to have a system 
such that it could respond to the stimuli from the environment surrounding (such as pH or 
temperature of the pathological area) or applied from the outside of the body (such as magnetic 
field, ultrasound, laser irradiation). In response to these requirements, more evolved NCs have 
been provided. For instance NCs whose outer layer is composed of a pH-sensitive polymer that 
will swell or degrade and release drugs preferentially in the acidic environments of tumor lesions 
have been developed. Another possibility involves the activation of nanoparticles conteined in 
the shells of nanocarriers by, for example, NIR. This radiation penetrates deeply into the tissue 
and irradiates the nanoparpicles causing their heating, leading to the rupture of the carrier and 
then the following release of the carrier entrapped-drug. A further approach involves excitation 
of iron oxide NPs by rapidly switching magnetic fields so that it is possible to provide 
information on their distribution and on the location and extent of the target lesion as well as to 
create over-heating for hypothermia treatment [8]. 
Even more complex are the “multistage systems” NCs, where in a first stage (A) there is the 
injection of NCs landing on the inner wall of tumor-associated blood vessel, in a second stage 
(B) the release of “nanoshuttles” of the carrier that penetrate both the blood vessel wall and the 
tumor cell membrane and in the last stage (C) the delivery to the tumor of doses of a therapeutic 
agent [59] (Figure 1.10).  
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Figure 1.10. Scheme of a multistage DDS with bigger NCs targeting vessel walls and smaller NCs delivered in the 
tumor and releasing drug in tumor cells. 
An alternative is a multistage approach in which NCs change their size to facilitate transport by 
adapting to each physiological barrier. The “original” NCs preferentially extravasate from the 
leaky regions of the tumor vasculature. After extravasation into tumor tissue, they are triggered 
to release smaller particles in to the tumor via an external stimulus (light, heat, ultrasound, 
magnetic field) significantly lowering their diffusion hindrance in the interstitial matrix and 
allowing penetration into the tumor parenchyma [16]. These smaller NCs can carry therapeutics 
released as the particles penetrate deep into the tumor (Figure 1.11).  
 
 
Figure 1.11. Scheme of a multistage DDS with NCs extravasating from blood vessel and reducing size in tumor 
tissue to deeply penetrate inside and reach all tumor cells. 
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In the most evolved context a novel type of polyelectrolyte multilayer capsules (e.g. polymer 
walls around cavities) with given size in the nanometer range and tunable wall properties has 
been recently introduced as an interesting platform for the assembly of simply multifunctional 
carrier systems for several reasons [60]. Firstly, they can be synthesized under mild conditions 
by using numerous different materials. Secondly, their functional properties can be well-defined 
by embedding different nanoscale building blocks (as colloidal inorganic nanoparticles or 
biomolecules) within and on top of their wall. Thirdly, they can efficiently host biological 
macromolecules within their cavity for numerous biomedical applications. Finally, they can be 
composed of biocompatible materials for the delivery of encapsulated materials into cells. The 
distinct advantage of using these systems lies in the potential of combining a variety of 
substances with different functionalities in one unique system by proper functionalizion of its 
layers together with possible cargo molecules into their cavities.  
1.2.6. Administration routes 
The administration route is another important aspect to consider. Oral administration represents 
by far the easiest and most convenient route of drug delivery, especially in the case of chronic 
therapies [43]. In comparison with other possible routes of administration, it has many 
advantages. Not only it is non-invasive and relatively free from complications arising from the 
need for sterile techniques that usually occurs with parenteral formulations, but it is also easily 
dosed with low preparation costs, all of which should encourage patient compliance. Although 
oral drug formulation is convenient from the patient’s perspective, it presents some problems 
including the stability of the DDS in the GI tract. The GI tract presents a variety of hurdles for a 
drug, from morphological barriers (mucus layer, microvilli, etc.) to stringent physiological 
factors (a wide range of pH, enzymatic activities, specific transport mechanisms, etc.), which all 
conspire to limit intestinal absorption of drug. The transport of a drug across the intestinal 
membrane is a complex transfer process involving several mechanisms. Based on the physiology 
of the intestinal epithelium, three potential routes for drug transport across intestinal barriers 
have been considered (Figure 1.12): (A) the paracellular route, a passive, diffusional transport 
pathway taken by small, hydrophilic molecules (e.g., mannitol) which can pass through the tight 
junction channels between adjacent epithelial cells; (B) transcellular passive diffusion of 
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lipophilic molecules through the lipid bilayer and the membrane-bound protein regions of the 
cell membrane; and (C) transcellular receptor-mediated transcytosis through specific 
surfacebound ligands.  
 
 
Figure 1.12. Schematic representation of intestinal epithelial cells showing potential transepithelial pathways: 
(A) paracellular route; (B) transcellular passive diffusion; and (C) transcellular receptor-mediated transcytosis. 
To be absorbed a specific drug must cross the barrier, which comprises an unstirred water 
layer, mucus layer, apical and basal cell membranes and cell contents, tight junctions, basement 
membrane, the walls of lymph and blood capillaries. Structure, composition, thickness, surface 
area, and pH of this barrier are then important considerations in drug delivery systems. Another 
method to administer drug is by parenteral route. This is a method of choice due to the network 
of blood and lymphatic vessels in the body that provide natural routes for the distribution of 
nutrients and delivery of therapeutic agents [40]. It allows avoiding the hostile gastro-intestinal 
environment which prevents the use of many drug and DDS systems. However, this is an 
invasive route, which can lead to a reduced acceptance by patients and, consequently, increased 
costs of therapy, especially when a prolonged or chronic treatment is required [61]. Anyway 
most of the treatments are made with this kind of administration because it remains the most 
effective as it allows exploiting all the different generations of drug loaded NCs.  
Another administration route is through the skin [62]. The cutaneous administration could 
avoid a variety of disadvantages compared with the oral administration including drastic pH 
changes, deleterious presence of food and enzymes and first-pass effect of the liver. It also 
avoids injection inconvenience and needle phobia. In addition, it is no invasive with the 
minimization of side-effects in the traditionally drug therapy. However, so few applications 
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using this kind of administration are present in the market because few molecules yielded skin 
permeability coefficients sufficiently high to meet the clinical therapeutic needs and because of 
their very low skin permeation rates. The continuous stratum corneum (the outer layer of skin) 
provided a major barricade for drug penetration to the deeper skin layers and was therefore the 
usual target for attempts to strength drug permeation ability. Nevertheless, some applications are 
designed for treating of skin diseases. One of these is the Dermosome Technology for topical 
treatment of psoriasis with a formulation of cyclosporine. The Dermosome Technology is a 
product developed by Advancell [63] made up of chitosan nanocapsules for topical 
administration of active ingredients. These nanocapsules are formed by an oily core, which 
houses the active ingredient. The technology adheres to the skin, allowing a longer time of 
contact, combined with its tiny size, increases the contact area between skin and structure, 
causing the active to accumulate significantly at the level of the epidermis. 
1.3. Nanotechnology in food  
Functional foods contain larger profit margins than conventional foods (30 to 500 percent 
higher) [4]. The global market size was estimated in 2008 between 30 and 60 billion US$, with 
Japan, USA, and Europe occupying the biggest share and is increasing at high rate. In many 
cases the difference between pharmaceuticals and nutraceuticals is identified in the diseases 
treating in the first case and diseases prevention in the second case. Actually, this distintion is 
cute but superficial and erroneous. Indeed, pharmaceuticals are substances which have (or have 
had) patent protection as a result of expensive testing to conform to the specifications of 
respective Governments. Whereas, many nutrients may never receive government approval since 
no one could justify the expense of testing requirements for substances that in principle cannot 
be protected by patent laws. Both pharmaceuticals and nutrients can cure and prevent diseases 
but only pharmaceuticals have governmental sanction. Many pharmaceuticals have their origin in 
plants and animals and are no less "natural" than nutrients. Classic example of nutrients is 
synthetic vitamins. When functional food aids in the prevention and/or treatment of diseases and 
or disorders it is called a “nutraceutical”. Examples of nutraceuticals include fortified dairy 
products (milk as such is a nutrient and its product casein is a pharmaceutical) and citrus fruits 
(orange juice is nutrient and its constituent ascorbic acid is a pharmaceutical). In practice, 
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nutraceuticals have been claimed to have a physiological benefit or provide diseases protection 
as cardiovascular, antiobese, antidiabetics, anticancer agents, as immune boosters and for chronic 
inflammatory disorders and degenerative diseases. Therefore, the interest towards nutraceuticals 
is increasing and a nutraceutical research community is absolutely necessary to convert the 
majority of potentiality of nutraceuticals in established ones.  
The field of nanotechnology is experiencing significant growth in the nutraceutical delivery due 
to the confluence of interests of industry, government and academia [5]. Indeed, there have been 
important advances made in NPs formulations designed to improve the bioavailability of poorly 
water-soluble ingredients. Fundamental thermodynamic and mass transfer equations reveal that, 
in order to generate a broad spectrum delivery system, NPs with 100 nm diameter (or less) 
should be produced. However, experimental data reveal that, in some cases, even NPs in the 
100–1000 nm range are capable of producing substantial improvement in the bioavailability of 
the active ingredients. In most cases, this improvement in bioavailability seems to be linked to 
the direct uptake of the NP. Furthermore, direct NP uptake is controlled by the size and surface 
chemistry of the NP system.  
The confluence of pharmaceutical, nutrition, and colloid sciences with food engineering will be 
the key to unlock the full potential of NP delivery systems in food applications. In addition to the 
potential technological impact of nanoparticle delivery systems in the food industry, there are 
also concerns about unforeseen side effects of the technology. The fact that these carriers are 
designed with food-grade ingredients does not mean that they might not cause undesired effects 
such as transporting or depositing active ingredients or excipients in tissue that they are not 
supposed to, or enhancing the absorption of substances that they are not meant to transport but 
that are present in the food matrix. Regulations on food nanotechnology are a likely development 
in the near future that may have a significant impact on the methods of preparations, dosages, 
and ingredients used in these systems. 
1.4. Nanotechnology in cosmetics 
The applications of nanotechnology and nanomaterials can be found in many cosmetic products 
including moisturisers, hair care products, make up and sunscreen. Almost all of major cosmetic 
manufacturers use nanomaterials in their products. L’Oréal has a number of nanotechnology-
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related products in the market and ranks 6th in US in the number of nanotech related patents in 
US. The European Commission estimated in 2006, that 5 % of cosmetic products contained 
nanoparticles. The application of nanomaterials in cosmetic products has been the subject of 
continuous discussion in the media, scientific circles and among policy makers for the past few 
years. Toxicity issues have been raised due to conflicting research papers about the safety of 
nanomaterials and lack of agreement between researchers on whether the nanomaterials are safe 
for dermal use. There are a number of classes of nanoparticles used, or proposed for use, in 
cosmetic applications. In cosmetics there are currently two main uses for nanotechnology. The 
first of these is the use of nanoparticles as UV filters. Titanium dioxide (TiO2) and zinc oxide 
(ZnO) are the main compounds used in these applications. Organic alternatives to these have also 
been developed [6]. 
The second use is nanotechnology for delivery of active substances. Like for the nutraceutical 
also in this case there is a field so called cosmeceutical which is a combination of the two words 
cosmetics and pharmaceutical. And again it has to be pointed out that even if cosmeceutics can 
have therapeutic effects cosmetics products are not approved by FDA therefore they cannot be 
defined as drug. On the contrary if they are defined drugs that means they are pharmaceutical 
products. Lipid based nanocarriers like liposomes [64], SLN [65] and emulsions [66] are 
examples of effective NCs through skin. In particular, for the latter case it is worth noticing that 
NEs have a number of advantages over larger size emulsions. They can be stabilized to increase 
the time before creaming occurs, therefore increasing the shelf life of products containing them. 
They are transparent or translucent, and have a larger surface area due to the small particle size. 
It has been found that the smaller the size of the emulsion, the higher the stability and better 
suitability to carry active ingredients.  
Polymer NPs, such as nanospheres and nanocapsules [67] have also been identified as potential 
cosmetic NCs. The trend in the skincare applications of polymers is moving from self repair 
(those that repair the skin damage according to changes in the environment using 
nanoencapsulation, controlled release etc.) to self predicting polymers that can predict future 
changes and change their properties accordingly to prevent the damage. An example of this is a 
hydrogel which can respond to temperature and be used as a facial mask. The patented 
technology called Facial Switch™ shrinks the hydrogel by increasing the temperature, thus 
allowing release of nutrients. 
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1.5. Thesis objective: new solutions to Nano-Bio-technologies 
In this thesis we focused the attention on the use of nanocapsules like carriers for their 
capability to embed high payloads of active substances. Moreover we just used natural materials 
like vegetal oils and natural polysaccharides to avoid side effects from the preparations of such 
NCs. In particular, we chose to start from an oil core template for the preparation of NCs to be 
used in bio-nano-technology fields.  
Indeed, oil in water emulsions can easily reach sizes down to 100nm making these systems 
very interesting from a nanotechnology point of view. Then, there is strong need to load and 
vehicle lipophilic active substances and drugs in order to face their scarce solubility in water 
which typically prevents an effective bio-distribution of such molecules. Moreover, it is possible 
to use vegetal oils and natural surfactants like the soybean and the Lipoid E80 used in this work. 
However, the widespread use of oil carriers in the above said fields is generally limited or 
prevented by the intrinsic instability of immiscible systems like an emulsion. Herein we have 
focused on the stabilization of oil in water emulsions of sizes below 200 nm by decorating them 
with a biodegradable polymer and trying to find out optimal process conditions. The objective 
was then to develop nanoemulsions based product monodisperse and stable over time to be used 
by their own and as liquid template for the layer-bylayer preparation of biodegradable polymer 
nanocapsules. Biodegradable polymer nanocapsules can indeed have a huge impact on the 
development of new carriers for cancer treatment for a series of advantages such as high payload 
of lipophilic drugs, possibility to easily functionalize them for active targeting, long circulation 
in the blood, penetration capability, embed tracers for imaging and so on. Moreover, looking at 
the possible use of these nanocapsules as carriers to be injected in the blood, polymers have been 
successfully modified in order to be cross-linked once coupled in the multilayer to provide 
stability against the physiological environment to be explored during their use. Finally it was 
also tried to prepare monodisperse inorganic nanocapsules made of silica to demonstrate the 
potentiality of nanoemulsions template once optimized its preparation. Silica is a very interesting 
bio-interface recognized for its biocompatibility, capability to be functionalized like polymeric 
capsules. Moreover, by tuning the thickness and porosity it is possible to obtain completely 
impermeable systems or permeable and more degradable systems. These systems can have a 
huge impact for diagnostics in vivo both for single and multimodal imaging. Specifically, the use 
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of an oil core, like in our case, allows high payloads of drugs for a possible theranostic approach 
where silica nanocapsules are not only meant to make diagnostics but also to deliver drug in 
certain conditions.  
During this thesis one of the main objective was to assess the capability to use nano-emulsions 
stable over time for times comparable to the stable inorganic templates, opening a fascinating 
scenario in the templating synthesis. Indeed oil template does not need to be removed, which is 
risky for the capsule, especially in the case of small sizes and natural polymers, and time 
consuming; capsules can be pre-loaded with high payloads of scarcely or no soluble bio-
molecules, drugs, tracers and so on.  
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Chapter II: Monodisperse and biodegradable oil in 
water emulsions with tunable stability 
2.1. Introduction on NEs 
2.1.1. Applications 
NEs are oil-in-water emulsions with mean droplet diameters usually ranging from 100 and 
500nm [66]. They can be made from surfactants approved for human consumption and common 
food substances that are “generally recognized as safe” (GRAS) by the FDA. Differently from 
microemulsions, which are systems thermodynamically stable, they present a reasonable low 
concentration of surfactant (typically less than 10%). Their small size allows improved stability 
over time, due to the low gravity and the acquired elasticity, confers certain transparency to the 
product, as well as capability to reach and target tumor area. In general NEs show a great 
promise for the future of food, cosmetics, diagnostics, drug therapies, and so on. [68]. 
Their capacity to dissolve large quantities of hydrophobics, along with their mutual 
compatibility and ability to protect the drugs from hydrolysis and enzymatic degradation make 
them ideal vehicles for the purpose of parenteral transport [47]. In this case, frequency and 
dosage of injections can be reduced as these systems guarantee the release of drugs in a sustained 
and controlled mode over long periods of time. For instance, NEs loaded with thalidomide did 
lead to therapeutic plasma concentrations with a starting dose as low as 25 mg. Moreover, 
treatment of colon adenocarcinoma in the mouse with NEs brought to higher tumor suppression 
rate compared to plain drug solution treatment. NEs were also used as theranostic platform for 
instance by using prednisolone acetate valerate (PAV) for therapeutic purposes and iron oxide 
NPs for MRI imaging as well as die Cy7 for near infrared fluorescence (NIRF) imaging with 
promising results in terms of animal tumor inhibition.  
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One interesting administration route of NEs is the nasal mucosa which is interesting for its 
reduced enzymatic activity, the moderately permeable epithelium, its direct connection with the 
brain and non-invasiveness. For instance Alzheimer, Parkinson’s diseases, meningitis, 
depression, and schizophrenia can be treated by this route.  
Moreover, NEs are able to easily penetrate the pores of the skin and reach the systemic 
circulation thus getting channelized for effective delivery. For instance, they improved 
transdermal permeation of many drugs over the conventional topical formulations such as 
emulsions and gels. The main advantage of this route is the absence of gastrointestinal side 
effects associated with oral delivery. At the same time, NEs have recently become increasingly 
important as potential vehicles for the controlled delivery of cosmetics and for the optimized 
dispersion of active ingredients [68]. In general they are acceptable both in skin care (cosmetics) 
and in care through skin (transdermal pharmaceutical) also because they are quite stable products 
and the incorporation of potentially irritating surfactants can usually be avoided by using high-
energy equipments during manufacturing to obtain reduced size. Then, they possess good 
sensorial properties (rapid penetration, merging textures) and biophysical properties (especially, 
hydrating power) [69]. An example of skin care is the treatment of dry hair aspect; significant 
improvement and a prolonged effect was obtained after exposure to a cationic NE with hair more 
fluid and shiny, less brittle and non-greasy [70]. 
Further, due to the renewed interest in herbal drug formulations, NEs may be the ideal delivery 
platform for these phytopharmaceuticals, generally difficult to formulate, with expected high 
businesses for the pharmaceutical industries [47]. NEs could also be exploited to overcome the 
poor absorption of flavonoid nutrients - a group of antioxidant compounds found primarily in plants 
- and poor miscibility of these compounds. An example is the breviscapine, flavones 
glucuronide, which is a medicine extracted from a Chinese herb so called Erigeron breviscapinus 
[71]. It was observed how loading breviscapine into lipid emulsions produced a significant 
change in pharmacokinetic parameters with a much higher breviscapine concentration in plasma 
over time compared with free substance. All NEs used for nutraceuticals and pharmaceuticals, 
can also be engineered to further improve their efficacy [72]. This can be made possible by 
covering NEs with multilayer polymer shell so that a functional component trapped within the 
core could be released in response to a specific environmental trigger by designing the response 
of the shell to the environment. Then, as already described in Chapter I NEs have a huge 
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applicability in the field of functional foods like “healthy food”. Especially in this case to make 
possible the exploitation of such products it is necessary to find a way to reduce the high 
production cost due to the high energy utilized for production of NEs. 
NEs have an antimicrobial behavior against bacteria (e.g. E. coil, Salmonella, S. aureus), 
enveloped viruses (e.g. HIV, Herpes simplex), fungi (e.g. Candida, dermatophytes) and spores 
(e.g. anthrax) [68]. Indeed, they are thermodynamically driven to fuse with lipid-containing 
organisms and when enough nanoparticles fuse with pathogens, they release part of the energy 
trapped within the emulsion destabilizing pathogen lipid membrane and producing their lysis and 
death. In the case of spores, additional germination enhancers are incorporated into the emulsion. 
NEs can be applied for delivery of fragrant, which may be incorporated in many personal care 
products. This could also be applied in perfumes, which are desirable to be formulated alcohol 
free [47]. 
2.1.2. Preparation methods 
As said, NEs are heterogeneous system consisting of at least two immiscible liquid phases. 
Consequently, they do not form spontaneously and their properties depend not only on the 
thermodynamic conditions such as composition, temperature or pressure, but also on the 
preparation method and the order of addition of components. The structure of an emulsion 
generally consists of droplets of the dispersed phase (or internal) in a continuous phase (or 
external), stabilized by a surfactant, as illustrated in Figure 2.1. This structure decisively 
determines the physical properties and, thus, the functionality and quality of the emulsion. In the 
preparation of emulsions, from both fundamental and technological point of view, it is 
fundamental to obtain a desired droplet size and a narrow size distribution [73]. 
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Figure 2.1. Typical structure of an emulsion. 
Being non-equilibrium systems of structured liquids, NEs preparation typically involves the 
input of a large amount of either energy or surfactants [66].  
The high-energy method utilizes mechanical equipments, such as ultrasonicators, 
microfluidizer and high pressure homogenisers, to create intensely disruptive forces which break 
up the oil and water phases to form nano-sized droplets. Final particle size here will depend on 
the type of instruments employed and their operating conditions like time and temperature along 
with sample properties and composition. This method allows for a great control of particle size 
and a large choice of composition, which in turn controls the stability, rheology and colour of the 
emulsion.  
NEs can also be prepared by a low-energy emulsification method, which has been recently 
developed according to the phase behavior and properties of the constituents, to promote the 
formation of ultra-small droplets. These low-energy techniques include phase inversion 
temperature (PIT) technique, solvent displacement methods and phase inversion composition 
(PIC) method. This emulsification can be brought about by changing the parameters which 
would affect the hydrophilic lipophilic balance of the system like temperature (in the case of 
PIT), composition, etc.. The low energy method is interesting because it utilizes the stored 
energy of the system to form small droplets. Moreover, in the case of solvent displacement 
method and PIC, emulsification conditions are quite gentle making possible the use of 
thermolabile drugs such as retinoids and macromolecules, including proteins, enzymes and 
nucleic acids. However, also in the high energy process temperature can be controlled.  
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2.1.2.1. Low energy emulsification  
PIT method employs temperature dependent solubility of non ionic surfactants like 
polyethoxylated, which become hydrophobic above certain temperature allowing therefore a 
formation of water in oil emulsion due to the acquired solubility of the surfactant in the oil.  
However, it typically uses high temperature to create the phase inversion.  
In the case of solvent displacement, the oily phase is dissolved in water-miscible organic 
solvents, such as acetone, ethanol and ethyl methyl ketone and it is poured into an aqueous phase 
containing surfactant to yield spontaneous NE by rapid diffusion of organic solvent. The organic 
solvent is removed from the NE by a suitable means, such as vacuum evaporation. Spontaneous 
nanoemulsification were also reported when solution of organic solvents containing a small 
percentage of oil is poured into aqueous phase without any surfactant. A major drawback of this 
method is the use of organic solvents, such as acetone, which require additional inputs for their 
removal from NE. In particular, a high ratio of solvent to oil is required to obtain NEs with a 
desirable droplet size.  
PIC method has drawn a great deal of attention from scientists in various fields (including 
pharmaceutical sciences) as it generates NEs at room temperature without use of any organic 
solvent. Kinetically stable nanoemulsions with small droplet size (~50 nm) were generated by 
the stepwise addition of water into solution of surfactant in oil, with gentle stirring and at 
constant temperature. The spontaneous nanoemulsification was related to the phase inversion. 
The main limitation of low energy techniques is that they pose several difficulties during scale-
up. It has been demonstrated this capability in the case of PIC even though more experimentation 
should be done at higher scales in order to prove it [74]. 
2.1.2.2. High energy emulsification  
One technique for producing NEs is based on the use of an immersion sonicator. The 
emulsification power of ultrasound has been known and applied for long. The ultrasonic power is 
adjustable and can be adapted to particular products and emulsification requirements. Highly 
intensive ultrasound provided by a vibrating metal probe supplies the power needed to disperse a 
liquid phase in small droplets in a second phase continuous phase. In the dispersing zone, 
imploding cavitation bubbles cause intensive shock waves in the surrounding liquid and result in 
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the formation of liquid jets of high liquid velocity. The most important aspect is to stabilize the 
newly formed droplets of the dispersed phase against, for example, coalescence in order to 
maintain the final droplet size distribution at a level that is equal to the distribution immediately 
after the droplet disruption in the ultrasonic dispersing zone (coalescence of the droplets after 
disruption influences the final droplet size distribution). Studies on emulsions have shown 
correlation between the energy density and droplet size. There is a clear tendency for smaller 
droplet size at increasing energy density. At appropriate energy density levels, ultrasound can 
well achieve a mean droplet size below micrometer scale. However, this method presents several 
limitations mainly due to the polydispersion, the difficulty to scale up to large volumes and also 
in terms of minimum size of the dispersion which can be reached. To make possible NE 
preparation at industrial scale high pressure homogenization techniques are needed. 
High pressure homogenization allows producing extremely low particle sizes due to several 
forces, such as hydraulic shear, intense turbulence and cavitation [66]. The resultant product can 
be re-subjected to high-pressure homogenization until nanoemulsion with desired droplet size 
and polydispersity index is obtained. The smaller droplet size the higher the energy thus the 
pressure required. The emulsion is preferably prepared at high volume fraction of the disperse 
phase and diluted afterwards. However, very high phase volume ratios may result in coalescence 
during emulsification, even though more surfactant could be added to create a smaller reduction 
in effective surface tension and possibly diminishing recoalescence. If possible the surfactant is 
dissolved in the disperse phase rather than the continuous phase; this often leads to smaller 
droplets. It may be useful to emulsify in steps of increasing intensity, particularly with emulsions 
having highly viscous disperse phase.  
To the field of high pressure homogenizer it belongs also a patented mixing technology called 
microfluidization, which makes use of a device called microfluidizer. This device uses a high-
pressure positive displacement pump (500 - 20,000 psi), which forces the product through the 
interaction chamber, consisting of small channels called “microchannels”. The principle of the 
technology consists of a liquid that is divided into two microchannels and then is recombined 
later in a reacting chamber where the jets of liquid collide together. This allows for reducing of 
the size of suspended particles, resulting in stable, uniform and consistent mixtures of product. 
The emulsion can be passed through the interaction chamber of the microfluidizer repeatedly 
until the desired particle size is obtained. 
Chapter II: Monodisperse and biodegradable oil in water emulsions with tunable stability
 
2.1.3. NE stability  
As said emulsions are thermodynamically unstable due t
two phases, by their different densities, and they need an emulsifier to reduce destabilization
mechanisms over time. Emulsion destabilization is generally due to creaming and
as a consequence of the different densities of oil and water
fusion of emulsion droplets, f
sometimes reversible, and finally by
water is further increased with decreasing drop size. Single oil molecules leave the smaller 
droplets into the water phase and they can diffuse around and condense in a larger droplet so the 
larger droplets grow at the cost of the smaller ones. The driving
decrease of interfacial area and, thus, interfacial 
in Figure. 2.2. 
Figure 2.2. Breakdown mechanisms of emul
The smaller the droplet size the more stable is the emulsions 
creaming. Indeed, small sizes cause a large reduction in the force of gravity, and 
motion may be sufficient for overcoming it
One of the most important and perhaps the most widely used methods to 
the use of an emulsifier [66]. The latter adsorb to the surface of freshly formed oil 
during homogenization and facilitate further droplet disruption by lowering the interfac
tension, thereby reducing the size of the droplets produced during 
Emulsifiers also reduce the tendency for droplets to aggregate by forming protective membranes 
and/or by generating repulsive forces between the droplets. A good em
adsorb to the surface of the lipid droplets formed during homogenization, rapidly lower the 
interfacial tension by a significant amount, and protect the droplets against aggregation during 
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emulsion processing, storage, and utilization. A wide variety of different kinds of synthetic and 
natural emulsifiers can be legally used in food emulsions, including low-molecular mass 
surfactants (leader groups are fatty alcohols, glycolipids and fatty acids) and macromolecular 
(high-molecular-mass) emulsifiers extracted from naturally occurring materials, polysaccharides 
and proteins [77]. Emulsifiers vary considerably in their ability to form and stabilize emulsions, 
as well as in their cost, ease of utilization, ingredient compatibility, and environmental sensitivity 
[76]. Consequently, there is not a single emulsifier that is ideal for use in every food product. 
Instead, the development of each new food product depends on the rational selection of the most 
appropriate emulsifier for that particular system. This selection depends on the composition and 
structure of the food matrix, as well as on the changes in environmental conditions that the 
emulsifier experiences during processing, storage, and utilization, such as mechanical agitation, 
temperature, and pressure. Each type of emulsifier has its own particular advantages and 
disadvantages. For example, some emulsifiers are highly effective at generating small emulsion 
droplets during homogenization because of their rapid adsorption rates, but are poor at providing 
long-term stability against droplet aggregation because they do not provide strong enough 
droplet-droplet repulsive interactions, e.g., some small molecule surfactants. On the other hand, 
some emulsifiers are highly effective at imparting long-term stability to emulsions, but are 
inefficient at creating emulsions with small droplet sizes during homogenization, e.g., some 
polysaccharides and proteins.  
A strategy to improve emulsion stability which combines both kinds of emulsifier was 
proposed by MacClements and his group [76, 78, 79]. It consisted in producing secondary 
emulsions obtained with a polyelectrolyte thin layer, adsorbed through the interaction with an 
ionic emulsifier of opposite charge standing on the surface of oil droplets. One example is the 
use of lecithin, an anionic emulsifier, which rapidly adsorbs to the surface of lipid droplets 
during homogenization, producing a primary emulsion with small droplet sizes and then the 
addition of chitosan, a cationic biopolymer, to produce secondary emulsions containing droplets 
coated with a lecithin-chitosan membrane (Figure 2.3).  
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Figure 2.3. Two-stage mechanism for producing emulsion droplets coated by a two-layer interfacial membrane. 
At low concentrations of chitosan, the emulsions become unstable to flocculation due to charge 
neutralization and bridging flocculation. Instead, at high concentration there is typically a 
depletion flocculation which can bring to creaming. However, at the right chitosan concentration, 
the net droplet charge switches from negative to positive, and kinetically stable emulsions can be 
produced. It was also reported in literature the possibility to re-disperse secondary emulsion by 
using sonication or stronger sources like a high pressure homogenizer even though in terms of 
size and monodispersion results were still scarce [80, 81]. 
Starting from this approach, herein we implemented a new post-processing method on 
secondary emulsions, which allowed us to improve emulsion homogeneity and therefore 
stability. In particular, emulsion behavior was monitored in terms of stability over time. It was 
possible to find the proper conditions - in terms of formulation and process - to obtain 
unprecedented, ultra-stable emulsions. Stability over time depending on polymer concentration is 
schematically represented in Figure 2.4. The absence of flocculation at high polymer 
concentrations was possible due to the innovative multiple re-dispersion process here developed.  
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Figure 2.4. Stability scheme for multiple re-dispersed secondary emulsions at different polymer concentrations. 
2.2. Materials and Methods 
2.2.1. Materials 
For the preparation of nano-sized O/W emulsions, Lipoid E80 an egg lecithin powder enriched 
of phosphatidyl choline (PC 80%; phosphatidylethanolamines (PE) 7,8%; lyso-
phosphatidylcholine (LPC), lyso-phosphatidylethanolamine (LPE), sphingomyelin (SPH) in 
traces), as surfactant, and soybean oil (Medium chain triglyceride (MCT) oil; density at 20 °C of 
0,0922 g/ml), both purcheased from Lipoid, have been used. For water phase MilliQ® water was 
used. In some preparations, oil phase was loaded with a lipophilic fluorophore like Nile Red 
(NR) (m.w.=318.37 g/mol) purchased from Sigma Aldrich. All these reagents were used without 
further purification. Then, NEs were further treated by depositing a layer of chitosan (polycation, 
low molecular weight (LMW) 90-150 kDa, DDA 84%) purchased from Sigma Aldrich and 
subjected to purification as well as dehydration as it will be described. Chitosan was also 
functionalized with Fluorescein 5(6)-isothiocyanate (FITC) (m.w.=389.38 g/mol), as it will be 
described later, always purchased from Sigma Aldrich. 1,4-diazabicyclo[2.2.2]octane (dabco) 
(m.w.=112.17 g/mol) antifade, also purchased from Sigma Aldrich, was used to avoid the 
bleaching phenomenon of FITC while analyzing samples by confocal and STED. 
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Lecithin Lipoid E80 has been chosen to be perfectly biocompatible, perfectly biodegradable 
and anionic which imparts a negatively charged surface on emulsion drops.  It has been 
a fridge at a temperature of about 
atmosphere before its use. Vacuum is used to prevent its water absorbing and therefore 
difficulties in mixing with soy oil. As 
(for the reasons already described). 
important precursor for many biochemical functions
 
Figure 
Choline provides structure and fluidity in cell membranes, improves transfer of nerve impulses 
to the brain and circulatory system, and aids in lipid and cholesterol transport and metabolism. 
The consumption of an adequate daily intake of choline supports brain, liver,
 
Soybean oil is a popular vegetable oil that is valued for its affordability, high smoke point 
and health benefits. It often has a dark yellow or faint green color. Standard vegetable oil is often 
composed of soybean oil. Soybean oil acc
States. This is a good all around oil that can be used for baking, cooking and frying.
is made by extracting oils from the soybean. This is done by cracking the beans and then heating 
the beans to remove any unnecessary moisture. Next, the beans are sliced and then rolled to 
extract the oil with hexanes. Often, commercial brands mix soybean oil with other cheaper oils to 
make it more affordable. You can also find unrefined soybean oil, which
expeller-pressed. Often unrefined oils have a stronger flavor, but usually retain a higher 
nutritional value than refined oils.
Soybean oil contains no cholesterol, which makes it a perfect choice for 
disease or high cholesterol. The fats in soybean oil are polyunsaturated which have shown to 
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help reduce total cholesterol, lower low density lipoproteins (LDL) or bad cholesterol levels and 
increase high density lipoproteins (HDL) or good cholesterol levels. Soybean oil has omega-3 
fatty acids, which have shown to reduce the risk of cardiovascular disease, slow the growth of 
atherosclerotic plaque, slow the risk of arrhythmias or abnormal heartbeats and decrease 
triglyceride levels. Soybeans naturally contain antioxidants, which remain in the oil even after it 
is pressed. These antioxidants help prevent the damage caused by free radicals, which may help 
prevent certain cancers. 
 
Figure 2.6. Picture of the soybean from which it is extracted the soybean oil. 
Chitosan is a heterogeneous polysaccharide that consists primarily of acetylglucosamine 
(uncharged) and glucosamine (pKa ≈	6,3-7) subunits (Figure 2.7).  
 
 
Figure 2.7. Chemical structure of the chitosan. 
Although present in biomass, this polysaccharide is preferentially obtained by alkaline N-
deacetylation of chitin, a structural polysaccharide, more highly acetylated and insoluble of 
chitosan, present in exoskeleton of crustaceans and many insects as well as the cell-wall of many 
fungal species. [82, 83]. At relatively low pH (< 6.5), chitosan is positively charged and tends to 
be soluble in dilute aqueous solutions, but at higher pH, it tends to lose its charge and may 
precipitate from solution due to deprotonation of the amino groups. 
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This biopolymer possesses a variety of biological and physiological properties, including 
biocompatibility, biodegradability and low toxicity [84]. All these important characteristics have 
led to the development of numerous application of chitosan in food, agriculture, and in particular 
in medicine and drug delivery. Indeed, chitosan was used for surgical suture, biodegradable 
sponges and bandages, matrices in microspheres and/or microcapsules, and in the delivery of 
drugs. Chitosan can also be used for heavy metal chelation, wastewater treatment, cholesterol 
lowering, texture modification, emulsion stabilization and so on. Many of these applications 
depend on interactions with surface-active materials, e.g., phospholipids, small molecule 
surfactants or bile acids. Chitosan has also been shown to be capable of adsorbing to the surfaces 
of lipid droplets and indeed it was used in this work to stabilize primary emulsions.  
 
Flurescein isothiocyanate is a yellow coloured low molecular weight (m. w. 389,38 g / 
mol) dye whose  chemical structure is illustred in the following Figure 2.8.  
 
 
Figure 2.8. FITC chemical structure. 
FITC is excitable at a wavelenght of 494 nm and produces maximum fluorescence emission at 
around 520 nm. This emission also depends on pH. In particular FITC has a small and steady 
increase of the fluorescence intensity between a pH of 3 and 6 and a most sudden increase after 
pH 7 to reach the maximum fluorescence intensity around pH 10 (see Appendix Figure A.E.2).  
 
Quercetine (QR) belongs to a group of polyphenolic substances known as flavonoids. QR is 
a member of the class of flavonoids called flavonols. It is widely distributed in the plant kingdom 
in rinds and barks [4]. Especially rich sources of QR include onions, red wine and green tea. QR 
is a natural antihistamine and opposes the actions of the histamine in the body. 
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QR inhibits some inflammatory enzymes, such as lipid peroxidases, and decreases leukotriene 
formation. QR has anti-inflammatory, antiviral, immunomodulatory, anticancer and 
gastroprotective activities. QR blocks an enzyme that leads to accumulation of sorbitol, which 
has been linked to nerve, eye, and kidney damage in those with diabetes. QR also possesses 
potent antioxidant properties. It protects LDL cholesterol from becoming damaged. QR prevents 
damage to blood vessels by certain forms of cholesterol and other chemicals produced by the 
body. QR also works as an antioxidant by scavenging damaging particles in the body known as 
free radicals. People with diabetes are at higher risk of blood vessel damage from free radicals. 
For its antioxidant properties it could also be helpful in combination with tumor treatment where 
radicals are produced.  
2.2.2. Methods 
2.2.2.1. Preparation of primary NEs  
Several oil in water emulsions were prepared varying oil percentage and amount of lecithin 
used, by adding soybean oil to Lipoid E80 previously weighted with a high precision balance in 
a beaker. The surfactant was allowed to dissolve in the oil phase by stirring (for 10 minutes at a 
temperature of 60 °C and at a speed of about 500 r.p.m.) using a high speed blender (RZR 2102 
control, Heidolph), and then, after reaching room temperature, it was sonicated for 1.5 min 
(sonication amplitude of 60%; both pulse-on and pulse-off of 10 s) with an immersion sonicator 
(Ultrasonic liquid processor Q700, Misonix Sonicators). These two steps were repeated until 
lecithin was completely dissolved. After measuring the aqueous phase (milliQ water), to obtain 
the pre-emulsion, the oil phase was added dropwise to the aqueous phase, using for mixing an 
immersion sonicator for 3 minutes (70% of sonication amplitude, pulse on and a pulse off 
respectively of 10 and 5 seconds) and then sonication was continued for other 5 min in the same 
conditions. The pre-emulsion preparation was performed in a large beaker in which a jacket of 
ice was created, to keep temperature low and avoid pre-emulsion overheating during sonication. 
Such warming could lead to thermal agitation of pre-emulsion droplets and then increase the 
probability of coalescence. The pre-emulsion was finally passed at 2000 bar through the high 
pressure homogenizer (Microfluidics© M-110PS Series Microfluidizer”, details of the working 
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principles of this instruments can be found in the Appendix A.I.2) for 3 single cycles (those that 
more effectively contribute to reduce the droplet size) and then in continuous steps modality, 
recycling the product without any reduction of volume and taking out small volumes of emulsion 
at 50, 100, 150 and 200 steps and in first individual cycles in order to follow the behavior of size, 
PDI and Z-potential versus number of processing steps.  
Tests were conducted to study stability over time and reproducibility of emulsions preparation 
procedures. The instrument used both for size, PDI and Z-potential measurements is Zetasizer 
Nanoseries by Malvern© (detailed description are described in the Appendix A.I.3).  
2.2.2.2. Chitosan purification 
Briefly, a 1% wt acetic acid solution of chitosan (pH=2) was prepared. After complete 
dissolution of chitosan under magnetic stirring, the solution was filtered and after filtration pH of 
the solution was changed by adding a solution of NaOH 6M until pH was basic thus allowing the 
precipitation of chitosan. The polymer was collected by centrifugation (15 min, 4°C, 9000 rpm), 
redispersed in MilliQ water and recollected by centrifugation (5 min, 4°C, 9000 rpm) several 
times until all NaCH3COO- was removed and pH of chitosan suspension was neutral. Then the 
sample was freeze-dried for 48 h and further dried in oven for 3 h at 80°C to maximize removal 
of water, since chitosan is strongly hygroscopic as measured by thermogravimetric analysis 
(TGA) (see Appendix Figure A.E.1).  
2.2.2.3. Preparation of secondary NEs 
It has been seen in preliminary experiments that purified samples of chitosan are necessary for 
good deposition on primary emulsions. Therefore, starting from purified chitosan, solution at 
several concentration (0.0025%, 0.005%, 0.00875%, 0.0125%, 0.025%, 0.05%, 0.0875%, 
0.125% 0.250%, 0.5%, 0.875%, 1.25% wt), were prepared in 0.1 M acetic acid Milli-Q water. 9 
ml of these solutions were diluted 1:4 with Milli-Q water to 36 ml and brought to pH 4 with 
small addition of NaOH 6 M solution. Then 9 ml of the emulsion diluted to 5% oil phase were 
added quickly under vigorous stirring and kept under stirring for 15 min to allow uniform 
chitosan deposition. So the emulsion was diluted 1:5 with chitosan solution (thus final oil 
concentration was 1% whereas final chitosan concentrations were 1/5 of the initial). 
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2.2.2.4. Synthesis of FITC labeled chitosan 
To carry out some in fluorescence analysis such as in fluorescence microscopy of secondary 
emulsions, in some preparations it was used a chitosan modified with FITC. Briefly, due to its 
isothiocyanate moiety FITC could be linked to chitosan’s primary amine forming a thiourea 
bond (Figure 2.9).  
 
. 
 
 
 
 
 
 
 
Figure 2.9. Schematic illustration of the synthesized FITC-labeled chitosan. 
In particular, 500 mg of purified and dried chitosan where dissolved in 50 ml of aqueous acetic 
acid solution (0.10 M). After complete dissolution 50 ml of methanol were added. Then 25 mL 
of a 1 mg/ml solution of FITC in anhydrous methanol was prepared. This solution was slowly 
added to chitosan solution and the reaction was allowed to proceed in the dark under magnetic 
stirring for 18h at room temperature. Finally, chitosan was precipitated with a solution of NaOH 
and the precipitate was collected by centrifugation (9000 rpm; 4°C; 15 min). The obtained FITC-
chitosan was dispersed in MilliQ water, washed and centrifuged 6 times until pH had a neutral 
value and no traces of FITC were visible in the waste washing solutions. As additional evidence 
that all the FITC was removed, a small amount of the functionalized sample was dispersed in a 
basic water solution (pH=10) (FITC, is pH sensitive and the fluorescence is very strong in these 
conditions), allowed to stay and then centrifuged. Negligible fluorescence was revealed at 
spectrofluorimeter in the solution separated from the dispersed polymer, so the sample could be 
considered purified. After reaction, the degree of functionalization was determined by means of 
UV-Vis analysis (see Appendix A.I.8), comparing the absorbance with a FITC calibration line 
(see Appendix Figure A.I.3).  
O
O
HO NH
O
OH
NH
S
OO OH
n
COOH
Chapter II: Monodisperse and biodegradable oil in water emulsions with tunable stability 
 
52 
 
2.2.2.5. DLS characterization 
Particle size distribution and Z-potential of emulsions and emulsion-based nanocapsules were 
determined using a particle electrophoresis instrument (Zetasizer zs nano series ZEN 3600, 
Malvern Instruments Ltd., Malvern, U.K.). Detailed description of the physical principles of 
these analyses and of the instrument are reported in the Appendix (A.E.3). 
For particles size measurements all the samples were diluted up to a droplet concentration of 
approximately 0.025% (wt), by using Milli-Q water in the case of primary emulsions and an 
acetic acid Milli-Q water solution (pH 4, 20 mM) in the case of secondary emulsions. The 
diluition is important to prevent the overlapping of scattered light intensity, for example, from 
two droplets if they are extremely close each other (multiple scattering phenomenon) during 
measurement. A default refractive index ratio (1.52) and 5 runs for each measurement (1 run 
lasting 100 s) were used in the calculations of the particle size distribution. 
For Z-potential measurements the samples were diluted in the same conditions and the analysis 
was carried out by setting 50 runs for each measurement. 
2.2.2.6. Spectrofluorimetry analysis 
In order to evaluate polymer coverage on primary emulsions, a FITC emission spectrum 
analysis was performed (EnSpire Multimode Plate Reader 2300-0000, Perkin Elmer). 100 µl of 
sample at different FITC-labeled chitosan concentrations (0.01%, 0.00175%, 0.0025%, 0.005%, 
0.01%, 0.0175%, 0.025%, 0.05%, 0.1%, 0.175%, 0.25% wt) were loaded in a multi-well (3 
replicates for each sample were prepared) and irradiated at 488nm (the light coming from a flash 
lamp can be filtered in order to have a light with the desired wavelength) Samples were diluted 
from 1% wt of oil to 0.025 % wt with the same buffer solution used for DLS analysis in order to 
limit final fluorescence emission. The fluorescence signal was detected at 510 nm. The used 
flashes number was 100. 
2.2.2.7. STED analysis description 
A procedure was also developed to allow observation of all the samples with the STED 
(stimulated emission depletion) high resolution in fluorescence optical microscope. Each sample 
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was diluted (1:50) in a heppendorf with a 20 mM acetic acid buffer solution at pH 4 and was put 
in a FD3510 dish for 30 min to allow it to adhere to the surface of the dish. After that, 3 washes 
with a 5% wt dabco antifade solution were performed and at the end the central part of the dish 
was left full of dabco during sample observation. Dabco antifade was introduced to avoid the 
bleaching effect of the FITC-labeled chitosan. Samples were imaged with a Leica TCS STED-
CW microscope. The resolution of the microscope was estimated to be < 80nm. For each sample, 
10 images were acquired with a field of view of 25.6 x 25.6 µm for a pixel size of 25 x 25 nm. 
The STED-CW beam power was 430 mW, measured at objective back focal plane. The analysis 
of the images was carried out by Imagej software.  
2.2.2.8. Cryo-TEM characterization 
The morphology of the secondary emulsion was observed by transmission electron microscopy 
(TEM) in cryo conditions. Samples were prepared by putting a droplet of dispersion on the grid; 
the excess of water was removed by an automatic system (Vitrobot of Leica), described in the 
Appendix (A.I.6) to obtain a thin liquid film on the grid which was immediately immersed into 
the liquid nitrogen to get a vitreous solid water film. Cryo-TEM images were recorded by a 
Tecnai 12 electron microscope (Philips, Eindhoven, Netherlands,) described in the Appendix 
(A.I.6) at approximately -170 °C under 120 kV acceleration voltage equipped with a Multiscan 
600W CCD camera (Gantan Inc., Warrendale, PA, USA).(Verificare modello cryo-TEM). 
2.3. Results and Discussion 
2.3.1. Primary emulsions: DLS analysis  
In terms of emulsion fabrication, the main effort was to identify the right conditions to obtain 
NEs with tunable sizes, in a range of interest for bio-nanotechnology applications (below 200nm 
and down to 100nm), and low PDI (down to 0.1), along with the choice of a biocompatible 
formulation consisting of soy-bean oil and Lecithin Lipoid E80, both pharmagrade products and 
used in parenteral nutrition thanks to their well known biodegradability. 
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As described in detail in the method section, first, the oil phase was prepared by adding a 
certain amount of Lipoid E 80 to a volume of soy-bean oil. Then the pre-emulsion was obtained 
by adding the oil phase dropwise to a weighted amount of aqueous phase (Milli-Q water) and 
emulsified using the immersion sonicator. The pre-emulsions were finally passed at 2000 bar 
through the high-pressure valve homogenizer (Microfluidics M110PS) for first three individual 
cycles to strongly reduce the initial size and then continuously by re-filling the reservoir for 
several steps, thus recycling the product without any loss of volume and taking out small 
volumes of emulsion at 50, 100, 150 and 200 steps. This method was used for the preparation of 
all oil-in-water emulsions at different concentrations of oil phase (10, 20, 30 % wt). NEs with 
different oil and lecithin concentration were classified according to the Lipoid E80/oil phase 
ratio that remains constant in all oil concentrations, as reported in Table 2.1. 
 
Emulsion Lipoid E80 /Oil phase (g/mg) 
L1 0.06 
L2 0.12 
L3 0.18 
L4 0.24 
L5 0.3 
Table 2.1. List of surfactant formulation. 
A first DLS analysis was performed to understand the influence of increasing the number of 
processing steps on the droplet sizes as well as the lecithin concentration at a fixed concentration 
of oil of 10 % wt. 
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Figure 2.10. DLS results on 10% oil phase emulsions. 
As can be seen from Figure 2.10, independently from lecithin and oil concentration a longer 
processing to Microfluidizer led to smaller droplets, but it was decided to stop the process after 
200 steps because it was not observed a significant emulsion droplet sizes decreasing with a 
further increasing of number of microfluidizer steps; on the contrary, in some cases, this over-
processing led to emulsion destabilization. Furthermore it was found that using a greater 
percentage of oil, while maintaining the same surfactant/oil ratio, brought to smaller droplets and 
smaller PDI (Figure. 2.11).  
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Figure 2.11. Example of droplet size and PDI size distribution measurement. 
As reported in the name of the experiment this is a sample corresponding to the sample L3 of 
the previous experiment. Here we have 3.6g of Lecithing in 20ml of oil whereas in the previous 
case they were 1.8g in 10ml therefore the same ratio surfactant/oil. This time the average size 
and PDI (99.94nm, 0.056) were lower than previous case (107nm, 0.09).  
Just as an example of Z-potential test, in Figure 2.12 there is a representation of a typical Z-
potential measurement. 
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Figure 2.12. Example of Z-potential droplet measurement. 
Considering the improvement in terms of size and PDI obtained by doubling the oil content, it 
was decided to repeat the preparation and characterization of all the previous samples at an oil 
concentration of 20% wt. Also in this case DLS analysis made it possible to observe how the 
variation in the number of processing passes and steps and of lecithin concentration affected the 
droplet size and PDI (Figure 2.13). 
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Figure. 2.13. Emulsion size at different processing cycles and surfactant amount. 
Like in the case of 10% wt of oil a significant decrease in the emulsion size after the single 
cycles and a further decrease during continuous processing up to a plateau were observed. In 
addition, it was confirmed for all the samples the better results compared to the 10 % wt of oil.  
Remarkably, a reproducible size was attained at each formulation from around 160 nm, with the 
lowest concentration of lecithin, to around 80 nm with the highest one. L5 was slightly smaller 
than L4, meaning that a further increase in the amount of lecithin would have been ineffective. In 
the same way, PDI decreased with the number of cycles, but increased with the amount of 
surfactant, even though it remained below 0.1. The precise values of size, PDI, and Z-potential 
for all the samples are summarized in the appendix (Table A.E.1) for both 10 and 20% wt of oil. 
Each emulsion was characterized in terms of stability by carrying out size and PDI 
measurements over time as shown in the following Table 2.2. 
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Emulsion 
Composition  
Stability tests  
 
0 time  1 day  3 days  1 week  2 weeks  4 weeks 10 weeks  10 weeks 4C 
1,2 g lecithin / 20 
ml soyoil  
Size[nm] 158,3 162 169,5 162,6 160,7 153,5 1010 211 
PDI 0,042 0,028 0,153 0,066 0,052 0,057 0.330 0.259 
2,4 g lecithin / 20 
ml soyoil  
Size[nm] 119 124,5 126,5 126,6 131,1 130,1 149.8 129 
PDI 0,073 0,051 0,05 0,055 0,078 0,055 0.063 0.05 
3,6 g lecithin / 20 
ml soyoil  
Size[nm] 100,8 102,3 105,6 111,9 113,8 131,9 125.6 100.7 
PDI 0,073 0,085 0,097 0,128 0,122 0,137 0.2 0.085 
4,8 g lecithin / 20 
ml soyoil  
Size[nm] 82,33 84 84,92 84,77 83,95 85,34 87.41 86.76 
PDI 0,103 0,107 0,093 0,104 0,089 0,102 0.1 0.106 
6 g lecithin / 20 ml 
soyoil  
Size[nm] 77,87 78,58 81,01 80,12 78,51 82,2 82.99 82.1 
PDI 0,1 0,113 0,124 0,116 0,126 0,097 0.099 0.1 
Table 2.2. Stability tests on emulsions of different size at room temperature and 4 °C. 
As it is possible to see, at room temperature the last two emulsions were quite stable while the 
first three changed a lot as predictable by the different size. As a matter of fact droplets with 
bigger sizes are more flexible and can coalesce more easily. By keeping the emulsions at 4°C 
also the first three gained stability maybe due to the slowing down of the droplets which reduces 
the efficacy of hits and following coalescence.  
To further scale down NEs sizes it was also tried to increase viscosity of the dispersant phase 
with the addition of glycerol which should reduce emulsion coalescence while processing and 
stabilize smaller oil nano-droplets as consequence. In the case of formulations including glycerol 
it was needed to blend the two phases in advance and then process by ultrasound sonicator at the 
usual conditions. Different concentrations of glycerol were tested in combination with different 
oil concentrations. After several trials in terms of formulation it was possible to optimize and 
gain in terms of size reduction without disturbing the PDI. Formulation was varied in terms of 
both oil concentration, volume ratio between water and glycerol and surfactant concentration 
(Figure 2.14).  
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Figure 2.14. Emulsion size at different formulations in presence of glycero
The best formulation allowed us 
resulted much more unstable over time. 
of the dispersant phase maybe with different substances could allow a further strong reduction of 
the emulsion size down to few tens of nanometers.
Among the several tests carried out to optimize the preparatio
and equipment, it was also tested the reproducibility of the procedure. In the following 
the average size and PDI for three different preparations with same formulation and procedure 
are reported. 
 
Procedure
1.2% wt Lipoid E80; 10 % wt 
Soy oil; 88.8 ml H2O distillata
Ciclo 3 + 150 step
Table 2.3. Reproducibility of an emulsion with a lecithin / soybean oil ratio of 1,2 g / 10 ml.
 
60 
l.
to produce NE size down to 42nm. However, these NEs 
Anyway, it was shown how working with the viscosity 
 
n method in terms of formulation 
 Sample Mean size (nm) PDI 
 
 
1 131,4 0,087 
2 127,3 0,073 
3 126,1 0,064 
 
 
 
 
Table 2.3 
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As it is possible to see there is a perfect reproducibility both in terms of size and PDI. Then, 
they were weighed 6 g of lecithin and dissolved in 20 mg of soybean oil. It was followed the 
procedure previously described for the realization of the pre-emulsion. The pre-emulsion, which 
in this case had a volume of 200 ml, was divided into two equal parts each of 100 ml, therefore 
with the same lecithin/soybean oil ratio. One of the two pre-emulsions was processed and 
characterized in the day of preparation while the other one, after 3 days. The results are reported 
in the following Figure 2.15. 
 
 
Figure 2.15. Reproducibility of emulsion with a lecithin / soybean oil ratio of 3 g / 10 mg. 
As it is possible to see from the graph, emulsions are almost identical for each processing cycle 
and step. That means once prepared the pre-emulsion, it is not subject to a fast destabilization but 
it can be processed even after a few days; then the high pressure homogenizer guarantees a 
perfect reproducibility. 
2.3.2. Secondary emulsions 
2.3.2.1. DLS analysis 
It is well known [78] that emulsions with a surface charge can be stabilized using a 
polyelectrolyte coating; they are then called secondary emulsions, and their stabilization 
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capability depends on the concentration of the polymer itself. If concentration is not appropriate, 
stability can be even lower. In this work, not only it was varied the polymer concentration, but it 
was also attempted to identify an optimal process procedure to improve stability. The main issue 
in this kind of coating is that polymer concentration inside the mixing cannot be uniform. 
Therefore, after one day from preparation all the secondary emulsions were homogenized at 
medium pressure (around 700 bar) following the procedure reported in the experimental part; a 
beneficial effect on polidispersity and stability was observed. In particular, it was found out that, 
by re-processing all the secondary emulsions still alive after one month at the same conditions, a 
further significant enhancement of their long-term stability evaluated in terms of size and PDI 
over time was obtained. The re-dispersion scheme is reported in the following Figure 2.16.  
 
 
Figure 2.16. Scheme of re-dispersion processing of secondary emulsions. 
For instance, the evolution of the size over time for L1 (large), L2 (medium) and L4 (small) 
double re-processed secondary emulsions (Figure 1.17.b) and just for L1, a comparison between 
double re-processed, single re-processed and no re-processed samples (Figure 2.17.a) are 
reported. (All the other data are in the Table A.E.2 in the Appendix).  
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(a) 
 
(b) 
Figure 2.17. L1 secondary emulsion size at different chitosan polymer concentrations over time processed twice, 
once and not at all (a); secondary emulsions on L1, L2, L4 processed twice (b). 
In particular, from Figure 2.17.a it is clear how the double re-processed samples behave better 
than the single re-processed ones and much better than non-processed ones both in terms of size 
and possible destabilization time (the same is for PDI, see Table A.E.2 in the Appendix). For no 
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re-processed samples, the destabilization trend was already evident in the first month therefore 
no further data were collected. It is also worth noticing how the size of the double processed 
samples is slightly higher than the starting primary emulsions meaning no aggregations 
compared with single re-processed and even more to no reprocessed samples. Data related to 
double re-processed samples start at 1 month since this time corresponds to their birth. Finally 
for what concerns polymer concentration it is clear how the stability increased with it. In 
particular, polymer concentrations needed to give stability were dependent on the emulsion size, 
as it was predictable looking at the different surface amount; the smaller the droplets, the higher 
the surface, and therefore the polymer needed. Figure 2.17.b confirms this stability trend with 
polymer concentration independently of starting primary emulsion size. Specifically, a low 
concentration of chitosan brought to destabilization faster than that of the primary emulsions; 
specifically, the lower the concentration, the faster the de-mixing as expected. At polymer 
concentrations below 0.01% wt, secondary emulsions re-processed one time were readily de-
mixed, and therefore not suitable for further re-dispersion treatment after 1 month. On the other 
hand, by increasing polymer concentration, emulsion stability improved maybe due to a more 
and more complete coverage of the emulsions. However, high polymer concentrations are 
typically excluded, due to depletion flocculation that we also noticed in different degrees in the 
case of single and no re-dispersion process, as shown in the Figure 2.17.a. On the contrary by 
double re-dispersing this aggregation was avoided due to an enhanced homogenization of the 
polymer in solution. In this way it was possible to obtain unprecedented ultrastable secondary 
emulsions. 
2.3.2.2. Granulometric analysis 
In terms of stability, the micrometric percentage of secondary emulsions was also evaluated. 
Indeed, in the field of lipid injectable emulsions for parenteral nutrition, the volume percentage 
of particles larger than 5 µm has to stay below 0.05%, which is the maximum value specified by 
United States Pharmacopea (USP) (Chapter729). In Figure 2.18 it is shown the size distribution 
of a primary emulsion during the first two weeks after preparation and the same emulsion 
stabilized by double re-dispersion and by using chitosan at the last three polymer concentrations.  
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Figure 2.18. Particle size distribution by granulometer analysis. The inset magnify bottom part of the graph. 
The difference is evident and by quantifying the percentage of volume fraction above 5 µm in 
size it was found that emulsions with no polymer coating after 2 weeks had already overcome the 
specified threshold, while the stabilized secondary emulsions after 7 months still met the 
specification standard (see Table 2.4).  
 
 
Sample Days after % wt of particles > 5 
Template 0 0.001 
Template afetr 1 day 1 0.015 
Template after 14 days 14 0.069 
Monolayer 0.1% CT 210 0.029 
Monolayer 0.175% CT 210 0.034 
Monolayer 0.25% CT 210 0.051 
 
Table 2.4. Amount in % wt of particles above 5 µm in size in the case of L4 for a primary emulsion in first 2 weeks 
and for secondary double re-dispersed emulsions at the three highest concentrations of polymers (0.1, 0.175, 
0.25 % wt) after 7 months. 
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2.3.2.3. Morphological analysis 
To support the DLS analysis L1, L2 and L4 secondary emulsions - coated with chitosan (0.1% 
wt) and double processed were analyzed by in fluorescence microscopy. This analysis was 
performed using chitosan labeled with FITC. In Figure 2.19 the absorption (left) and the 
emission (right) spectra of the chitosan labeled FITC are reported.  
 
 
Figure 2.19. Absorption (left) and emission (right) spectra of FITC labeled chitosan. 
In particular, it was necessary to carry out a STED analysis due to the expected small size, as 
demonstrated by the comparison with a confocal analysis (Figure 2.20).  
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Figure 2.20. In fluorescence microscopy analysis by confocal and STED on L1, l2, l4 based secondary emulsions. 
The results are consistent with the analysis carried out in the conventional way by DLS. 
In terms of morphological analysis a Cryo-TEM was carried out too. To better distinguish the 
shell from the oil core a tomography analysis was needed. It is shown this analysis for a stable 
secondary emulsion built up on the L4 template at 0.1% chitosan concentration after five months 
(Figure 2.21). Indeed, L4 template is the right compromise between smallest sizes and suitable 
PDI.  
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Figure 2.21. Cryo-TEM tomography of a chitosan based secondary emulsion and magnification  (Top on the left) 
showing the nanoshell. 
As expected for this system from DLS measurements, size is slightly below 100 nm and the 
shell is around 5 nm. 
2.3.2.4. Sprectrofluorimeter analysis 
The use of nanoemulsions as template for further build up of oil core based nanocapsules and in 
particular layer-by-layer polymer nanoshells on liquid templates can be very advantageous in 
drug delivery [85, 86]. Typically, for secondary emulsions a significant excess of polymer in 
solution is avoided in order to prevent further deposition due to aggregations.  
There is a model reported in literature which evaluates the amount of polyelectrolyte to reach 
saturation level on emulsion droplets [87]. This model considers polymer only on droplet surface 
until complete saturation and uses the following expression: 
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where  is the droplet volume fraction, 
(in Kg), d is the volume-surface mean droplet diameter (in m), and 
concentration of polyelectrolyte in the whole system required to saturate the surfaces (in kg
This equation shows that polyelectrolyte concentration required
surface, increases with particle concentration, surface load, and 
For a particular system, this concentration
is proposed to use the Z-potential measurement as method to evaluate the saturation 
concentration of the polymer around the primary emulsion.
Here, to estimate the saturation concentration, we proposed a
a fluorophore chemically labeled to the polyelectrolyte, in particular, FITC
With this method we evaluated the emission 
template, as an example, at increasing 
normalized with respect to the polymer concentration itself.
  
Figure 2.22. Emission analysis by spectrofluorimeter on secondary emulsions at FITC labeled chitosan
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An initial increase of the emission was observed up to a maximum followed by a decreasing 
curve. We explained the presence of the peak considering that after oil saturation, there is a 
significant increase of the polymer content in solution 
curve of free polymer in solution. 
the oil surface, as confirmed by the successful further deposition attempts on second
emulsions at around this chitosan concentration. Compared to the zeta potential method, which 
evaluates the saturation concentration by measuring the plateau of the zeta potential, the 
proposed method is much more sensitive, being able to identify very
peak (see Figure A.E.4 in the Appendix)
The comparison between these samples and free FITC labeled chitosan 
concentrations (Figure 2.23) (from 0.01 % wt to 0.1 % wt of chitosan
the saturation peak the slope of the two curves is different until concentrations 
This was attributed to a complete coverage of the primary emulsions which would 
the progressive improvement of the stability 
described experiments of stability on secondary emulsions.
 
Figure 2.23. Emission comparison by spectrofluorimeter between secondary emulsions and free FITC labeled
chitosan in the range between 0.01 and 0.1 % wt.
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In the Appendix (Table A.E.3) the emission data at different concentration for FITC labeled 
chitosan alone and in the presence of nanoemulsion are reported. 
The proposed method not only provides a very accurate way to identify saturation 
concentration, but it also shows that saturation is a relative concept. Indeed, after a main 
saturation, the real complete coverage happens only at much higher polymer concentrations 
maybe due to equilibrium between polymer on emulsion and polymer in solution. Moreover, 
even at very low polymer concentration there is such equilibrium as demonstrated by the 
increase of the normalized emission which can only be attributed to the increase of polymer in 
solution which is more fluorescent than polymer on emulsion. 
2.3.2.5. Loading analysis  
As anticipated in method section, to demonstrate loading capability, oil was pre-loaded with a 
lipophilic molecule like NR fluorophore. In Figure 2.24 it is reported a confocal analysis of an 
L1 based secondary emulsion (0.1 % wt of chitosan) where oil was loaded with Nile Red and 
chitosan labeled with FITC.  
 
 
Figure 2.24. Sample with DABCO antifade to stabilize and visualize CT-FITC. 
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It is evident by the co-localization of the two colours oil loading capability and encapsulation 
capability of the chitosan. Moreover, the presence of NR clearly did not affect the 
monodispersion feature of the secondary emulsion. 
In terms of lipophilic molecules loading it was also tried to embed a real drug molecule like QR 
into oil (400 µM). Also in this case emulsion preparation was not affected by the presence of the 
molecule as well as the coating with chitosan even though it was needed a minimum 
concentration of chitosan (0.0175 % wt) higher than usual (0.01 % wt). In the following Table 
2.5 DLS results are reported for primary and secondary emulsion. 
 
 Size (nm) PDI Z-pot (mV) 
Emulsion 207.3 0.073 -35 
Monolayer 0.01 % wt 258.2 0.234 + 21.7 
Monolayer 0.0175 wt 212.8 0.092 + 22.6 
Table 2.5. DLS results on primary and secondary emulsion loading quercetin. 
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Chapter III: Natural polymer nanocapsules via 
Layer-by-Layer on oil core templates 
3.1. Introduction on Nanocapsules 
3.1.1. Methods for preparation of nanocapsules 
As previously said, among different nanocarriers, nanocapsules present the advantage to really 
protect drug or biomolecules from degradation and they present the highest possible payloads 
(till 80 % or more) [88]. Of course payload depends on the kind of capsule and method used for 
production. Moreover, always due to the complete insulation of the inner phase, nanocapsules 
can mask unpleasant tastes. Finally, as in the case of the other NCs, due to the small size they 
can improve the biodistribution of active substances which is extremely advantageous especially 
in the case of lipophilic active substances.  
Polymer nanocapsules can be produced starting from monomers or preformed polymers. In the 
first case (e.g., emulsion polymerization and interfacial polymerization), one limitation is in the 
consequence to work with synthetic polymers. Moreover, even washing the suspension after 
preparation, there is always the risk to have some contaminants like monomers residue or 
chemical initiators typically used. For these reasons the attention was just focused on the second 
case based on the use of preformed polymers.  
Generally, the main methods used for the preparation of nanocapsules starting from preformed 
polymers are: nanoprecipitation, emulsion-diffusion, emulsion-coacervation, polymer-coating 
and LBL. It will be provided a brief description of these methods including some details on the 
procedures and technological advantages, as well as examples of polymers and encapsulants. 
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3.1.1.1. Nanoprecipitation method 
The nanoprecipitation method also called solvent displacement or interfacial deposition is 
based on spontaneous emulsification formed when the organic phase, containing the dissolved 
polymer, is added under stirring to the aqueous external phase (Figure 3.1) [89]. However, 
spontaneous emulsification is not observed if the coalescence rate of the formed droplets is 
sufficiently high. 
 
 
Figure 3.1. Schematic representation of the nanoprecipitation technique. 
The inner organic phase contains polymer, active substance and optionally lipophilic 
tensioactive whereas the external water phase just contains a surfactant. If the organic phase 
includes an oil, which is immiscible with water, interfacial deposition is always guarantied due to 
the fact that even after diffusion of the solvent from the inner to the outer phase there is always 
an organic phase with a surface where polymer can deposit. On the contrary, in absence of oil, 
solvent diffusion could also bring to the formation of bulky polymer nanoparticles. It depends on 
the comparison between polymer precipitation and solvent diffusion. However, when capsules 
are obtained they are hollow whereas in the previous case they are filled with an oil core. 
The polymers commonly used are biodegradable polyesters, especially PCL, PLA and PLGA. 
Considering the oil-based central cavities of the nanocapsules, high loading efficiencies are 
generally reported for lipophilic drugs when nanocapsules are prepared (up to 70 %) [88].  
Up to now, this is one of the most used methods thanks to the simplicity of its procedure and 
low cost. However, some limitations regard the kind of polymers used which are synthetic and 
then, even though biodegradable they can produce possible side effects [56]. Moreover, the 
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simplicity of the method is translated in the simplicity of the final capsules and therefore low 
versatility in term of multifunctional behavior which on the contrary is more and more desired 
especially in drug delivery. 
3.1.1.2. Emulsion diffusion method 
This method also involves the diffusion of polymer solvent from an emulsion formed by 
emulsifying oil phase in water phase. In this case, polymer is dissolved in a partially water-
soluble solvent whereas the external phase is water saturated with such solvent in order to ensure 
the initial thermodynamic equilibrium of both liquids. In fact, to produce the precipitation of the 
polymer and the consequent formation of nanocapsules, it is necessary to promote the diffusion 
of the solvent of the dispersed phase by dilution with an excess of water. The procedure is 
illustrated in Figure 3.2 [88].  
 
Figure 3.2. Schematic illustration of the Emulsion Diffusion technique. 
Organic phase contains polymer, active substance, solvent partially soluble in water and oil. 
The polymers commonly used are biodegradable polyesters especially PCL, PLA, but also 
poly(hydroxybuttyrate-co-hydroxyvalerate) (PHBHV). Regarding the solvents, ethyl acetate is 
the first option even though propylene carbonate, benzyl alcohol and dichloromethane have also 
been used. Finally, regarding the external phase typically it is used water with poly(vinyl 
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alcohol) (PVA) or poloxamers or other stabilizing agents as surfactant. Solvent and a great 
quantity of water are eliminated by evaporation. 
This technique presents several advantages, such as high encapsulation efficiencies in the case 
of lipophilic drugs (generally >70%), the use of pharmaceutically acceptable organic solvents, no 
need for homogenization, high batch-to-batch reproducibility, ease of scale-up, simplicity, and 
narrow size distribution [89]. Disadvantages are the high volumes of water to be eliminated from 
the suspension and the leakage of water-soluble drug into the saturated-aqueous external phase 
during emulsification, reducing encapsulation efficiency. However, preliminary results have 
been provided on the formation of nanocapsules made of PCL where water dilution effect was 
replaced by the use of high pressure treatment to induce the diffusion of organic solvents during 
the emulsion-diffusion procedure [90] which could economize the total processing time.  
The same considerations regarding capsule materials and simplicity said in the case of 
nanoprecipitation are also true in this case. 
3.1.1.3. Emulsion-Coacervation method 
The emulsion-coacervation process is mainly presented as a strategy for the preparation of 
nanocapsules from naturally occurring polymeric materials. Up to now, sodium alginate and 
gelatin have been mostly used though synthetic polymeric materials can also be used. The 
procedure involves the o/w emulsification of an organic phase including oil and active 
substances with an aqueous phase dissolving polymer and stabilizing agent, by mechanical 
stirring or ultrasound. Then, coacervation process can be performed by using electrolytes, by 
adding a water miscible non-solvent or a dehydration agent or by varying temperature [88]. 
Finally, to obtain a rigid nanocapsule shell structure, polymer film can be stabilized by physical 
intermolecular or covalent cross-linking, which typically can be achieved by varying pH or 
temperature or by adding a cross-linking agent. The procedure is illustrated in Figure 3.3.  
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Figure 3.3. Schematic illustration of polymer capsules preparation by emulsion coacervation method. 
In terms of loading efficiency it is generally much lower (below 50 %) than in the two previous 
methods. Moreover, due to the little literature available on this method and to the different 
methodologies used each time the method is considered premature for general criteria for 
materials and composition usable. In terms of materials there are also examples of natural 
polymers like chitosan deposited with this technique; however again the simplicity of the final 
product makes them low versatile in terms of multi-functionality.  
3.1.1.4. Polymer coating 
This method is similar to coacervation, though polymer solution is added after emulsification 
followed by polymer adsorption at the interface of the emulsion. Sometimes, such a process is 
defined as coacervation. As an example, this method was chosen to produce PLA capsules using 
thyme oil as the core material [91]. First, a thyme oil emulsion in water stabilized with Tween 20 
(as surfactant) and a PLA solution in dimethylformamide (DMF) were prepared. Thereafter, the 
PLA solution was dropwise to the previously prepared o/w emulsion. Upon contact with water, 
the homogeneous solution of PLA in DMF promoted the precipitation of PLA around the thyme 
oil core. Capsules were hardened by adding octamethylcyclotetrasiloxane (OCMTS) that acts as 
a nonsolvent for the PLA, thus promoting capsules solidification. The complete flow process is 
represented in Figure 3.4. 
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Figure 3.4. Schematic illustration of microcapsule preparation by polymer coating. 
In terms of limitations the same consideration seen in the case of coacervation can be replaced 
here even though slightly higher loading capabilities have been registered (up to 60 %). 
3.1.1.5. Layer-by-Layer method  
Among various methods LBL technique - consisting in an alternate deposition of 
polyelectrolytes with opposite charge – is the only one capable to allow a fine control of the 
thickness at nanometric level (since any layer can be nanometric) and give a multifunctional 
behavior to the capsule. Indeed, with a multilayer system it is possible to embed magnetic (e.g., 
Fe3O4) or plasmonic nanoparticles (e.g., Au) which can be used both for imaging or to determine 
capsule rupture under external stimuli [2]. It is possible to embed biomolecules between layers 
which can be isulated each other. Polyelectrolytes can also bring biomolecules such as DNA, 
small-interfering RNA (si-RNA) and enzymes by conjugation with polymer chain. The outer 
layer can have some modifications for active targeting and or for long circulation capability. Due 
to their charge they can be pH responsive and release their cargo by physiological or external 
induced pH variation [92, 93]. Therefore, there is a huge interest in using LBL nanocapsules in 
the field of drug delivery [94].  
3.1.1.5.1. Layer by Layer on solid templates  
This method was first introduced to deposit polyelectrolyte multi-layers on flat substrates 
(Figure 3.5) [95]. 
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Figure 3.5. Scheme of the layer by layer on flat surfaces. 
As represented in the scheme, LBL technique is based on the absorbtion of a certain number of 
alternate layers of polyelectrolytes of opposite sign (polymers presenting ionic moieties along the 
backbone chain) onto a charged surface. The assembly of the shell is simply led by Van der 
Waals and ionic interactions between functional oppositely charged groups. All the parameters 
affecting polyelectrolyte charge have an impact on the deposition conditions. However, an 
important parameter is the molecular weight of the polyelectrolytes which can determine a linear 
or an exponential growth [96].  
For the realization of nanocapsules this method requires a colloidal template onto which 
polyelectrolytes of opposite charge are alternatively deposited [88]. 
They are typically fabricated using a solid template such as CaCO3 [97, 98], silica [99] and 
mesoporous silica (MSN) nanoparticles, melamine formaldehyde (MF) [93] or polystyrene (PS) 
latex nanoparticles [100] upon which the LbL shell is constructed. The cores can be 
subsequentely dissolved by using the proper solvent like ethylenediaminetetraacetate (EDTA) in 
the case of CaCO3, HCl solution for MF beads or HF/NH4F for silica cores. In the Figure 3.6 it 
is reported a schematic illustration of the LBL method applied on silica template. 
 
Figure 3.6. Production of hollow nanocapsules. 
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Generally, the drug is loaded by swelling holow capsule once varied the permeability of the 
multilayer shell through variations in pH, solvent polarity, ionic strength or temperature. In the 
case of the post-loading method, the necessity of removing the core can determine the damage of 
the constructed capsule or some residual core can remain in the shell toghether with the active 
molecule. For istance, in the case of MF capsule, it is demostrated that there is incomplete 
elimination of melamine formaldehyde oligomers (formed during dissolution) and that they have 
biological incompatibility [101].  
Alternatively, in the case of biocompatible [102, 97] porous inorganic cores such as MSN or 
porous CaCO3, the drug can be pre-loaded inside the porous templates by diffusion, followed by 
the LbL coating. However, adsorption is influenced by diffusion into pores and depends on 
molecular weight of drug. Therefore, loading can be difficult and the amount of drug loaded can 
be insufficient and variable depending on the system conditions.  
The choice of the initial core significantly influences the properties of the capsules such as their 
size distribution and the strategy used for loading the active molecules inside the cavities. In that 
sense, the main advantage of using capsules built up on organic solid cores is that they are 
typically characterized by a good monodispersity, but the capsules synthesized are generally 
bigger than 200 nm [88] therefore bigger than the ones useful in drug delivery especially if 
extravasation is the mechanism exploited for delivery. LBL capsule sizes below 200nm can 
easily be prepared starting from a dispersion of drug crystals [103] or nanoparticles meant to be 
used for therapy by their own as in the case of gold nanoparticles [104].  
3.1.1.5.2. Layer by Layer on liquid templates  
However, a general strategy to obtain LBL nanocapsules with sizes lower than 200 nm and 
down to 100 nm and embedding single drug molecules, instead of crystals, is based on the use of 
a liquid template. In this method the core part of the capsule is made of emulsion droplets (O/W 
emulsion, generally stabilized with surfactants) and the shell is made with the same technique 
[85, 86] The difference is that the core is not removed and the drug can be previously loaded by 
simple mixing with the oil phase or any organic phase immiscible with water solutions and, thus 
the preparation is simpler and there is a major efficiency in drug loading. Moreover, the use of 
emulsion droplets as a liquid core gives the possibility to encapsulate high payloads of oil 
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soluble active molecules. Furthermore, template is not sacrificial therefore there is no need for 
the use of robust synthetic polymers to afford template removal conditions. Natural polymers 
like chitosan, sodium alginate, heparine, ialuronic acids, and so on can be easily used in this 
case.   
Actually, there is no much literature on the use of oil template for layer by layer due to the 
polydispersity and following instability of such templates [105]. However, their development 
could really opens new possibilities for applications in many fields such as the cosmetic, 
medicine, pharmacy and food industries [106-109]. For example, capsules with liquid cores can 
be used in drug delivery systems or as microreactors [110-115]. Liquid core can be chosen 
depending on the type of drug dissolved. Also the choice of surfactant is fundamental, especially 
for stability and further deposition of LbL shell; finally the choice of polymer composing the 
shell is important depending on the administration route and the target environment.  
Considering the above considerations, the main topic of this PhD work was the study of LbL 
nanocapsules on a liquid core.  
3.1.2. Multi-layer cross-linkage 
Biodegradable nanocapsules should be resistant to physiological environment like blood in 
order to survive until reaching target site. In the case of multilayer polymer shell single polymer 
layers are kept together by electrostatic or hydrogen bonds. In literature we can find several 
examples of cross-linking [116, 117] where cross-linking is achieved exploiting the reactivity of 
suitable functional groups inserted on the nanocapsules during their build-up or a as a post-
functionalization process. For example, amide formation with carbodiimide coupling between 
chitosan amine and alginate carboxylates could be realized. In this procedure one of the 
problems is the possible destabilization due to the addition of reactant to the nanocapsule 
suspension. Furthermore additives such as catalysts, coupling agents or functionalizing 
molecules can permeate the layers and contaminate the nanocarriers, bringing problems for 
eventual subsequent applications. So it would be ideal to previously functionalize the polycation 
and polyanion that are forming LbL nanocapsule shell, carefully purifying them from side 
products or unreacted molecules and then use them. Furthermore it would be advisable to create 
a method of cross-linking not too invasive, such as for example photo-cross-linking reaction 
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even better if with no photo-initiator needed. For instance thiol-ene based chemistry was 
proposed as advantageous method for the stabilization and functionalization of polymer capsules 
[118]. This process is photo-initiated, the reaction can be performed at room temperature in the 
presence of oxygen, and the process is environmentally benign. Importantly, this process does 
not require any potentially toxic metal catalyst. Furthermore, the vast array of commercially 
available molecules and biomolecules with either thiol- or ene-functionality makes this a 
powerful technique to introduce functionality.  
Herein, we also decided to exploit a photo-click chemistry reaction based on thio-ene reaction 
between polymer layers. However, compared to literature this reaction has been applied to 
completely biodegradable polymers such as chitosan as polycation and sodium alginate or 
heparin as polyanion. A scheme of this reaction is reported in the following Figure 3.7. 
 
 
Figure 3.7. Scheme odium alginate chemical structure. 
Actually due to the advantage to work on deformable template, we also claim cross-linkage 
could pave the way for the consolidation of certain shape different from sphere. In other words 
while deforming in flow such oil core based nanocapsules polymer multi-layer could be cross-
linked to consolidate such elongated or in general deformed shape. Reaction should be activated 
from the outside and this could be done by photo-activation. Indeed it was shown that spherical 
NPs tend to stay in the center of the capillary blood flow, thus adversely impacting their 
extavasation trough the fenestrations that are associated with the tumor neovasculature as well as 
limiting their ability to recognize specific molecular markers on the tumor-associated 
endothelium. On the contrary, non-spherical shapes facilitate the carrier in its way towards the 
vessel walls with the advantage to promote extravasation and avoid phagocytic cells [119; 33]. 
Moreover, there are some studies showing capability of elongated shapes to better elude RES 
system and enhance the circulation time without any specific surface treatment like PEG-ylation 
[35].  
The general idea was to functionalize chitosan with a thiol group (N-acetylcysteine), firstly 
varying the type of chitosan (low molecular weight chitosan, depolymerised chitosan or glycol 
chitosan) in order to improve the degree of functionalization, and then using sulphur rich 
Chapter III: Natural polymer nanocapsules via Layer
 
chitosan to link covalently with 
allylamine (Figure 3.8). 
 
Figure 3.8. Scheme of reaction between thiolated chitosan and allylamine
Sulfur-rich chitosan are already known to be
For instance, thiolated chitosans were successful
as they are able to form covalent 
chitosan were used for the formation of disulfide bridges 
biodegradable nanocapsule to be used in the field of drug delivery 
3.2. Materials and Methods
3.2.1. Materials 
For the built up of layer by layer nanocapsules on oil core, chitosan as polycation and sodium 
alginate and heparine as polyanions 
previous chapter. Sodium alginate from brown algae (
-by-Layer on oil core templates
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biopolymers like sodium alginate or heparin modified with 
-sodium alginate
 useful for several bio-applications
ly used as mucoadhesive drug delivery system, 
bond with mucus glycoproteine [120]. Moreover
linking chitosan polymer layers of a 
[121].  
 
were employed. Chitosan LMW is the one used in the 
low viscosity, 100-300 cP in 2% solution 
 
 
. 
 by their own. 
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Chapter III: Natural polymer nanocapsules via Layer-by-Layer on oil core templates 
 
84 
 
at 25°C) and heparin (Heparin sodium salt from porcine intestinal mucosa, 17-19 KDa) were 
purchased from Sigma Aldrich. Polyelectrolytes were functionalized in order to obtain 
crosslinkable materials for achieving more rigid and resistant nanocapsules. All the reactions 
were amide formation reaction catalyzed by a water soluble carbodiimide. Reagents like N-
Acetyl-L-cysteine, (NAC, m.w.=163.19 g/mol), 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB) 
(Ellman reagent) (m.w.=396.35 g/mol), allylamine (m.w.= 57.09 g/mol; d= 0.761 g/mL at 25 C), 
1-hydroxybenzotriazole hydrate (HOBt, m.w.= 135.12 g/mol) were purchased from Sigma 
Aldrich, wherease N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC·or 
the same EDC, m.w. =191,70 g/mol) was purchased from Thermo scientific. All reagents were 
used without further purification except chitosan used for LbL that needed to be purified as 
described above. Glycol chitosan, purchased from Wako Chemicals, was also tested to improve 
the degree of modification of chitosan. To evaluate multilayer cross-linkage, modified polymers 
were deposited on carboxyl latex (4% w/v 0.1 µm) purchased from Invitrogen. Photo-reaction 
was tried with no photoinitiator but also for comparison in presence of a photoinitiator like 
Irgacure 2959 purchased by Ciba Specialty Chemicals. Dialysis Membranes were purchased 
from Spectrum Laboratories Inc. Finally, to purify secondary emulsions from the excess of 
polymer and make possible further deposition of polymer layers, magnetic carboxilate 
nanobeads, purchased from TurboBeads, were used. 
 
Sodium alginate is a natural polymer, extracted from marine brown algae and consists of 
linear chains of α-L-guluronic acid and β-D-mannuronic acid residues joined by 1,4-glycosidic 
linkages (Figure 3.9). 
 
 
Figure 3.9. Sodium alginate chemical structure. 
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It can be cross-linked using calcium chloride, with formation of insoluble calcium alginate 
particles on a nanometer scale depending on the concentrations of sodium alginate and calcium 
chloride. Low stability and loss of encapsulated materials have been observed with capsules 
formed by an alginate polymer, but these problems can be overcome by using cationic polymers 
such as chitosan covering the alginate layer [122]. 
 
Heparine is a natural polysaccharide being major component of extracellular matrix (ECM), 
is a negatively charged linear glycosaminoglycan (GAG) consisting of repeated sulfated 
disaccharide [123]. It is also known to have diverse biological functions such as anti-coagulation, 
anti-inflammation, anti-angiogenesis, and anti-tumor cell proliferation. For metastatic cancer 
cells, heparanase and heparinase, which degrade heparine, are overexpressed in the ECM. Its 
chemical structure is reported in Figure 3.10. 
 
 
Figure 3.10. Heparine chemical structure. 
Being negative charged it can be used as polyanion in the build up of layer by layer polymer 
films as demonstrated in the case of a flat substrate [124]. 
 
Magnetic carboxylated nanobeads are highly magnetic nanoparticles with diameters of 
below 50 nm. The surface of the particles is covalently functionalized with carboxyl groups (> 
0.1 mmol/g) and can be used for further functionalization and for the recovery of chemical and 
biological compounds from complex mixtures. The stock magnetic nanobeads concentration 
used to perform tests was 3%. 
  
Glycol chitosan is a derivative of chitosan. While chitosan has demonstrated 
biocompatibility, its usage is limited by its poor water solubility. glycol chitosan, chitosan 
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conjugated with ethylene glycol, is water soluble at the entire pH ranges and, at the same time, it 
retains its positive charge at physiological pH values [125, 126] (Figure 3.11). 
 
 
Figure 3.11. Chemical structure of glycol chitosan. 
Due to its positive charge it was already used in the layer by layer alternated with bovine serum 
albumin (BSA) to be applied for protein delivery [127]. 
3.2.2. Methods 
3.2.2.1. Chitosan depolymerization and molecular weight determination 
During this work there was a need to reduce the molecular weight of chitosan both to improve 
deposition capability in the LBL (from the third layer on) and try to improve solubility thus 
degree of modification with NAC. The method chosen for chitosan de-polymerization was based 
on NO2 de-polymerization reaction, which is fast and can be conducted in mild conditions. 
Furthermore, with this method it is possible to easily control the degree of de-polymerization of 
the polymer by choosing the appropriate D-glucosamine/NaNO2 molar ratio and temperature at 
which reaction is conducted. By controlling the degree of de-polymerization it is possible to 
obtain a wide range of chitosans with different molecular weights (Figure 3.12) [128, 129].  
 
 
Figure 3.12. Scheme or chitosan de-polymerization reaction by means of HNO2 FITC calibration line for 
determination of chitosan-FITC degree of functionalizaton. 
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500 mg of chitosan LMW were dissolved gradually in 25 mL of HCl 1 M at room temperature. 
Dissolution was brought to completion by adding slowly the samples to solution under stirring. 
All chitosan solutions were heated at 50°C and this temperature was kept stable during all the 
reaction time. Different amounts of NaNO2 were added in order to obtain chitosan with different 
molecular weights. After 45 minutes the solution was cooled at room temperature and a mixture 
of MeOH/NH3 (7:3) was added gradually until basic pH (pH=10) was reached to allow the 
precipitation of de-polymerized polymers. The solution was then filtrated with a Buchner funnel 
and washed with MilliQ water until reaching neutrality. Chitosan was recovered and freeze-dried 
for 48 h. In particular, 4 different D-glucosamine/NaNO2 molar ratios were tried: 
- 1,725 mg of NaNO2 molar ratio CT/NaNO2 0.0031118/2,500x10-5 
- 4,3 mg di NaNO2 molar ratio CT/NaNO2 0.0031118/6,2319x10-5 
- 9,7 mg di NaNO2 molar ratio CT/NaNO2 0.0031118/1,4058x10-4 
- 17,25 mg di NaNO2 molar ratio CT/NaNO2 0.0031118/2,5x10-4 
The molecular weight of each sample was measured by viscosimetry, according to literature 
[130]. Specific viscosities of chitosan LMW and de-polymerized chitosan in 2% HAc/0.2M 
NaAc were measured using an Ubbelohde capillary viscometer at a controlled temperature (25 ± 
0.01 °C) in a water bath. From these measurements it was calculated the molecular weight of five 
different samples by using the Mark-Houwink equation. The details are reported in the Appendix 
(A.E.7) (see also Figure A.E.5) as well as the results of the different molecular weights 
corresponding to the different concentrations of NaNO2 (Table A.E.4). 
3.2.2.2. Layer by Layer on saturated secondary NEs 
For the layer by layer, both sodium alginate and heparin were used as polyanions with heparin 
behaving better in terms of deposition. For the first layer, we started from secondary emulsions 
with an oil concentration of 1% wt and a chitosan concentration of 0.01% wt (L1 and L4 were 
chosen as template). These secondary emulsions were re-dispersed at least once through the 
high-pressure homogenizer for 100 continuous steps at a pressure of 700 bar before further 
deposition according to the process described in Chapter II.  
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Case of sodium alginate as polyanion: For second layer deposition, secondary emulsion was 
diluted 1:2 with a solution of alginate dissolved in MilliQ water. In particular, secondary 
emulsion was added to the polyelectrolyte solution under stirring for 15 minutes. The same 
procedure was adopted for third layer deposition where the previous bi-layer suspension was 
diluted 1:2 with a solution of chitosan dissolved in a solution of chitosan dissolved in MilliQ 
water at pH 4. Both bi-layers and three-layers oil core based nanocapsules were passed, after one 
day from deposition, in the Microfluidizer for 100 steps at 850 bars. All the LbL nanocapsules 
were stored at room temperature. 
 
Case of heparin as polyanion: The second layer was deposited after one day, by preparing a 
solution of heparin in Milli-Q water and using this solution to dilute the secondary emulsion 1:2. 
The tri-layer was prepared by depositing, after one day, chitosan dissolved in an acetic acid 
Milli-Q water solution (pH 4, 20 mM) and using this solution to dilute the dispersion again 1:2. 
This time bi-layer did not need any passage through the high pressure homogenizer. For the tri-
layer in order to keep monodispersion with no re-dispersion processes, it was used a chitosan 
with a lower molecular weight, chitosan-B (17 kDa), obtained by using the previous described 
de-polymerization process. Then, it was also demonstrated the capability to produce multi-layer 
up to five layers by alternating chitosan-B and heparine with the same dilution and using again 
Milli-Q water for heparine and acetic acid Milli-Q water solution for chitosan (pH 4, 20 mM). 
3.2.2.3. Layer by Layer on ultra-stable secondary NEs 
As seen in the previous chapter, it was possible to produce ultra-stable secondary emulsions by 
implementing an optimized re-dispersion process in combination with high concentrations of 
polymer. In these conditions, due to the excess of polymer in solution further deposition of 
polymers by means of the layer by layer method is prevented. However we developed a method 
to purify and deposit on ultra-stable emulsions. 
 
Secondary emulsions purification: To purify emulsions from the excess of chitosan LMW a 
new fishing-based method was established. It consists in the use of 30 nm magnetic and 
carboxylated beads. Particularly, starting from a stock dispersion at 3 % w/v of beads in water 
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solution it was diluted at different concentrations and mixed in the same amount of volume with 
the secondary emulsion (chitosan ratio with oil 0.1:1) with a stirrer for 30 min at 1500 r.p.m. to 
allow the chitosan polymer in solution to cover the magnetic nano-beads. The mixture was then 
moved in an eppendorf and kept in a magnetic rack overnight in order to separate magnetic nano-
beads covered with chitosan from the secondary emulsion. At the end, to check the absence of 
magnetic nano-beads in the secondary emulsion a centrifugation step was performed. The 
secondary emulsion was centrifuged for 30 min at 13000 r.p.m., at a temperature of 25°C and no 
magnetic nano-beads were noticed. Moreover, the right amount of nano-beads was also 
evaluated by carrying out a DLS analysis on the purified chitosan, by monitoring capability of 
bi-layer deposition, as well as by energy dispersive x-ray (EDX) spectroscopy analysis of 
lyophilized samples to check the chemical composition of the system. 
 
Multilayer deposition: A second layer of Heparine was deposited on the secondary emulsion, 
and again chitosan was finally deposited as third layer. For the first layer we started from an oil 
concentration of 1% wt (L1 and L4 were chosen as template) and an excess of chitosan 
concentration of 0.1% wt. After double processing and purification, heparin was deposited at 
different concentrations to first verify capability to deposit, which was instead prevented with no 
purification and then to identify right concentration. After few hours a tri-layer was prepared by 
depositing reduced molecular weight chitosan (chitosan-B) at different concentrations to verify 
again deposition capability. Then, preliminary penta-layers were also obtained by alternating 
chitosan-B and heparine with the same dilution (1:1) and using again Milli-Q water for heparine 
and acetic acid Milli-Q water solution for chitosan (pH 4, 20 mM). 
3.2.2.4. Chitosan modification with N-Acetylcysteine 
Low molecular weight, depolymerized and glycol chitosan were used for modification with N-
Acetylcysteine. Their de-acetylation degrees determined with nuclear magnetic resonance 
(NMR) experiments were 84%, 84.5, 87.5 % respectively. For modification reaction 0.5 mM of 
chitosan was dissolved in 10 mL of MilliQ water. Variable amounts of HOBt (Table 3.6) were 
added and pH was adjusted to a value of 4 with HCl 1 M to allow complete dissolution in the 
case of low molecular weight and chitosan-B. Then, different amounts of NAC and EDC (Table 
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3.6) were added to the solution. The pH was adjusted and maintained to a value of 5 for all the 
reaction (3h, RT). Samples were dialyzed (dialysis tubing of 12-14 kDa c.o.; 4 cycles of 1% 
NaCl at pH 3 solution and 4 cycles without NaCl with a HCl pH 3 solution; 3 h each dialysis 
cycle) and freeze-dried for 48 h.  
EDC is a common coupling agent used to form an active ester with cysteine. Indeed, the 
byproduct of the reaction between this ester and the amine group of the chitosan is the urea 
which is a good leaving group. However, the ester group could react with water forming acilurea 
subtracting NAC to the reaction therefore HOBt is used to form a less reactive ester which react 
with the amine group of chitosan with higher probability.  
 
Ellman test for free thiols groups. 2 mg of each chitosan-NAC sample were weighted and 
dissolved in 0.5 ml of acetic acid solution at pH 3. After partial or complete dissolution with 
sonication, 3.5 ml of a solution of DTNB in a buffer phosphate solution at pH 8.03 (0,2 mg/ml) 
were added and the reaction was allowed to proceed in the dark at room temperature for 2 h 
under magnetic stirring. The final pH was 7.4. Absorbance values of TNB2- were registered at 
412 nm. The TNB2- and so the sulfhydryls groups concentration were determined by means of a 
calibration line constructed in the same conditions by allowing the reaction between standard 
amounts of free N-acetyl-L-cysteine with DTNB. ε of TNB- was 12,7·104.  
3.2.2.5. Sodium alginate and heparine modification with Allilammine 
Heparin (100 mg, 0.150 mmol of –COOH groups) or sodium alginate (100 mg, 0.505 mmol) 
was dissolved in 10 ml of MilliQ water. After complete dissolution Allylamine (112.5 µl, 1.5 
mmol) was added to the solution and pH adjusted to a value of 6.8. Then, HOBt (81.22 mg, 0.6 
mmol) and EDC (115.2 mg, 0.6 mmol) were added. The pH was adjusted again to 6.8 and 
maintained to this value for all reaction time (6h, RT). Samples were finally dialyzed (with 
dialysis tubing of 6-8 kDa c.o.; 4 cycles of 1% NaCl and 4 other cycles with MilliQ water) and 
freeze-dried for 48 h. Preliminary tests of sodium alginate functionalization with allylamine were 
conducted to optimize the procedure and they are reported in the Appendix (Table A.E.5). 
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3.2.2.6. NMR spectroscopy 
Modified chitosans and alginates structures were investigated by NMR technique using a 
Bruker 600 MHz NMR spectrometer. The experiments were run at 25°C; D2O with 1% TFA was 
used as solvent for thiolated and unmodified chistosans while modified and unmodified alginate 
samples were dissolved in D2O.  
3.2.2.7. Cross-linkage tests on modified multi-layer 
Click chemistry reaction was first demonstrated on modified chitosan in contact with 
allylamine and finally between modified polymers.  
In the first case 8 mg of thiolated glycol chitosan were dissolved in 2 ml of acetic acid 0.1 M, 
pH 4, in a flask or in a beaker. Then 2.5 µl of allylamine and in some cases 3.6 mg of 
photoinitiator were added. Finally half sample was irradiated under stirring with UV light at 365 
nm or 254 nm using a UV Hand Lamp (Spectroline® E-Series UV lamp, output 6 W) fixed at a 
distance of 3 cm or a High Intensity Lamp (Blak-Ray® UV, Ultraviolet Lamp with Spot Bulb, 
output 100 W) fixed at a distance of 10 cm equipped with a water bath to avoid overheating. 
Some tests were conducted under nitrogen. After 2 hours of irradiation the reduction of thiol 
group amount, respect to the not irradiated sample, was determined using the Ellman’s test on 
both samples and making the subtraction. 
In the second case, to easily see and quantify the reaction effectiveness, modified polymers 
were deposited on PS NPs with sizes similar to that of the emulsions (100 nm) but more easily 
manageable. First, 10 ml of a water dispersion of PS NPs (0.5 % w/v) were added, under 
vigorous stirring, to 40 ml of a solution of glycol chitosan (0.032 % w/v) in acetic acid (20 mM). 
After 15 minutes the stirring was stopped and the solution processed through a high pressure 
homogenizer (Microfluidics M110PS) at mild conditions (600 bar, 100 steps, 4°C) to improve 
PDI value. Then, 25 ml of a water solution of heparin (0.05% w/v) under vigorous stirring were 
added to 25 ml of monolayer solution (0.1% PS microspheres; 0.0256% glycol chitosan). After 
15 minutes the stirring was stopped and the product measured by DLS in the usual conditions. 
To evaluate photo-reaction between layers, the solutions were concentrated to 2 mL by 
centrifuge (13000 rpm, 10 minutes, 4 °C), re-dispersed in water and sonicated (10 minutes, 40 
MHz, 50 % of power, 4 °C). 1 mL of solution was irradiated with UV light for 2 h, while 1 mL 
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was stored at room temperature for 2 h, in presence of natural light and atmospheric oxygen. 
Then 0.5 mL of each sample was added to a solution containing Ellman’s reagent, according to 
Ellman’s test shown above. After 2 h, each sample was centrifuged (13000 rpm, 15 min) and 
supernatant was collected for UV measurement.  
3.3. Results and Discussion 
3.3.1. Layer by Layer on saturated secondary NEs 
On secondary emulsions with no significant excess of polymer it was demonstrated the 
capability to grow a polymer multilayer by keeping monodispersion feature. In particular, it was 
used the LBL method by exploiting the positive feature of the secondary emulsions. As 
polyanion alternating to the chitosan they were used both sodium alginate and heparin as said. In 
particular we observed a much more control in the deposition of the heparin. Indeed, with 
sodium alginate it was needed a re-dispersion process to re-gain monodispersion while with 
heparin, once found the right concentration such a process was not needed. For the first layer, we 
started from secondary emulsions with an oil concentration of 1% wt and a chitosan 
concentration of 0.01% wt. This chitosan concentration was chosen for several reasons. First at 
0.01 % wt Z-potential was switched and almost completely saturated meaning a high coverage 
level to further deposit the polyanion. Moreover, in terms of spectrofluorimeter analysis this 
concentration was approaching the emission peak (at 0.175 % wt) which we associated to the 
saturation concentration. Finally, testing concentrations above 0.01% as starting point for further 
depositions usually there was a worse PDI or even a second peak for higher and higher 
concentration meaning aggregation due to a significant excess of chitosan in solution.  
3.3.1.1. Case of sodium alginate as polyanion  
As described in materials and methods section for second layer deposition, after the dilution 1:2 
of the secondary emulsion with the solution of alginate dissolved in MilliQ water, it was needed 
to pass the bilayer in the Microfluidizer for 100 steps at 850 bars. The same happened after the 
deposition of the chitosan as third layer. In terms of polymer concentrations we started from a 
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secondary emulsion at a concentration of chitosan of 0.01 % wt. This monolayer was mixed with 
a solution of sodium alginate with the same concentration 0.01 % wt identified as good 
concentration. Indeed, previous attempts of using different chitosan/sodium alginate ratios (1/3; 
1/2; 1/5; 5/1 3/1) brought to quick destabilization. Finally, the bilayer system with a final 
concentration of sodium alginate of 0.005 % wt was mixed with a chitosan solution at a 
concentration of 0.005 % wt and this allowed complete switching of Z-potential. In Figure 3.13 
it is reported the DLS of a final tri-layer obtained as described.  
 
 
Figure 3.13. DLS of the final tri-layer with chitosan (monolayer) sodium alginate (bilayer) and chitosan (trilayer). 
The final trilayer was monodisperse (size 196.5 nm and PDI 0.106) and with a positive Z-
potential positive, as expected, and equal to 50 mV. Due to the labeling of the third layer with 
FITC it was also possible to perform a STED analysis as reported in the Figure 3.14. 
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Figure 3.14. STED image of final tri-layer with chitosan (monolayer) sodium alginate (bilayer) and chitosan-
FITC(trilayer). Scale bar is 2 µm.  
Even after few days the trilayer kept is monodispersion feature and the size was around 180nm 
therefore in agreement with DLS. 
3.3.1.2. Case of heparin as polyanion 
To optimize the deposition of the second layer different heparin concentrations were tried. 
Starting from L1 based secondary emulsion template and from a heparin stock solution 0.27 % 
wt in Milli-Q water, different dilutions were tried as schematized in the Table 3.1. In particular, 
after mixing heparin and secondary emulsion (as said 1:1), the bi-layer with lower heparin 
concentration (Bi 5) demixed very soon. Instead the other samples were all stable over time, with 
PDI below 0.1 and with stabilities increasing with the concentration of heparin. Therefore it was 
chosen Bi 4 in order to have the minimum amount of free heparin in solution and considering 
that it was anyway stable over few days thanks to the almost complete switching of the Z-
potential. 
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Heparin code 
Heparin  
% wt 
Heparin  
% wt 
Chitosan  
% wt 
Z-pot 
bilayer (mV) 
Size 
bilayer (nm) 
PDI 
bilayer 
before mixing After mixing 
Bi 0 0.27 (No dil) 0.0135 
0.005 
- 39.2± 6.54 196.9 0.041 
Bi 1 0.135 (dil. 1:2) 0.0675 -31.7± 6.99 200 0.04 
Bi 2 0.09 (dil. 1:3) 0.045 -33±7.01 193.7 0.06 
Bi 3 0.054 (dil. 1:5) 0.027 -27.4± 6.01 211.4 0.092 
Bi 4 0.027 (dil. 1:10) 0.00135 -28.9±5.96 200 0.077 
Bi 5 0.02(dil. 1:27) 0.01 Aggregates 
Table 3.1. Summary of the heparine concentrations tried on L1 based secondary emulsions at 0.01 % wt of 
chitosan. Results are referred to samples just after mixing. Starting template was 180nm (around 20nm more 
than usual being few months old). 
To optimize tri-layer preparation on Bi 4 as bilayer, the same procedure was used to find the 
best chitosan concentration as tri-layer. In particular, it was used a stock solution of chitosan 0.27 
% wt in acetic acid Milli-Q water (pH 4, 20 mM) and it was diluted at different concentrations 
by using the same solution (pH 4, 20 mM) as shown in the Table 3.2. In this table DLS results 
related to the different tri-layers built up with chitosan LMW and chitosan-B are also reported.  
 
Heparin 
code 
Chitosan  
% wt 
Chitosan  
% wt 
Heparin  
% wt Chitosan LMW Chitosan-B 
before mixing After mixing 
Tri 0 0.27 (No dil) 0.0135 
0.00675 
(= B4) 
Size=298.6 nm Size=218.4 
PDI=0.204 PDI=0.080 
Z-pot=68.2±5.2 mV Z-Pot=52.3±6.03 mV 
Tri 1 0.135 (dil. 1:2) 0.0675 
Size=216.5 nm Size=214.5 nm 
PDI=0.115 PDI=0.059 
Z-Pot=49.8±7.11 mV Z-Pot=45.1 mV±6.23 
Tri 2 0.09 (dil. 1:3) 0.045 
Size=244.5 nm Size=216.3 nm 
PDI=0.151 PDI=0.063 
Z-Pot=57.1±6.30 mV Z-Pot=46.03±6.07 mV 
Tri 3 0.054 (dil. 1:5) 0.027 
Size=212.4 nm Size=206.3 nm 
PDI=0.064 PDI=0.058 
Z-Pot=46.9±7.33 mV Z-Pot=44.5±5.92 mV 
Tri 4 0.027 (dil. 1:10) 0.00135 Aggregates 
Size=218.1 nm 
PDI=0.070 
Z-Pot=42.5 ±5.73 mV 
Tri 5 0.02(dil. 1:27) 0.01 Aggregates 
Table 3.2. DLS results for tri-layer deposition both in the case of chitosan and chitosan-B. 
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From the comparison between chitosan LMW and chitosan-B it is evident how the lower 
molecular weight behaves better for each concentration. In the case of chitosan LMW only the 
sample Tri 3 is acceptable. On the contrary for chitosan-B it is possible to use concentrations of 
polymers ranging from Tri 4 to Tri 1. In particular, in the case of further deposition we used for 
chitosan-B the minimum acceptable concentration (Tri 4) whereas in the case of samples to be 
tested as their own we used the concentration Tri 3 which guaranties more stability over time.  
By making similar tests on smaller secondary emulsions, in particular on L4 there was no 
acceptable concentration of chitosan LMW therefore in this case it was just used chitosan B. As 
an example, Table 3.3 reprot the DLS results of a trilayer where as heparin it was used the 
concentration of 0.0276% wt (Bi 4) and as trilayer chitosan-B at the concentration of 0.0552% 
wt (Tri 3). 
 
 Emulsion Monolayer Bilayer Trilayer 
 Size 
(nm) 
PDI Z-pot 
(mV) 
Size 
(nm) 
PDI Z-pot 
(mV) 
Size 
(nm) 
PDI Z-pot 
(mV) 
Size 
(nm) 
PDI Z-pot 
(mV) 
L4 98 0.069 -49 105 0.107 +25 110 0.116 -27 126 0.125 +38.6 
Table 3.3. Summary of the size, PDI and z-potential of a complete tri-layer on L4. 
DLS results reported in the above table confirm a satisfying control on size and PDI.  
In this trylayer, last layer of chitosan was labeled with FITC and the oil was pre-loaded with 
NR as a lipophilic model drug, in order to perform a fluorescence confocal and STED analysis as 
shown in Figure 3.15.  
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Figure 3.15. In fluorescence analysis of a trilayer made of CT-Heparine-CTB-FITC on L4 oil droplets. 
The image confirms the formation of the tri-layer, as demonstrated by the matching of the two 
colors, green from FITC and red from NR, as well as its loading capability without affecting the 
monodispersion feature of the nanocarrier itself. 
Preliminary tests were also carried out to obtain capsules made of pentalayers. In the following 
Table 3.4 the concentrations of the polyelectrolytes used to build up pentalayers are reported. In 
Figure 3.16 it is instead reported the DLS analysis from a monolayer to a pentalayer in the case 
of L1 based template prepared following the concentrations listed in the table.  
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Layers Oil CT-LMW Hep CT-B Hep CT-B 
Mono 1 0,01     
Bi 0.5 0.005 0,0138    
Tri 0.25 0.0025 0.0069 0,0138   
Tetra 0.125 0.00125 0.00345 0.0069 0.019  
Penta 0.0625 0.000625 0.00172 0.00345 0.0095 0.019 
Table. 3.4. Summary of the final optimized concentrations in % wt for each layer. 
 
Figure 3.16. DLS analysis from mono to pentalayer built up on an L1 based primary emulsion. 
It is possible to see the monomodal feature of all oil core based nanocapsules from single to 
pentalayer. In terms of monodispersion there is an increase of the PDI with the addition of more 
and more layers (up to 0.14 for pentalayer). However, by playing with polymer molecular weight 
it is expected to further optimize monodispersion also in the case of high layers number. 
3.3.2. Layer by Layer on ultrastable secondary NEs 
Layer by layer polymer nanocapsules are typically prepared by starting from solid templates for 
two reasons that are the lack of monodispersion and stability of oil templates which instead we 
were able to obtain by choosing optimal formulation and process. In the previous paragraph 
multi-layer depositions were made on secondary emulsions characterized by a saturation 
concentration of the polymer which indeed does not guaranty stability over time. In this section 
we demonstrate that it is possible to use also the ultrastable secondary emulsions to build up 
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layer by layer nanocapsules. To do that the excess of polyelectrolyte used for the stabilization of 
the droplets was properly removed by implementing a nano-beads mediated fishing procedure. 
This procedure was also originally developed in this work and it was made possible thanks to the 
monodispersion of the starting secondary emulsions. A scheme of this method is reported in 
Figure 3.17. 
  
 
Figure 3.17. Scheme of the Layer by Layer on pre-loaded liquid template by means of  a nano-beads mediated 
fishing procedure to purify secondary emulsions. 
As said secondary emulsions stability was only possible with an excess of polymer in solution 
preventing the deposition of the successive layer. Differently from solid templates secondary 
emulsions cannot be purified by filtration and centrifugation due to their delicacy. Not even 
dialysis is feasible mainly due to the charge of polymer and emulsion involved. Anyway, 
monodispersion feature of our product allowed us to carry out an effective purification by 
developing a nanobeads-mediated fishing procedure. It is worth noticing that without purification 
there was no way to deposit any concentration of negative polyelectrolyte even diluting 
secondary emulsions due to the excess of chitosan in solution while after purification LBL was 
again possible. 
In particular, for purification we used 30 nm magnetic beads which are carboxilated on the 
surface therefore exhibiting an opposite charge compared to the one of the chitosan thus making 
possible fishing. This method was successfully proved on the biggest and the smallest secondary 
emulsions with an excess of chitosan (0.1 % wt). We started from a stock dispersion of magnetic 
beads at a concentration of 3 % w/v. Generally to not waste too many beads we worked in 
dilution conditions. Specifically, the secondary emulsion was diluted 10 times with acetic acid 
solution 20 mM (from 1 % wt of oil and 0.01 % wt of chitosan to 0.1 % wt of oil and 0.01 % wt 
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of chitosan) whereas the dispersion of magnetic nanobeads was first diluted to 1 % w/v and then 
a volume between 180 to 60 µl (at 1 % w/v) of such nanobeads was mixed to the previous 
secondary emulsion. The objective was to identify the right amount of purifying nanobeads in 
order to obtain a good DLS on the purified secondary emulsion, capability to deposit second 
layer and no significant beads residue. The first two conditions were obtained for the entire 
interval in the case of L1 whereas for L4 the right interval resulted between 180 a 75 µl of beads 
(at 1 % w/v). In Table 3.5 DLS results of monolayers after purification are reported for the 
extreme of such range for both L1 and L4 based secondary emulsions.  
Then, for the deposition of the heparin different concentrations were tried and the best found 
was a concentration of around 13 times the one of the first layer of chitosan. Infact, lower 
concentrations presented a high PDI whereas higher concentrations did not allow chitosan 
deposition. In previous experiments of layer by layer on secondary emulsion at 0.01 % wt of 
chitosan the ratio between heparin and first layer of chitosan was 2.76 times therefore 5 times 
less than here. In other words, in previous case we started from a concentration of heparin of 
0.027 % wt (with the first layer of chitosan at a concentration of 0.01 % wt) whereas here we 
needed five times this concentration divided by 10 times due to the dilution we said previously to 
avoid wasting of beads (0.027x5/10=0.0135 % wt). We attributed this difference to a higher 
coverage of oil droplets with chitosan in the case of purified secondary emulsions which indeed 
required higher heparin to completely switch surface charge. Final heparin concentration after 
mixing with secondary emulsion was therefore 0.0069 % wt.  
After heparine coating it was deposited a third layer of chitosan-B. In particular, the optimal 
concentration of chitosan was 5 times the one of the heparin (5 x 0.0069 = 0.0345). The DLS 
results of these depositions are also summarized in Table 3.5.  
 
 Beads Monolayer Bilayer Trilayer 
 
µl 
(1 % w/v) 
Size 
(nm) 
PDI 
z-Pot 
(mV) 
Size 
(nm) 
PDI 
z-Pot 
(mV) 
Size 
(nm) 
PDI 
z-Pot 
(mV) 
L1 
180 183.1 0.081 31.4 179.4 0.062 -29 207 0.085 42 
60 189.6 0.112 28.1 190.4 0.097 -27.6 214 0.093 25 
L4 
180 92.7 0.077 42.4 92.7 0.099 -35 115.9 0.123 36 
75 96 0.095 26 99 0.095 -29 121 0.124 32.1 
Table 3.5. DLS results for trilayer deposition on both L1 and L4 purified secondary emulsions. 
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In the above experiments, last chitosan layer was labeled with FITC in order to perform a 
STED analysis while the oil was pre-loaded with NR in order to check loading capability. In 
Figure 3.18 the STED analysis on the L4 based (Figure 3.18.A) and L1 based (Figure 3.18.B) 
trilayers are reported. 
 
(A) 
  
(B) 
Figure 3.18. Trilayers on L4 (A), L1 (B) secondary emulsions for purified samples (75, 60 µl beads respectively). 
STED analysis, in agreement with the DLS measurements, proves the monodispersion feature 
of the developed nanocapsules on both the sizes as well a perfect match between the bright red 
fluorescence of the NR with the bright green fluorescence of the chitosan-FITC. This analysis 
confirms from one side the formation of the tri-layer being only the last layer labeled with FITC 
and that all the nano-droplets containing the lipophilic drug model are covered by the tri-layer. 
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Also in this case, regarding the loading aspect it is worth noticing how the presence of the NR 
did not affect the behavior of the emulsion in terms of size, PDI and templating capability. 
For what concerns the dilution it is worth noticing that it did not affect the procedure since with 
no dilution of the secondary emulsion, purification results were confirmed (see Table A.E.5 in 
the Appendix).  
Instead, in terms of possible magnetic beads residue it was verified by EDX spectroscopy 
analysis that by lowering enough the amount of beads useful for separation it is possible to keep 
it negligible (see Appendix, Table A.E.6).  
However, apart from the magnetic nano-beads mediated fishing and purification the important 
thing to remark was the demonstration for the first time of the capability to use an ultrastable 
emulsion as template to deposit on it once properly purified. That means it is possible to store 
liquid templates for months and use them whenever needed, like in the case of solid templates, to 
build up nanocapsules. This was made possible due to monodispersion feature of our emulsion 
which can guaranty purification by keeping monodispersion and therefore further deposition 
with low PDI. Nowadays, more and more sophisticated separation systems are being developed 
also on large scale thus making purification and use of such emulsions scalable at an industrial 
level.  
3.3.3 Multi-layer cross-linkage 
3.3.3.1. Chitosan modification with N-Acetylcysteine  
In this work it was tried to find the best conditions to improve the degree of functionalization of 
chitosan without preventing the solubility of the final product, also varying the type of chitosan 
used (de-polymerized and glycol chitosan). In particular, as anticipated in the methods section 
chitosan was modified with NAC as reported in Figure 3.19.  
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Figure 3.19. Scheme of chitosan reaction with NAC and final chemical structure. 
Analysis of modification degree of chitosan with NAC by Ellman test 
To evaluate the degree of chitosan modification with NAC it was preliminarly carried out an 
NMR analysis. Even though it was possible to observe the appearance of a peak at 2.73 ppm 
associable to CH2-SH group, another peak partially overlaid with peaks of chitosan in the range 
between 3.00 and 3.40 ppm and a peak at 4.50 that could be assigned to the anomeric proton H1 
of NAC-functionalized units, it was not simple to determine degree of functionalization by NMR 
analysis. Indeed, the absence of well resolved new peaks did not allow such determination. It 
was therefore decided to use a well established colorimetric test, the Ellman’s test, in order to 
calculate the amount of thiol groups present.  
In this method Ellman reagent (DTNB) reacts with free thiols in slightly basic solution in a 
thiol-disulfide interchange reaction (Figure 3.20). 
 
 
Figure 3.20. Scheme of the reaction between Ellman reagent and free thiols. 
TNB2- absorbs light in the UV-Vis range, with a maximum of absorbance at 412 nm. TNB2- 
formation can be used to assess the number of thiols present due to the stoichiometry of thiolated 
chitosan to TNB2- formed which is 1:1. So it was calculated a calibration line fot TNB2- using 
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precise amounts of NAC in order to generate known amounts of TNB2-. An ε value of 10320 M-1 
cm-1 was calculated (see Appendix Figure A.E.6) by following the method reported in literature 
[131]. It is noteworthy that this test underestimates the degree of functionalization, determining 
only free and accessible thiols. However, free thiols are the ones involved in the final cross-
linking reaction and thus useful to be evaluated. As an example in the Appendix (Figure A.E.7) 
it is reported a spectrum of absorbance of modified glycol chitosan from which it can be possible 
to quantify TNB2- content, therefore modification degree. 
It is important to underline that primary amine groups are crucial for solubilisation of chitosan 
in water and, consequently, for the degree of thiolation. Indeed, an increase of thiol groups 
determines the insolubility of the polymer in water as it is reported and as we noticed [132].  
The degree of functionalization, determined by Ellman test, for some selected chitosan samples 
with corresponding reaction formulations are reported in Table 3.6. 
 
Polysaccharide HOBt:Chitosan:NAH:EDC Free thiols % 
Chitosan LMW 1:1:4:8 2.2 
Chitosan LMW 1:1:4:16 4.3 
Chitosan-B 1:1:4:16 4.8 
Glycol Chitosan 1:1:4:16 13.2 
Table 3.6. Determination of degree of functionalization using Ellman’s test. 
In the case of chitosan LMW by increasing the EDC amount it was possible to increase 
modification degree up to 4 %. With chitosan B at the same reaction conditions the % of free 
thiol was only slightly increased. However, in the case of glycol chitosan, there was a significant 
enhancement of modification and this kind of modified chitosan, also called glycol chitosan 
NAC, was therefore used for all the click reactions tests described in paragraph 3.3.3.3. 
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3.3.3.2. Degree of functionalization by NMR analysis for allylated polyanions  
Allylated Sodium alginate  
As said in the materials and methods section of this chapter, sodium alginate was 
functionalized with allylamine. The scheme of reaction and the final structure of the modified 
polymer is reported in the following Figure 3.21. 
 
  
 
 
 
 
Figure 3.21. Scheme of alginate allylamine functionalization. 
Degree of functionalization of alginate was determinated by NMR spectra. In particular, tests at 
different molar ratios between polymer, EDC, HOBt and allylamine were conducted to identify 
an optimal degree of functionalization (see Appendix Table A.E.7) choosing at the end the 
procedure reported in the materials and method section. 
Comparing NMR spectrum of allylated alginate and non allylated alginate (Figure 3.22) it can 
be seen that two signals appear, corresponding to allylic group: the signals at 5.85 and 5.15 ppm, 
corresponding respectively to CH and CH2 protons of terminal olefin. Between these two peaks 
only the one at 5.85 results not overlapped. Therefore, by integration of the peak at 5.85 and and 
the region between 3.3 and 4.3, related to 5 protons of glucuronic or mannuronic units, it was 
possible to estimate the degree of functionalization that was ∼71 %.  
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Figure 3.22. Offset 1H NMR spectra of sodium alginate and allylated alginate (on top) in D2O.
Allylated Heparin 
The same considerations done for alginate functionalization are also valid for heparin 
functionalization. As shown in F
terminal olefin that results not overlapped with heparin signals. So by integration of this peak 
and the region between 3.00 ppm and 4.40 ppm, related to 10 protons 
glucosamine units, it was possible to determine the degree of functionalization that is 80.0 %.
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igure 3.23 there is a signal at 5.84 ppm related to CH proton of 
 
 
 
of iduronic and 
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Figure 3.23. Offset 1H NMR spectra of heparin sodium salt and allylated heparin (on top) in D2O.
3.3.3.3. Cross-linkage results
In order to demonstrate the appl
was first chosen to optimize the reaction conditions (pH, wavelength, exposition time to light, 
etc.) carrying out the thiol-ene photo click reaction 
polyelectrolyte with higher degree of functionalization) and 
 
 
 
Figure 3.24. Scheme of reaction between modified 
To assess the successful of click reaction the reduction of free thiol was determined
Ellman’s test. In Table 3.7 the conditions used and related redu
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icability of thiol-ene photoreaction for this thiolated polymer, it 
between thiolated glycol chitosan (the
just allylamine (Figure 
chitosan and allylamine
ctions of free thiols are shown
 
 
 
 
3.24).  
 
 using the 
. 
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 Irradiation source (nm) Time 
exposure 
Sperimental 
condition 
Photoinitiatior % reduction of 
free thiols 
1 Sunlight 2h In N2 No 1.4 % 
2 365 (Hg lamp) 2h In N2 Yes 49.4% 
3 365 (Hand lamp) 2h N2, pH 4 Yes 34.7% 
4 365 (Hg lamp) 2h In N2 No 17.2 % 
5 365 (Hand lamp) 2h N2, pH 4 No 1% 
6 365 (Hg lamp) 2h 25°C, pH 4 No 12.11% 
7 254 (Hand lamp) 2h N2, pH 4 No 39.8 % 
8 254 (Hand lamp) 2h pH 4 No 35.25% 
9 254 (Hand lamp) 2h pH 4 Yes 76.8% 
10 254 (Hand lamp) 2h N2, pH 4 Yes (1/2) 45.5% 
11 254 (Hand lamp) 1h N2, pH 4 Yes 45.3% 
Table 3.7. Degree of reduction of thiol group by irradiation of Thiolated Glycol Chitosan in presence of 
Allylamine. 
Comparing tests 5 and 8, results show that the use of irradiation at 254 nm behaves better than 
365 nm as expected by literature [133]. It is also clear that natural light (test 1) has no effects on 
the reaction, as well as the presence of oxygen (comparing tests 7 and 8) does not significantly 
affect the final reaction. Instead, comparing tests 4 and 5 it is evident that by increasing the 
power of the lamp it is possible to obtain cross-linkage also with 365nm wavelength even though 
much less than 254 nm. Moreover, comparing tests 2 and 4, tests 3 and 5 and tests 8, 9 and 10 it 
is clear how the yield is positively affected as expected from the presence of photoinitiator. 
However, the yields obtained with no photoinitiators are quite high too with the advantage to 
avoid the photoinitiator.  
After these preliminary results it was tested directly the reaction between the two modified 
polymers according to the scheme presented in previous Figure 3.8. 
Finally, thiolated glycol chitosan and allylated heparin or alginate was successfully deposited 
on PS NPs by LbL technique (Figure 3.25).  
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Figure 3.25. TEM image of beads of PS beads non coated (a) and coated with chitosan and heparin. 
The bilayer was then irradiated using UV light at 254 nm. Also in this case Ellman’s test was 
used to determine the reduction of free thiol groups that corresponds to the amount of bonds 
formed. The test was opportunely modified in order to apply it to a system containing particles 
which can produce scattering effects affecting the final results. For this reason, after irradiation 
of half amount of nanoparticles suspension, we proceeded by adding the Ellman’s reagent to 
both suspensions, letting them to react for two hours, and centrifuging the suspensions before 
measurement with spectrophotometer. In this way measurements were carried out on the 
supernatant containing only TNB2-, collected for UV measurement. The reduction of free thiol 
group could be determined by comparing sample irradiated and not irradiated (see Appendix 
Figure A.E.8). The results are reported in Table 3.8. 
  
Test Polyelectrolyts Conditions Reduction % of free thiols 
1 Glicol chitosan-NAC Alg-P6 
254 nm (TLC), 2h, 
with PI 40.7 
2 Glicol chitosan -NAC Hep-P6 
254 nm (TLC), 2h, 
with PI 66.5 
3 Glicol chitosan -NAC Hep-P6 
254 nm (TLC), 2h, 
without PI 24.4 
Table 3.8. Degree of reduction of free thiols on bilayer nanoparticles. 
Table clearly shows the effectiveness of the photo-reaction both in the case of sodium alginate 
and heparin even though better in the latter one as expected by the higher modification degree of 
heparin. Moreover, by comparing tests 2 and 3 it is evident how the photoreaction can happen 
also in absence of photo-initiator, even though with lower yield, which is an enormous advantage 
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in bio-applications as it was meant to be. It is finally noteworthy that irradiation is effective at 
254 nm even if it was used a TLC (or compact) lamp, that provides low power. The advantage of 
using low intensity light is that reaction can be carried out with no need for a temperature control 
of the solution. To further improve the reaction yield, the solution was directly irradiated, using 
open containers. This is possible because, as reported in literature [133, 134] and as 
demonstrated in our preliminary experiments (see Table 3.7), the presence of oxygen has no 
negative effects on the reaction.  
Only preliminary results were produced on the use of such reaction applied to the oil core based 
nanocapsules. However, by making a comparison between a cross-linked and not cross-linked 
trilayer with modified polymers and with the outer layer of chitosan at a saturation concentration 
(Tri4) (pH 4, 20 mM of acetic acid) it was observed an increase in stability. Indeed after one day 
of preparation first sample was already not stable whereas the cross-linked one after few days 
was still stable. Of course these are preliminary results which have to be confirmed and explored 
at different and also more aggressive conditions like the physiological environment of blood.  
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Appendix 
A.E. Experimental 
A.E.1. TGA on chitosan 
On all chitosan samples (un-funtionalized and functionalized) a termogravimetric analysis was 
carried out to obtain the total content of water. Specifically, 3-5 mg of each sample were put into 
an alumina crucible and brought up to 600°C with a constant ramp from 25°C to 600°C at 
20°C/min. At around 100°C, in the graph of wt % versus temperature, a step followed by a 
plateau can be seen and this loss of weight corresponds to a loss in water content that was not 
eliminated during the freeze drying procedure. This water content was found to be variable, 
ranging from 8 to 15 % and dependent on the specific freeze drying process from which the 
samples have been recovered. The water content was taken into account in the calculation of 
masses used in functionalization and LbL experiments. The instrument used was simultaneuos 
DSC/TGA - TA instruments SDT2960. As an example TGA of LMW chitosan is reported below 
(Figure A.E.1) showing in this case a weight loss at around 100° of 10% wt. 
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Figure A.E.1. TGA on chitosan samples.  
A.E.2. Fluorescence emission of FITC with pH 
The effect of pH on the fluorescence intensity of FITC was measured and it is reported in 
Figure A.E.2.  
 
 
Figure A.E.2. Effect of pH on the fluorecscence intensity of FITC. 
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A.E.3. Degree of chitosan functionalization with FITC  
To determine degree of chitosan functionalization with FITC, a calibration line was calculated 
by considering FITC concentrations from 6 µg/ml to 1.2 µg/ml in a solution 8:2 water/DMSO 
(Dimethylsulfoxide) with water phase at pH 6.13 (HAc/Ac buffer). At this pH, FITC’s ε was 
4.71·104 M-1cm-1. Calibration line is reported in Figure A.E.3. 
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Figure A.E.3. FITC calibration line for determination of chitosan-FITC degree of functionalizaton. 
The absorbance of FITC modified chitosan sample was recorded in the same conditions and 
from this absorbance, taking into account the calibration line, it was calculated a degree of 
functionalization of around 1.3 %. 
A.E.4. DLS results on primary and secondary emulsions 
In Table A.E.1 the DLS characterization, in terms of size and PDI, is reported for the different 
lecithin formulations and both in the case of 10 and 20 % wt of oil. It is possible to see how the 
increase of lecithin concentration brings to lower sizes even though with an increase of the PDI 
and that at the same concentration of lecithin in oil the higher viscosities (case of 20 % wt of oil) 
helps in further reducing size.  
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Process 
conditions 
L1 L2 L3 L4 L5 
Size  
(nm) PDI 
Z-pot  
(mV) 
Size  
(nm) PDI 
Z-pot 
(mV) 
Size  
(nm) PDI 
Z-pot  
(mV) 
Size 
(nm) PDI 
Z-pot  
(mV) 
Size 
(nm) PDI 
Z-pot 
(mV) 
10 % wt oil 
Cycle 0 315 0.41 -43.3 248 0.34 -40 272 0.37 -44.1 280 0.39 -43.3 264 0.48 -39 
Cycle1 222 0.14 -39.9 192 0.12 -40.6 182 0.13 -41.3 176 0.13 -46.9 160 0.15 -41.7 
Cycle 2 204 0.09 -30.8 183 0.10 -35.8 169 0.11 -34.6 163 0.11 -37.2 150 0.11 -38.8 
Cycle 3 199 0.09 -40.2 168 0.08 -42.2 154 0.10 -36.3 153 0.09 -36.2 139 0.12 -36.8 
Cycle 3 + 50 steps 186 0.07 -42.1 153 0.06 -43.4 133 0.09 -38.7 127 0.75 -36.4 112 0.11 -38.3 
Cycle 3 + 100 steps 178 0.06 -42.4 142 0.07 -33.2 114 0.11 -30.8 112 0.09 -33 95 0.09 -37.1 
Cycle 3 + 150 steps 176 0.07 -41.8 138 0.08 -41.1 112 0.09 -34.1 103 0.08 -33.9 89 0.09 -32.7 
Cycle 3 + 200 steps 173 0.04 -41 136 0.10 -32.9 107 0.09 -30.9 101 0.14 -32.1 85 0.10 -35.1 
20 % wt oil 
Cycle 0 437 0.44 -42.7 317 0.38 -43.8 299 0.41 -42.9 261 0.37 -46.3 265 0.39 -42.9 
Cycle1 239 0.14 -48.9 201 0.17 -43.8 181 0.13 -40.9 156 0.14 -40.1 151 0.15 -43 
Cycle 2 212 0.09 -40 180 0.12 -43.1 167 0.09 -40.9 143 0.13 -43.6 141 0.14 -45.6 
Cycle 3 206 0.08 -40.3 172 0.09 -41.9 161 0.10 -34.1 134 0.11 -43.4 134 0.13 -43.1 
Cycle 3 + 50 
steps 
181 0.06 -43.9 150 0.07 -41.4 132 0.08 -40.2 109 0.12 -43.4 107 0.12 -37.9 
Cycl  3 + 100 
steps 
168 0.04 -42.5 133 0.07 -39.5 115 0.07 -37.4 97 0.11 -44.2 94 0.13 -28.5 
Cycl  3 + 150 
steps 
164 0.05 -40.3 127 0.06 -35.9 107 0.06 -37.2 88 0.10 -52.1 83 0.11 -42.9 
Cycl  3 + 200 
steps 
159 0.03 -42.1 119 0.06 -37.6 100 0.06 -36.2 82 0.09 -36.3 77 0.10 -38 
Table A.E.1. Primary emulsions at 10 and 20% wt of oil for the five different concentration of lecithin (L1÷L5) at 
the different processes cycles and cycles + steps. 
In Table A.E.2 it is reported the DLS characterization of secondary NEs at different chitosan 
concentrations for samples re-dispersed once (after 1 day) and twice (after 1 month) of 
preparation (for all the five templates L1÷L5), and as an example, for L1 not re-dispersed at all. 
 
L1 re-dispersed once through high pressure homogenizer (A) 
Chitosan 
concentration [%] 0.005 0.01 0.0175 0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 188.4 0.07 172.4 0.06 180.7 0.05 174.2 0.04 173.2 0.05 182.9 0.1 199.3 0.11 197.6 0.11 
1 215.9 0.12 195.6 0.08 192.7 0.08 185.8 0.09 186.7 0.10 191.2 0.13 220.4 0.12 249.1 0.16 
3 199.2 0.09 193.1 0.1 210.8 0.20 190.8 0.08 191.1 0.09 200 0.1 237.2 0.13 250 0.14 
7 208.6 0.08 197.1 0.09 200.2 0.08 189.4 0.07 191.3 0.09 195.2 0.12   249.2 0.17 
14  209.5 0.11 205.6 0.08 207.1 0.1 203.8 0.09 196.7 0.1 202.5 0.15   242.2 0.11 
28 215.1 0.10 204.1 0.06 206.8 0.07 204.6 0.07 202.1 0.09 199.5 0.10   247.2 0.12 
75     638.8 0.41 198.6 0.08 211 0.08 214.8 0.08   254.2 0.08 
90       338.7 0.35 205.5 0.04 224.8 0.06   248.3 0.07 
160         208.9 0.12 214 0.09   229 0.12 
190         286.4 0.32 197.1 0.1   201.7 0.1 
270           211.6 0.04   219.3 0.06 
360           214.3 0.1   214.2 0.07 
510           210.7 0.09   219.4 0.1 
L1 re-dispersed twice through high pressure homogenizer after 1 month (B) 
28 214.4 0.1 195.6 0.08 183.9 0.06 187 0.06 185.7 0.08 186.5 0.07 179.7 0.09 206.4 0.07 
31 247.4 0.11 189.4 0.09 194.1 0.08 190.1 0.08 181.9 0.07 184.4 0.07 182.6 0.08 200.7 0.06 
42   193.7 0.09 191.2 0.07 190.8 0.07 193 0.15 178.8 0.08 181.4 0.08 206 0.12 
60     189.7 0.06 183 0.1 184.5 0.07 182.3 0.08 181.9 0.07 196.7 0.08 
95       182.2 0.08 181.2 0.09 177.7 0.08 170.5 0.08 192.5 0.12 
160         175 0.11 174 0.09 167.8 0.09 177.5 0.09 
190         178.2 0.07 174.4 0.12 168 0.07 181.5 0.12 
270           180.2 0.08 170.8 0.08 185.9 0.09 
360           178.7 0.12 165 0.06 174.2 0.07 
510           182.8 0.1 169 0.05 182 0.06 
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L2 re-dispersed once through high pressure homogenizer (C) 
Chitosan 
concentration [%] 0.005 0.01 0.0175 0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 134.8 0.11 128.4 0.08 128.7 0.06 127 0.06 125.1 0.1 139.5 0.12 162 0.17 196.8 0.17 
1 134.4 0.10 130.3 0.09 131.3 0.06 132.2 0.07 128.7 0.09 138.3 0.11 167.6 0.16 189.1 0.17 
3 143.3 0.07 138.1 0.06 139.1 0.09 139.1 0.06 136.8 0.09 148.8 0.12 179.7 0.16 206.6 0.16 
7 148.2 0.11 135.7 0.09 131.9 0.07 141.7 0.08 143 0.09 155.1 0.11 185.4 0.14 203.8 0.15 
14  165.6 0.07 139.3 0.08 149.8 0.12 142.7 0.07 142.8 0.08 148.7 0.13 172.9 0.14 198 0.16 
28   134.9 0.05 137.4 0.07 145.5 0.07 150.1 0.09 154.7 0.08 171.9 0.12 193.6 0.15 
75       190.1 0.1 148.8 0.08 165.8 0.07 179.5 0.07 194.3 0.13 
90         144.7 0.06 166.8 0.06 177 0.09 187.7 0.13 
160         262.3 0.36 163.3 0.12 160.5 0.07 197.9 0.22 
190           142.4 0.13 146 0.09 151.6 0.11 
270           159.5 0.08 163.7 0.07 165.2 0.09 
360           160.4 0.1 152.9 0.07 162.8 0.17 
510             158.6 0.08 159.3 0.09 
L2 re-dispersed twice through high pressure homogenizer after 1 month (D) 
28   134.1 0.06 134.4 0.08 132.3 0.03 127 0.07 128.3 0.08 145.3 0.09 156.7 0.09 
31   134.1 0.07 135 0.06 136.1 0.04 135.7 0.07 134.6 0.08 147.6 0.09 158.2 0.09 
42     132 0.06 130.6 0.05 131.2 0.08 135.5 0.11 141.5 0.09 153.4 0.09 
60       128.9 0.06 127.9 0.04 131 0.06 137.6 0.09 145.8 0.09 
95         129.9 0.11 131.3 0.12 136.5 0.14 142.9 0.14 
160         121.6 0.07 122.5 0.04 124.8 0.09 133.3 0.15 
190         128.7 0.06 125 0.09 125.1 0.06 136.4 0.16 
270           127.8 0.06 117.8 0.17 137.7 0.14 
360           129.7 0.09 126.3 0.12 131.2 0.14 
510           131.1 0.08 129.5 0.09 131.1 0.1 
 
 
 
L3 re-dispersed once through high pressure homogenizer (E) 
Chitosan 
concentration [%] 0.005 0.01 0.0175 0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 102.5 0.08 101.9 0.08 103.4 0.1 102.6 0.10 108.7 0.12 115.4 0.13 126.4 0.18 142 0.2 
1 103.2 0.1 105.4 0.09 106.1 0.09 101.6 0.08 111.4 0.12 122 0.15 134.1 0.18 156 0.19 
3 108.6 0.09 107 0.09 110.2 0.08 111.2 0.13 110.2 0.11 125.4 0.14 144 0.17 167.3 0.12 
7 117.4 0.06 107.9 0.08 114 0.09 111.7 0.01 111.7 0.11 123.9 0.15 147.1 0.17 170.2 0.17 
14  226.3 0.32 111.2 0.07 111.5 0.06 109.5 0.07 106.4 0.08 123.2 0.13 128.4 0.15 127.9 0.14 
28   126.3 0.07 115.8 0.08 120.6 0.06 125 0.08 132 0.12 149.4 0.14 169.5 0.15 
L3 re-dispersed twice through high pressure homogenizer after 1 month (F) 
28   139 0.1 111 0.07 109.9 0.07 111.3 0.08 113.6 0.1 121 0.11 131.7 0.12 
31   218.9 0.12 108.5 0.1 106.5 0.07 108.2 0.07 110.8 0.09 121 0.13 131.5 0.1 
42     280.7 0.17 104.2 0.07 109.2 0.07 109.3 0.09 114.1 0.11 124.2 0.1 
60       155.3 0.05 107.8 0.08 107.4 0.1 111.7 0.11 115.2 0.1 
95         106 0.1 105.9 0.09 110.3 0.11 123.3 0.18 
160         101.7 0.07 99.09 0.06 103.9 0.01 104.6 0.08 
190         113.9 0.07 100.2 0.074 102.1 0.07 106.3 0.1 
270           105.3 0.09 102 0.07 101.8 0.06 
360           115.7 0.14 106.2 0.09 100.7 0.07 
510           120.2 0.23 105.3 0.08 104.9 0.07 
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L4 re-dispersed once through high pressure homogenizer (G) 
Chitosan 
concentration [%] 0.005 0.01 0.0175 0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 87.81 0.01 88.28 0.12 89.78 0.13 89.28 0.11 91.57 0.15 95.81 0.15 104.8 0.19 110.3 0.2 
1 89.78 0.09 91.08 0.11 91.96 0.11 91.8 0.12 94.73 0.14 107.4 0.2 111.9 0.19 131.2 0.22 
3 106.3 0.09 94.03 0.10 95.66 0.11 96.23 0.11 103 0.17 110 0.17 131.9 0.1 149.6 0.19 
7 172.8 0.13 104.5 0.09 101.4 0.1 93.59 0.11 104.7 0.17 119.1 0.21 146.3 0.23 193.8 0.35 
14    113.1 0.08 100.1 0.11 101.9 0.1 108.9 0.15 111.4 0.16 132.3 0.17 151.9 0.18 
28     102.3 0.08 103.2 0.09 110.9 0.11 117.3 0.13 131.5 0.16 142.9 0.16 
75         110.8 0.15 115 0.09 135.6 0.14 144.9 0.11 
90         167.4 0.13 117.2 0.11 126.1 0.1 138.5 0.1 
160           119.3 0.07 118.7 0.08 122 0.08 
190           137.6 0.09 123.5 0.08 127.7 0.06 
270           219.6 0.26 128.6 0.06 127.4 0.06 
360             134.5 0.1 122.4 0.09 
510             161.5 0.13 131.3 0.07 
L4 re-dispersed twice through high pressure homogenizer after 1 month (H) 
28   252.9 0.05 97.48 0.1 95.56 0.08 96.8 0.1 98.13 0.11 105.3 0.13 113.9 0.13 
31     95.51 0.07 94.37 0.08 96.51 0.08 96.83 0.12 104 0.14 114 0.14 
42       91.58 0.07 90.49 0.09 92.92 0.1 97.72 0.11 106.8 0.12 
60         91.19 0.11 91.34 0.11 99.12 0.13 104.6 0.14 
95         90.26 0.14 91.3 0.12 85.68 0.12 105.4 0.19 
160         101.4 0.06 84.88 0.08 87.62 0.01 91.19 0.01 
190         175.5 0.1 89.93 0.15 88.32 0.11 92.6 0.13 
270           91.73 0.12 88.98 0.1 89.45 0.1 
360           98.59 0.15 92.53 0.1 91.08 0.1 
510           120.7 0.3 98.14 0.13 96.02 0.1 
 
 
 
L5 re-dispersed once through high pressure homogenizer (I) 
Chitosan 
concentration [%] 0.005 0.01 0.0175 0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 84.58 0.1 83.19 0.12 83.61 0.13 82.27 0.12 81.87 0.12 88.42 0.17 95.38 0.18 108.2 0.21 
1 85.38 0.12 84.79 0.11 83.17 0.11 85.01 0.11 86.27 0.13 96.97 0.19 107.4 0.22 122.8 0.21 
3 103.4 0.18 91.28 0.14 90.15 0.14 84.76 0.11 93.41 0.15 101 0.19 117.8 0.21 147 0.22 
7 160.5 0.14 98.6 0.1 89.19 0.1 92.52 0.1 92.85 0.13 92.18 0.15 112.5 0.2 127.9 0.2 
14    107.7 0.07 96.07 0.11 97.67 0.1 99.6 0.13 106.6 0.15 137.1 0.23 133.9 0.17 
28     101.3 0.07 97.54 0.1 97.19 0.09 100.9 0.13 104.2 0.14 131.6 0.16 
75         142.4 0.09 116 0.13 125.8 0.12 132.2 0.12 
90           114.2 0.14 126.1 0.15 129 0.11 
160           138.9 0.14 115.3 0.09 117.5 0.1 
190           219.7 0.25 124.7 0.1 124.4 0.15 
270             133.3 0.08 123.5 0.06 
360             155.4 0.1   
510             240.1 0.34   
L5 re-dispersed twice through high pressure homogenizer after 1 month (L) 
28     96.98 0.1 90.44 0.09 88.33 0.11 92.05 0.13 98.16 0.13 107.6 0.15 
31     98.5 0.12 92.05 0.13 91.28 0.09 92.97 0.13 98.49 0.13 112.7 0.16 
42       125 0.06 87.07 0.08 85.53 0.1 93.93 0.11 101.1 0.14 
60         86.53 0.08 88.08 0.09 90.94 0.11 101.8 0.13 
95         82.65 0.11 83.52 0.12 89.13 0.13 94.01 0.11 
160           79.13 0.09 81.07 0.07 84.59 0.09 
190           82.13 0.11 89.04 0.19 84.88 0.09 
270           92.59 0.15 88.05 0.12 85.89 0.09 
360           104.7 0.19 96.62 0.18 91.64 0.12 
510           166.6 0.5 108.6 0.28 101.8 0.19 
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L1 no re-dispersion process (M) 
Chitosan 
concentration [%] 0.005 0.01 
 
0.0175 
 
0.025 0.05 0.1 0.175 0.25 
TIME (days) Size [nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
Size 
[nm] PDI 
0 192  0.22 182.7 0.08 184.5 0.11 179.3 0.08 187.7 0.12 190.9 0.13 203 0.15 236.1 0.22 
1 210.9 0.26 188.6 0.12 197.2 0.11 184.4 0.1 181.3 0.11 187.3 0.12 253.9 0.2 296.5 0.4 
3   178.4 0.05 183.2 0.09 176.2 0.07 185.5 0.1 188.2 0.1 232.6 0.19 324.9 0.29 
7   197.5 0.13 191.1 0.15 186.2 0.11 203.8 0.11 203.3 0.11 254.2 0.23 324.8 0.4 
14   194 0.15 183.8 0.1 185.2 0.06 205.6 0.12 225.6 0.14 275.5 0.17 372.1 0.3 
28     186.2 0.14 188.4 0.07 210 0.13 239.4 0.14 291 0.19 409.8 0.4 
Table A.E.2. Stability tests on secondary emulsions reprocessed once (A, C, E, G, I), reprocessed twice (B, D, F, H, 
L) and no re-processed (M). Some Notes: The data missing in A for the 0.175 % wt of CT are due to a mistake for 
which the sample was completely re-processed for the second time after three days; The sample in B 
corresponding to 0.175 % wt of chitosan as said was re-processed after three days instead of 1 month. As it is 
possible to see in this case the size is slightly less than the samples just above and below in terms of 
concentration; maybe the earlier processing avoided some aggregations ending up with a smaller average size; 
All the samples L3 in E were reprocessed after 1 month as planned but they were completely processed by 
mistake without keeping the sample for further stability tests. The times for measurements are rounded of few 
days. The red is related to double peaks. Missing boxes indicated destabilization.  
A.E.5. Analysis of chitosan coverage on NEs by Spectrofluorimetry  
 
Chitosan (% wt) Emission at 510 nm (AU) 
 
NE + 
Chitosan 
NE + 
Chitosan Chitosan 
0.001 1604   
0.00175 2869   
0.0025 6332   
0.005 26686   
0.01 71921 80194 181224 
0.0175 168359 158939 266550 
0.025 214812 214773 322734 
0.0375  301693 400490 
0.05 368064 348130 434998 
0.0625  420170 491428 
0.075  445800 496268 
0.0875  490375 494367 
0.1 529369  526043 
0.25 531200   
Table A.E.3. Fluorescence emission at 510nm for L4 secondary emulsions coated with chitosan-FITC and free 
chitosan at the same concentrations. Samples were diluted 1:4 to limit the emission of the more concentrated 
samples. 
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A.E.6. Saturation method by z-potential analysis 
In Figure A.E.4 it is reported an example of saturation method by using z-potential technique 
of NEs (L4 based) coated at different concentration of chitosan (from 0 to 0.2 % wt).  
 
Figure A.E.4. Z-Potential analysis on L4 based secondary emulsiont at different chitosan % wt from 0 to 0.2 %.  
As it is evident from the graph, there is not a very clear concentration which can be considered 
as saturation concentration.  
A.E.7. Method to evaluate molecular weight of depolymerized 
chitosan 
Five different concentrations were tested for each sample, each concentration measured five 
times. In particular, specific viscosity, ηspec, was determined using the following equation: 
 	


− 1 
where t0 is the flow time for solvent and t is the flow time for sample solution. The specific 
viscosity is related to a reduced viscosity, ηrid, by means of the concentration: 
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Intrinsic viscosity, [η] is then defined as: 
  	 lim
!→


 
and can be determined plotting on graph C versus ηrid and extrapolating the value for C = 0. As 
a representative example, the intrinsic viscosity calculation method of chitosan-B is shown in 
Figure A.E.5. Chitosan-B is the chitosan used for trilayer deposition. 
 
 
Figure A.E.5.Graphical determination of intrinsic viscosity. 
The viscosity-average molecular weights (Mv), at different degree of de-polymerisation, were 
then calculated using the Mark-Houwink equation: 
 
  #	$%&'
	
 
where [η] is the intrinsic viscosity, a and K are constants for a given solute-solvent system and 
temperature. The latter constant have been identified (K = 1.38 × 10−5 and a = 0.85) respect to 
the pH, solvent ionic strength and degree of deacetylation of chitosan used (see material section). 
Table A.E.4 summarizes the different concentrations utilized and the molecular weights 
obtained. 
y = 0.0891x + 0.2909
R² = 0.9963
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Name NaNO2 amount Mv 
Chitosan-LMW  126.0 kDa 
Chitosan -A 1.73 mg 26.0 kDa 
Chitosan -B 4.30 mg 17.5 kDa 
Chitosan -C 9.70 mg 6.7 kDa 
Chitosan -D 17.25 mg 2.1 kDa 
Table A.E.4. Summary of the different concentrations utilized and the molecular weights obtained. 
A.E.8. Analysis of magnetic beads residue after purification 
It was tried to purify without dilution starting from 0.6 ml of magnetic nanobeads at 3 % w/v 
and a secondary emulsion (L4) not diluted (oil 1 % wt; chitosan 0.1 % wt), following then the 
usual procedure in terms of mixing, stirring, beads separation. DLS results are reported in the 
Table A.E.5. 
 
Emulsion 
Average size =86 
PDI= 0.108 
Z-pot = -34.2 ± 6.26 mV 
Monolayer separation 
(Sample 1) 
Average size = 95.31 nm 
PDI= 0.075 
Z-pot = 37.5 ± 10.9 mV 
Monolayer separation 
(Sample 2) 
Average size = 93.24 nm 
PDI= 0.088 
Z-pot = 35.2  ± 10.7 mV 
Bilayer 
Average size=115.4 nm 
PDI= 0.109 
Z-pot = -39.8 ± 12.4 mV 
Table A.E.5. DLS results on purification without dilution. 
In order to verify if magnetic nanobeads were completely removed from the purified sample, 
EDX spectroscopy analysis was carried out at different magnetic beads amounts. Samples, after 
purification with beads, were first lyophilized before introducing in the scanning electron 
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microscopy (SEM) to eliminate oil phase. Table A.E.6 summarizes the DLS results of purified 
L1 based secondary emulsions (with an initial stability concentration of chitosan of 0.1 % wt) 
and corrisponding amount of Co residue, for different amounts of magnetic beads used for 
purification, specifically from 60 to 180 µl (at 1 % w/v) brought to 0.5 ml and mixed with 0.5 ml 
of secondary emulsion diluted ten times. 
  
  60 µl 90 µl 120 µl 150 µl 180 µl 
Monolayer L1 0.1% CT-
lmw_2 p 
Size (nm) 192.1 195.9 177.6 182.7 200.9 
PDI 0.04 0.06 0.04 0.07 0.05 
Z.pot (mV) 38.5 35.8  31.9  39.9 44.1 
Co by EDX spectroscopy % wt 0  5.5  18 
Table A.E.6. Summary of DLS and EDS analysis on purified L1 secondary emulsions. 
As it is possible to see in terms of DLS all the trials in the range from 60 to 180 µl were fine. 
However in terms of magnetic beads residue it was necessary to use the minimum possible 
amount of beads to avoid any final contamination.  
A.E.9. Spectra of absorbance of TNB2- 
To quantify the degree of functionalization of NAC modified chitosans as well as the degree of 
reticulation induced into the bilayer built on PS NPs, it was first calculated the calibration line by 
using NAC as standard. In particular, DTNB, at different concentrations, was dissolved by using 
acetic acid buffer solution at pH 3. Then 0.5 ml of each standard was added to 3.5 ml of a 0.5 M 
buffer phosphate at pH 8.03. The final pH is 7.4, a value necessary for the essay. The baseline 
was registered at t = 0 in order to subtract the absorbance due to DTNB at 412 nm. Then, 
standards were stored in the dark at 25 °C under stirring for 150 minutes. Finally, absorbance 
was measured for each sample following a known method [131] and the value at 412 nm was 
used to obtain the calibration line (see Figure A.E.6); the ɛ value of TNB2- at 412 nm was 
1.0320·104 M-1 cm-1. 
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Figure A.E.6. Calibration line for determination of chitosan-NAC degree of functionalizaton. 
Figure A.E.7 and Figure A.E.8 report respectively the absorbance spectrum for the modified 
glycol chitosan to determine functionalization degree and the two spectra of irradiated and not 
irradiated bilayer to determine free thiol reduction, therefore reticulation degree. 
 
 
Figure A.E.7. Absorbance spectrum of a modified chitosan (sample GC-NAC 10). 
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Figure A.E.8. Absorption spectra of irradiated (blu line) and not irradiated (red line) bilayer on PS NPs. 
A.E.10. Sodium Alginate modification with allylamine  
The first two attempts were carried out without HOBt and with the same molar concentration of 
sodium alginate, allylamine and EDC. In the first case, (AlgP1), EDC was added to sodium 
alginate before adding allylamine whereas in the second case, (AlgP2), after adding allylamine 
and the modification degree in both cases was low as quantified by NMR. Actually, a marked 
increase in functionalization was obtained with the use of HOBt together with EDC coupling 
agent, as it was for chitosan functionalization. Alginate and allylamine were dissolved together at 
different molar concentrations (30:1 molar ratio in AlgP3, 10:1 in AlgP4 and AlgP6). The pH 
was adjusted to a 6.8 value with the use of HCl and NaOH. The EDC/COO- ratio was 4:1 for 
samples AlgP3, AlgP4 and AlgP6, while HOBt/COO- ratio was mantained 4:1 as summarized in 
Table A.E.7. The only difference between AlgP4 and AlGP6 is due to the higher dilution of 
reagents in water as also reported in the table. The 6.8 pH was chosen as good compromise for 
activated ester formation (the optimal pH for EDC reaction would be around 5) and deprotonated 
allylamine reaction (the more the pH the lower the protonation at NH3+ of allylamine respect to 
NH2 that is much more reactive with ester).  
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Alginate 
sample 
HOBt:Allylamine:Alginate:EDC 
(molar ratio of functional groups) 
Alginate 
concentration 
pH of 
reaction 
Degree of 
functionalization 
AlgP1 0:3:1:2 10mg/ml 4-6 ∼10% 
AlgP2 0:3:1:2 10mg/ml 5 ∼8% 
AlgP3 4:30:1:4 3mg/ml 6.8 ∼40% 
AlgP4 4:10:1:4 10 mg/ml 6.8 ∼62% 
AlgP6  4:10:1:4 5mg/ml 6.8 ∼ 71 % 
Table A.E.7. Alginate functionalization: conditions of reaction and degree of functionalization. 
A.E.11. Preparation of oil core silica shell nanocapsules 
As anticipated in the first chapter, NEs were also used in this work to build hybrid organic 
inorganic nanocapsules. In particular, once prepared a bilayer with chitosan and heparin it was 
functionalized with 3-(aminopropyl)triethoxysilane (APTS) and then TEOS was added to allow 
the synthesis of a silica shell. The functionalization of heparin with APTS was ment to ensure 
silica synthesis just around oil based template. Oil core can embed tracers for imaging while 
silica shell which is a biocompatible interface can be used to insulate such tracers. Indeed some 
people can be allergic to tracers and exposure of body to them can cause in the worst case to 
death. On the other side silica shell could be used also as drug delivery where the function of the 
silica in that case would be the protection of the inner oil core and drug [135]. A remarkable 
advantage of inorganic NCs, as anticipated, is that they are more resistant than polymer to 
environment conditions such as temperature pH and so on.  
In terms of procedure it was prepared a primary emulsion based on L1 formulation. Chitosan 
was deposited at a final concentration of 0.01 % wt (at pH=4) whereas oil concentration was 1 % 
wt. Bilayer was prepared by mixing 4 ml of mono layer to 2.5 ml of heparin (0.044 % wt). After 
bilayer preparation heparin was activated with (APTS). Precisely, first 50 µl of EDC and NH3 
solution (with 1.23 mg EDC and 8.61 mg NH3 per 1 ml of water) and then 50 µl of APTS 
solution (with 3.5 µL of APTS per ml of 2-proponol), were added to 1 ml of bilayer at 4°C in ice 
bath. After 15 min under stirring silica synthesis was started by adding to the dispersion first 2.3 
ml of NH3 solution (18.5 µl of NH3) in 2-propanol and then, dropwise, 2.3 ml of tetra ethyl 
orthosilicate (TEOS) solution (13.8 µL of TEOS). 
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In Figure A.E.9 TEM images are reported as preliminary results on this kind of nanocapsules. 
It is possible to appreciate monodispersion (Figure A.E.9.A) and nanometric shell thickness 
(Figure A.E.9.B). In the analysis carried out and shown in upper part, samples were treated with 
osmium vapour to mark the inner oil core which indeed appears dark black. 
  
 
 
 
Figure A.E.9. TEM analysis of oil core based silica nanocapsules stained with osmium (top); magnified TEM image 
of one silica capsule (bottom) not stained.  
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A.I. Instruments 
A.I.1. Immersion sonicator 
One of the equipments used in the preparation of the pre-emulsions is the immersion sonicator. 
In Figure A.I.1 it is reported the one used in the thesis which was the Ultrasonic Processor 
VCX500 Sonic and Materials.  
 
Figure A.I.1. Picture of the Ultrasonic Processor VCX500 Sonic and Materials. 
The ultrasonic power supply converts 50/60 Hz line voltage to high frequency electrical energy 
transmitted to the piezoelectric transducer within the converter, where it is changed to 
mechanical vibrations. The vibrations from the converter are intensified by the probe, creating 
pressure waves in the liquid. This action forms millions of microscopic bubbles which expand 
during the negative pressure excursion, and implode violently during the positive excursion. This 
phenomenon, referred to as cavitation, creates millions of shock waves in the liquid, as well as 
elevated pressures (about 500 atm) and temperatures (about 5000 °C) at the implosion sites. 
Although the cavitational collapse lasts a few microseconds and the amount of energy released 
by each individual bubble is minimal, the cumulative effect causes extremely high levels of 
energy to be released into the liquid. Temperature is monitored therefore if a pre-fixed threshold 
is overcome, sonication will stop. To avoid this condition it is possible to alternate pulse off 
and/or more effectively create an ice jacket to improve heat dissipation and keep temperature 
below the threshold. The Ultrasonic Processor is designed to deliver constant amplitude. As the 
resistance to the movement of the probe increases, additional power will be delivered by the 
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power supply to ensure that the excursion at the probe tip remains constant. Furthermore, the 
amplitude control allows the ultrasonic vibrations at the probe tip to be set to any desired level.  
Probes consist of two sections each having different cross-sectional areas. Brought to resonant 
frequency, the probe expands and contracts longitudinally about its center. Amplification factor 
increases with the mass ratio between the upper section and the lower section. Probes with 
smaller tip (Figure A.I.2.A) diameters produce greater intensity of cavitation, but the energy 
released is restricted to a narrower, more concentrated field. Conversely, probes with larger tip 
(Figure A.I.2.B) diameters produce less intensity, but the energy is released over a greater area.  
 
 
Figure A.I.2. Small (A) and large (B) types of probes. 
High gain probes produce higher intensity than standard probes of the same diameter, and are 
usually recommended for processing larger volumes. Probes are fabricated from high grade 
titanium alloy Ti-6Al-4V because of its high tensile strength, good acoustical properties at 
ultrasonic frequencies, high resistance to corrosion, low toxicity, and excellent resistance to 
cavitation erosion. They are autoclavable and available with threaded ends to accept replaceable 
tips, microtips and extenders. 
A.I.2. M-110PS series Microfluidizer 
For the preparation of primary emulsions and for the re-dispersion of secondary emulsions it 
was used the Microfluidics M-110PS Series Microfluidizer (Figure A.I.3) that is a high pressure 
homogenizer designed for the high-performance micro-mixing of emulsions and dispersions.  
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Figure A.I.3. Microfluidics M-110PS Series Microfluidizer. 
The main components of the M-110PS model are following listed: 
- the hydraulic power system, which supplies pressurized hydraulic oil to an intensifier 
pump; 
- the intensifier pump which amplifies the hydraulic pressure and transfers it to liquid 
pressure in the process stream allowing pressure values as high as 2000 bar. During the 
suction stroke, the intensifier pump draws emulsion or dispersion from the inlet reservoir 
into the pressure chamber via the inlet check valve, which closes during the power stroke  
- the interaction chamber which is where size reduction occurs; the emulsion or the 
dispersion is accelerated to a high velocity (up to 400 m\s) with shear rates approaching 
107 s-1 therefore it is subjected to high forces capable to reduce size; 
- a possible auxiliary processing module (APM) in series with the operation chamber and 
so called back pressure chamber which allows smooth reduction of pressure. This can be 
useful both for de-aggregation and to minimize risk of chamber breakage in consequence 
of a cavitation event due to undesired presence of air bubbles combined with sharp 
reduction of pressure at the exit of channel of the operation chamber. 
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- a possible cooling coil which cools the product back to ambient temperature or lower if 
surrounded by a liquid refrigerator as it exits from the interaction chamber. This can 
preserve the product from possible thermal degradation. 
The operating principle is schematized in the following Figure A.I.4. 
 
 
Figure A.I.4. Operating principle of M-110P Microfluidizer. 
The schemes of a y and z chambers are following reported (Figure A.I.5 and Figure A.I.6). 
 
 
Figure A.I.5. Y-shaped interaction chamber: the pressurized emulsion stream enters the y-shaped interaction 
chamber and is split into two channels which then join in a central area where the impact allows the dispersed 
phase to reduce its size. 
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Figure A.I.6. Z-shaped interaction chamber: the pressurized fluid impacts against a stiff surface always at high 
speed, related to both the pressure and the section decreasing of the channel at the impact zone. 
The channels of the chambers are made of zirconia or diamond. Typically diamond enhances 
the lifetime in terms of wear reduction and is particularly suggested for solid dispersions. In 
terms of sizes, in the case of y chamber the channel has a lateral size of 100 µm and a vertical 
size ranging from 75 to 100 µm whereas in the case of z chamber the channel has a lateral 
dimension of 100 µm and a vertical dimension ranging from 87 to 500 µm. For large scale 
productions multi-slotted chambers with channels in parallel are available.  
A.I.3. Dynamic Light Scattering 
Mean size, size distribution, given by the PDI, and Z-potential were measured by Zetasizer 
Nano Series, purchased from Malvern, using the DLS technique (Figure A.I.7).  
 
 
Figure A.I.7. Zetasizer nano series. 
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A dynamic light scattering system, as schematized in Figure A.I.8, comprises six main 
components. Firstly, a laser (1) provides a light source to illuminate the sample contained in a 
cell (2). For dilute concentrations, most of the laser beam passes through the sample, but some is 
scattered by the particles within the sample at all angles. A detector (3) is used to measure the 
scattered light at one of different angles (for example 173° or 90° and so on). The intensity of 
scattered light must be within a specific range for the detector to successfully measure it. If too 
much light is detected, then the detector will become saturated. To overcome this, an attenuator 
(4) is used to reduce the intensity of the laser source and hence reduce the intensity of scattering. 
For samples that do not scatter much light, such as very small particles or samples of low 
concentration, the amount of scattered light must be increased. In this situation, the attenuator 
will allow more laser light through to the sample. 
 
       
Figure A.I.8. Configuration of a dynamic light scattering system. 
The appropriate attenuator position is automatically determined by software and covers a 
transmission range of 100% to 0.0003%. The scattering intensity signal from the detector is 
passed to a digital processing board called correlator (5). The correlator compares the scattering 
intensity at successive time intervals to derive the rate at which the intensity is varying. This 
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information, so called correlation function, coming from the correlator is then passed to a 
computer (6), where the software will analyze the data.  
A.I.3.1. Particle size measurements 
DLS (sometimes referred to as photon correlation spectroscopy or quasi-Elastic light 
scattering) technique measures the size of particles typically in the sub micron region. 
Particularly, it measures Brownian motion and relates this to the size of the particles. Brownian 
motion is the random movement of particles due to the bombardment by the solvent molecules 
that surround them. The larger the particle, the slower the Brownian motion is. Smaller particles 
are “kicked” further by the solvent molecules and move more rapidly. An accurately known 
temperature is necessary for DLS because knowledge of the viscosity is required. Moreover, 
temperature also needs to be stable otherwise convection currents in the sample will cause non-
random movements that will prevent the correct interpretation of size. The size of a particle is 
calculated from the translational diffusion coefficient by using the Stokes-Einstein equation: 
 
d(H) = ()
*η+
 
where d(H) is the  hydrodynamic diameter, D is the translational diffusion coefficient, k is the 
Boltzmann’s constant, T is the absolute temperature and η is the viscosity. The diameter that is 
obtained by this technique is the diameter of a sphere that has the same translational diffusion 
coefficient as the particle. The translational diffusion coefficient will depend not only on the size 
of the particle “core”, but also on any surface structure, as well as the concentration and type of 
ions in the medium. Any change to the surface of a particle that affects the diffusion speed will 
correspondingly change the apparent size of the particle.  
A real system is made of different sizes therefore the size given from the calculation is an 
average size (also known as the “cumulants mean”). The polydispersity of the system can be 
more or less wide; a parameter that provides this information is the polydispersity index (PDI). 
Both average size and PDI are given by cumulant analysis. It is the fit of a polynomial to the log 
of the G1 correlation function: 
Ln [G1] = a + bt +ct2+dt3 +et4 + ............. 
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The value of b is known as the second order cumulant, or the z-average diffusion coefficient. 
This is converted to a size using the dispersant viscosity and some instrumental constants. The 
coefficient of the squared term, c, when scaled as 2c/b2 is the PDI. It corresponds actually to the 
square of the standard deviation divided by the square of the average size. 
Only the first three terms a, b, c are used in the standard analysis to avoid over-resolving the 
data; however this means that the average size is likely to be interpreted incorrectly if the 
distribution is very broad (i.e. has a high polydispersity). Conversely, if polydispersion is very 
low, the distribution can be considered monodisperse. More precisely according to the standards 
of the National Institute of Standards and Technology (NIST) “particle distribution may be 
considered monodisperse if at least 90% of the distribution lies within 5% of the median size”.  
As previously mentioned, the Zetasizer nano series system detects the scattering information at 
173°. This is known as backscatter detection (Figure A.I.9).  
 
 
Figure A.I.9. Backscatter detection. 
In addition, the optics are not in contact with the sample and hence the detection optics are said 
to be non invasive. There are several advantages in using non-invasive backscatter (NIBS) 
detection. For example, high concentrated samples can be measured due to the fact that the laser 
does not have to travel through the entire sample therefore multiple scattering, where light from 
one particle is itself scattered by other particles, is reduced. Then, the effects of dust are greatly 
reduced. Indeed, large particles mainly scatter in the forward direction therefore not detected by 
using backscatter detection. Finally, the measurement position within the cuvette of the Zetasizer 
can be changed by moving the focusing lens and is determined automatically by the software. 
For small particles, or samples at low concentrations, it is beneficial to maximize the amount of 
scattering from the sample moving the measurement point away from the cuvette wall towards 
the centre of the cuvette (Figure A.I.10.A). Conversely, large particles or samples at high 
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concentrations scatter much more light. In this situation, measuring closer to the cuvette wall will 
reduce the effect of multiple scattering by minimizing the path length over which the scattered 
light has to pass (Figure A.I.10.B). 
  
 
Figure A.I.10. Schematic diagram showing the measurement position for (a) small, weakly scattering samples 
and for (b) concentrated, opaque samples. 
It is also worth making some other considerations. First it is necessary that particles are small 
compared to the wavelength of the laser used (typically less than d = λ/10), so that the scattering 
from a particle illuminated by a vertically polarized laser will be essentially isotropic, i.e. equal 
in all directions. Laser can be of various types, according to the wavelength desired for the 
experiment, in our case it is a He-Ne laser at a wavelength of 633 nm. Second, it is important to 
consider the Rayleigh approximation which tells us that Ι ∝ d6 and also that Ι ∝ 1/λ4 where Ι is 
the intensity of light scattered, d is the particle diameter and λ is the laser wavelength. Therefore 
a 50 nm particle will scatter light 106, in other words one million times, more than a 5 nm 
particle. The inverse relationship to λ- means that a higher scattering intensity is obtained as the 
wavelength of the laser used decreases.  
A.I.3.2. Particle Z-potential measurements 
Zeta potential is a physical property which is exhibited by any particle in suspension and is 
related to the surface charge of the particle itself. This charge at the particle surface affects the 
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distribution of ions in the surrounding interfacial region, resulting in an increased concentration 
of counter ions (ions of opposite charge to that of the particle) close to the surface. Thus an 
electrical double layer exists around each particle (Figure A.I.11). 
 
  
Figure  A.I.11. Schematic illustration of Z-potential. 
The liquid layer surrounding the particle exists as two parts; an inner region, called the Stern 
layer, where the ions are strongly bound and an outer, diffuse, layer where they are less firmly 
attached. Within the diffuse layer there is a notional boundary inside which the ions and particles 
form a stable entity. When a particle moves (e.g. due to gravity), ions within the boundary move 
with it, but any ions beyond the boundary do not travel with the particle. This boundary is called 
slipping plane and is the distance at which it is determined the z-potential.  
It has long been recognized that the zeta potential is a very good index of the magnitude of the 
interaction between colloidal particles and measurements of zeta potential are sometimes used to 
assess the stability of colloidal systems. If all the particles in suspension have a large negative or 
positive zeta potential then they will tend to repel each other and there will be no tendency for 
the particles to come together. However, if the particles have low zeta potential values then there 
will be no force to prevent the particles coming together and flocculating. The dividing line 
between stable and unstable suspensions is generally taken at either +30 or -30 mV. Particles 
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with zeta potentials more positive than +30 mV or more negative than -30 mV are normally 
considered stable. However, if the particles have a density different from the dispersant, they will 
eventually sediment forming a close packed bed (i.e. a hard cake).  
One of the most important factors that affect the z-potential is the pH of the sample. A zeta 
potential value on its own without defining the solution conditions is a virtually meaningless 
number. For instance, if we consider a particle in suspension with a negative zeta potential, by 
adding alkali to this suspension then the particles tend to acquire more negative charge whereas, 
by adding acid to this suspension then a point will be reached where the charge will be 
neutralized. Further addition of acid can cause a building up of positive charge. There may be a 
point where the zeta potential passes through zero. This point is called isoelectric point and is 
practically very important being normally the point where the colloidal system is least stable.  
Also ions in solution can affect the zeta potential. They can interact with charged particle 
surfaces in one of two distinct ways: 
1) non-specific ion adsorption where they have no effect on the isoelectric point; 
2) specific ion adsorption, which will lead to a change in the value of the isoelectric point.   
The specific adsorption of ions onto a particle surface, even at low concentrations, can have a 
dramatic effect on the zeta potential of the particle dispersion. In some cases, specific ion 
adsorption can lead to charge reversal of the surface. 
The Zetasizer Nano series calculates the zeta potential by determining the electrophoretic 
mobility and then applying the Henry equation. The electrophoretic mobility is obtained by 
performing an electrophoresis experiment on the sample and measuring the velocity of the 
particles using Laser Doppler Velocimetry (LDV). 
An important consequence of the existence of electrical charges on the surface of particles is 
that they will exhibit certain effects under the influence of an applied electric field. When an 
electric field is applied across an electrolyte, charged particles suspended in the electrolyte are 
attracted towards the electrode of opposite charge (Figure A.I.12).  
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Figure A.I.12. Zetasizer cell with electrodes at either end to wich a potential is applied.  
Viscous forces acting on the particles tend to oppose this movement. When equilibrium is 
reached between these two opposing forces, the particles move with constant velocity. The 
velocity of the particle is dependent on strength of electric field or voltage gradient, the dielectric 
constant of the medium, the viscosity of the medium and the Zeta potential. The velocity of a 
particle in an electric field is commonly referred to as its electrophoretic mobility. With this 
knowledge it is possible to obtain the zeta potential of the particle by application of the Henry 
equation: 
 
 
where z is the zeta potential, UE the electrophoretic mobility, ε the dielectric constant, η the 
viscosity and f(Ka) the Henry’s function. Two values are generally used as approximations for 
f(Ka): 1.5 when electrophoretic determinations of zeta potential are made in aqueous media with 
a moderate electrolyte concentration and 1.0 for small particles in low dielectric constant media.  
Finally, to evaluate the electrophoretic mobility it is used the LDV. This is a well established 
technique to measure the velocity of particles moving through a fluid in an electrophoresis 
experiment. The light scattered at an angle of 17° respect to the incident beam is collected by the 
detector (Figure A.I.13). This produces a fluctuating intensity signal where the rate of 
fluctuation is proportional to the speed of the particles. A digital signal processor is used to 
extract the characteristic frequencies in the scattered light. 
η
)f(KzεU aE 3
2
=
Appendix 
 
138 
 
 
Figure A.I.13. Laser Doppler Velocimetry technique. 
A.I.4. Confocal Microscopy 
Confocal microscopy is an optical imaging technique invented by Marvin Minsky in 1957 
while he was trying to study neural networks to understand how brain learns and needed a way to 
image these connections in their natural state (in three dimensions) [136]. Today, confocal 
microscopy is widely used in many fields of science.  
Illuminating and observing a sample, two physical processes significantly limit the sharpness of 
the observed image: 
1) by illuminating the entire sample, the light spreads in it disturbing the image of the focus 
plane: to solve this problem it is needed to illuminate only small areas of the sample. 
2) while it is possible to observe a focus plane of the sample, also the light reflected from 
the plans not in focus comes to the eyes, making a confusing picture: the revolutionary idea 
compared to conventional microscopy is to block as much as possible the information derived 
from the above and below planes to the desired through a small opening. 
Confocal microscopy allows overcoming the limits of conventional optical microscopy such as 
resolution, focus and contrast. Indeed it significantly improves the image resolution at the 
expense of field of view [137]. Confocal microscope consists of a pinhole in input and in output, 
which is a shutter that allows to illuminate only a very limited part of the sample and to collect 
only light coming from it. The image therefore is not disturbed by unwanted reflections or 
fluorescences by the plans not in focus and the points of focus plane that are not observed. As it 
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is possible to see from the Figure A.I.14, the beam excitation passes through the illuminating 
pinhole, irradiating only a small region of the sample. 
 
 
Figure A.I.14. Simplified optics of a Laser Scanning Confocal Microscope (LSCM). 
Before detection a second confocal aperture, a detector pinhole, reduces the contributions of the 
above and below planes to the focus. By scanning techniques, it is possible to study the entire 
sample surface. The fundamental principle of any scanning microscope is to illuminate a point of 
the sample at a time; the signal resulting from the interaction between the incident radiation and 
the sample is recorded and processed to form a reproduction of the sample to visualize. 
Compared to a conventional microscope that immediately provides the full image, with the 
confocal microscope the sample is probed point by point.  
In confocal microscopy, as excitation source it is often used a laser beam. This provides a high 
intensity and monocromatic light source. It is first filtered and attenuated so to use a correct 
intensity and proper excitation spectrum to produce fluorescence that is the emission of a 
secondary photon upon absorption of a photon of higher wavelength (Figure A.I.15) [136]. Most 
molecules at normal temperatures are at the lowest energy state, the so-called 'ground state'. 
Occasionally, a molecule may absorb a photon and increase its energy to the excited state. From 
here it can very quickly transfer some of that energy to other molecules through collisions (red) 
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and spontaneously emits the remaining energy by emitting a photon (green) with a lower 
wavelength to return to the ground state.  
 
 
Figure A.I.15. Scheme of the fluorescence mechanism. 
In fluorescence microscopy, fluorescent molecules, in order to increase the signal, are designed 
to be attached to specific parts of a sample, thus identifying them when imaged. Multiple 
fluorophores can be used to simultaneously identify different parts of a sample. There are two 
options when using multiple fluorophores: 
1) fluorophores can be chosen that respond to different wavelengths of a multi-line laser; 
2) fluorophores can be chosen that respond to the same excitation wavelength but emit at 
different wavelengths. 
However one limit is about the presence of too many fluorophores near the surface of the 
sample that may absorb enough light to limit the one available to the rest of the sample. While 
the intensity of incident radiation can be increased, fluorophores may become saturated if the 
intensity is too high. Moreover, they can present photobleaching that is an irreversible fade when 
they are exposed to excitation light for a long time being able to emit only a limited number of 
photons. This may be due to reaction of the molecules’ excited state with oxygen or oxygen 
radicals. Photobleaching can be limited by reducing the oxygen available or by using free-radical 
scavengers. Some fluorophores are more robust than others, so choice of fluorophore is very 
important.  
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The confocal microscope used in this work was the version capable to perform also STED -
which technique will be described in the next paragraph- that is a Leica TCS STED-CW 
microscope (Leica-Microsystems, Mannheim, Germany). 
A.I.5. Stimulated emission depletion microscopy 
STED microscopy, is a fluorescence microscopy technique that uses the non-linear de-
excitation of fluorescent dyes to overcome the resolution limit imposed by light diffraction [138]. 
As previously described, the resolution of a confocal microscope is limited to the spot size to 
which the excitation can be focused. This size depends on system parameters, but is limited by 
approximately half the wavelength of the light used (for example at about 200 nm if a blue light 
is used). Within the STED microscope the diffraction limit is surmounted by switching off dye 
molecules by means of a targeted strong de-excitation mechanism. Super resolutions beyond the 
diffraction limit can be achieved as shown in Figure A.I.16.  
 
 
Figure A.I.16. The Comparison of the confocal (a) and the STED (b) image demonstrates the superior resolution 
of STED microscopy. Scale bar 0.5µm. 
STED microscopy uses fluorescent dyes to label specific sites of a sample (such as Alexa 488, 
FITC Oregon Green and established fluorescent proteins such as yellow fluorescent protein 
(YFP)). Such dyes can be excited by light of certain wavelengths. Instead of spontaneous 
relaxation and fluorescence emission, the molecules of the sample can also return to their ground 
state by stimulated emission (Figure A.I.17) [139].  
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Figure A.I.17. Spontaneous emission (left), stimulated emission (right) by adding a depletion laser. 
The fluorophore at S1 can absorb a depletion photon, and go back to S0 by releasing two 
photons that have the same wavelength as the absorbed one. Since it is possible to precisely 
control the wavelength of stimulated emission output, it can be chosen significantly different 
from the typical wavelength of fluorescence (to avoid interferences with absorption and 
emission). Therefore the sample is excited with two spot lasers, one useful for spontaneous 
emission (Figure A.I.18.a) and one centered to this spot (Figure A.I.18.b) useful for depletion. 
Of course the objective is to deplete only a ring of the sample to keep the center part useful for 
emission (Figure A.I.18.c). To do that the de-excitation spot has a shape of a doughnut obtained 
by making pass the laser through a lens with an optical vortex which reduces the intensity of the 
laser in the central part (Figure A.I.19). This reduction can be decided by the rotation of this lens 
therefore tuning the final resolution of the analysis.  
 
Figure A.I.18. Excitation spot (A), doughnut-shaped de-excitation spot (B) and overlay with small green spot  
allowing fluorescence (C).  
Appendix 
 
143 
 
 
Figure A.I.19. Optical vortex to create doughnut-shaped de-excitation spot. 
Therefore structures which are smaller than the diffraction-limit can be made visible with 
STED and resolution can easily reach 70 nm with conventional equipments and go below this 
size with some optimization in terms of instrument and choice of phluorophores.  
A.I.6. Transmission electron microscopy 
TEM operates on the same basic principles as the light microscope but using electrons as light 
source [140]. Electrons have much lower wavelength than light, which makes possible to get a 
resolution of thousand times better than with a light microscope. By means of TEM it is possible 
to observe objects at nanometer resolution and for this reason electron microscopy is a powerful 
technique in medical, biological and materials science. After electrons are emitted from the 
electron gun, they travel over a vacuum column and pass through electromagnetic lenses that 
focus the electrons into a very thin beam that then travels to the sample. The objective lenses and 
the projector lenses magnify the transmitted beam and project it onto the fluorescent viewing 
screen. Impact of electrons excites the screen and produces a visible magnified image of the 
sample. This image is recorded with a CCD camera. Cryo-electron microscopy is a form of 
transmission electron microscopy where the sample is studied at cryogenic temperatures 
(generally liquid nitrogen temperatures). Indeed only in the early 80’s it was demonstrated the 
possibility to produce vitreous ice by different means, such as high pressure freezing or flash 
freezing. This gave the possibility to develop Cryo-TEM technology, which represents a great 
opportunity for very delicate samples like biological samples as well as liquid dispersions or 
nano-capsules with a small shell around liquid core (like ours) thanks to the fact that they are 
fixed in their own environment. Sample has to be prepared in a very accurate way since a thin 
layer of liquid has to be frozen in cryogenic conditions on the TEM grid. To do that it was used 
Appendix 
 
144 
 
specific equipment, the VITROBOT of FEI, reported in Figure A.I.20. First the grid is mounted 
onto sharp tweezers then vitrification parameters are set by using the display of the VITRIBOT 
and the sample is put with a pipette on the grid which communicates from the back with a filter 
paper. It follows the blot of the sample to obtain a thin film typically sub micrometric and the 
grid is instantaneously immersed in the cryogenic liquid. 
 
 
Figure A.I.20. Picture of the VITROBOT (right) and magnification of the pistons used for sample blotting (left). 
So the grid is ready to be mounted in the equipment. Transferring phase is also critical; indeed 
if the sample gets molten during this phase then it will freeze again in the sample holder of the 
TEM but this time not in a controlled way. Therefore the presence of abundant crystals will 
prevent a correct analysis.  
In particular we used a Tecnai 12 electron microscope (Philips, Eindhoven, Netherlands) which 
is represented in the Figure A.I.21.  
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Figure A.I.21. Picture of the Tecnai 12 electron microscope. 
A.I.7. Fluorescence Spectroscopy 
Fluorescence occurs when a substance that has absorbed light or other electromagnetic 
radiation, emits light with different wavelength. The emission process can be explained on the 
basis of the different electronic states of the molecules called energy levels. If light is absorbed 
by a substance, the electronic state of the molecule changes from the ground electronic state (low 
energy state) to a one of the vibrational states of the excited electronic state. Excited molecule 
can collide with other molecules causing as a result lose of energy until the molecule reaches the 
lowest vibrational state of the excited electronic state, and finally, as consequence of collisions, 
the molecule drops again into one of the various vibrational levels of the ground electronic state, 
emitting a photon in the process. Because the molecules can drop in any of the different 
vibrational levels of the ground state, the emitted photons will have different energies and in 
consequence, different frequencies [137]. In this work, fluorescence spectroscopy was used to 
characterize the emission of chitosan labeled with FITC both as free polymer and in the case of 
secondary emulsion for comparison. In the following Figure A.I.22 it is reported the EnSpire 
Multimode Plate Reader 2300-0000, Perkin Elmer used in this work.  
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Figure A.I.22. Picture of the spectrofluorimeter EnSpire Multimode Plate Reader 2300-0000, Perkin Elmer. 
A.I.8. UV Visible 
In some molecules and atoms, photons of UV and visible light have enough energy to cause 
transitions between the different electronic energy levels [141]. The wavelength of light 
absorbed is that having the energy required to move an electron from a lower energy level to a 
higher energy level. When light passes through or is reflected from a sample, the amount of light 
absorbed is the difference between the incident radiation (I0) and the transmitted radiation (I). 
The amount of light absorbed is expressed as either transmittance or absorbance. Transmittance 
usually is given in terms of a fraction of 1 or as a percentage and is defined as T=I/I0, whereas 
absorbance is defined as A=-logT.  
For most applications, absorbance values are used since the relationship between absorbance 
and both concentration and path length normally is linear. The presence of an absorbance band at 
a particular wavelength often is a good indicator of the presence of a chromophore.  
However, the position of the absorbance maximum is not fixed but depends partially on the 
molecular environment of the chromophore and on the solvent in which the sample may be 
dissolved. Other parameters, such as pH and temperature, also may cause changes in both the 
intensity and the wavelength of the absorbance maxima. 
The equipment we have used is the Cary® 100/300 UV-Vis from Varian (Figure A.I.23). 
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Figure A.I.23. Picture of the spectrophotometer Cary® 100/300 UV-Vis from Varian. 
A.I.9. Thermogravimetric analysis 
TGA is a method in which changes in physical and chemical properties of materials are 
measured as a function of increasing temperature (with constant heating rate), or as a function of 
time (with constant temperature and/or constant mass loss). TGA is commonly used to determine 
selected characteristics of materials that exhibit either mass loss or gain due to decomposition, 
oxidation, or loss of volatiles (such as moisture). It is an especially useful technique for the study 
of polymeric materials, including thermoplastics, thermosets, elastomers, composites, plastic 
films, fibers, coatings and paints.  
In terms of apparatus, TGA relies on a high degree of precision in three measurements: mass 
change, temperature, and temperature change. Therefore, the basic instrumental requirements for 
TGA are a precision balance with a pan loaded with the sample, and a programmable furnace. 
The furnace can be programmed either for a constant heating rate, or for heating to acquire a 
constant mass loss with time. Regardless of the furnace programming, the sample is placed in a 
small, electrically heated furnace equipped with a thermocouple to monitor accurate 
measurements of the temperature by comparing its voltage output with that of the voltage-
versus-temperature table stored in the computer’s memory. A reference sample may be placed on 
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another balance in a separate chamber. The atmosphere in the sample chamber may be purged 
with an inert gas to prevent oxidation or other undesired reactions. Figure A.I.24 represents the 
DSC/TGA - TA instruments SDT2960. 
 
Figure A.I.24. Picture of the DSC/TGA - TA instruments SDT2960. 
A.I.10. Nuclear magnetic resonance spectroscopy 
NMR spectroscopy exploits the magnetic properties of certain atomic nuclei. It is used by 
chemists and biochemists to investigate the properties of organic molecules, though it is 
applicable to any kind of sample that contains nuclei possessing spin. When placed in a magnetic 
field, NMR active nuclei (such as 1H or 13C) absorb electromagnetic radiation at a frequency 
characteristic of the isotope.[142]. The resonant frequency (energy of the absorption) and the 
intensity of the signal are proportional to the strength of the magnetic field measured in Tesla. 
From the strength of the magnet (B0) it is possible to evaluate the operating frequency ω0 of the 
spectrometer by Larmor equation:  
 
ω0=γB0 
where γ is the gyromagnetic ratio of the nucleus being tested. 
From the formula it arises that a range of magnetic strengths between 1 and 21 Tesla 
corresponds to operation frequencies between 42.5 and 900 MHz. Typically the higher the 
operating frequency the higher the sensitivity. Indeed, it has to be considered that upon 
application of an external magnetic field, electrons surrounding the proton in covalent 
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compounds move in response to the field and generate local magnetic fields that oppose the 
much stronger applied field for the Lenz’s law. This local field thus "shields" the proton from the 
applied magnetic field, which must therefore be increased in order to achieve resonance 
(absorption).  
Moreover, given that the location of different NMR signals is dependent on the external 
magnetic field strength and the rf frequency, the signals are usually reported relative to a 
reference signal, usually that of TMS (tetramethylsilane). Additionally, being the distribution of 
NMR signals field dependent, these frequencies are divided by the spectrometer frequency. 
However, since we are dividing Hz by MHz, the resulting number would be too small, and thus it 
is multiplied by a million. This operation therefore gives a locator number called the "chemical 
shift" with units of parts per million. To detect such small frequency differences the applied 
magnetic field must be constant throughout the sample volume. High resolution NMR 
spectrometers use shims to adjust the homogeneity of the magnetic field to parts per billion (ppb) 
in a volume of a few cubic centimeters. “Shimming” refers to the process of adjusting a series of 
electromagnets to maximize the homogeneity of the magnetic field. Indeed, possible in-
homogeneities cause broad peak in the NMR spectrum because nuclei from the top portion of the 
NMR tube have a different resonance frequency than nuclei from the bottom portion.  
For what concerns quantitative part, via software it is possible to analyze the size of peaks to 
understand how many protons give rise to the peak. In particular, by integrating the peak it is 
possible to evaluate the number of protons, or any other observed nucleus, at least in the case of 
simple one-dimensional NMR experiments. 
Some of the most useful information for structure determination in a one-dimensional NMR 
spectrum comes from scalar coupling between NMR active nuclei. This coupling arises from the 
interaction of different spin states through the chemical bonds of a molecule and results in the 
splitting of NMR signals. These splitting patterns can be complex or simple and, likewise, can be 
straightforwardly interpretable or deceptive. This coupling provides detailed insight into the 
connectivity of atoms in a molecule. Coupling to n equivalent nuclei splits the signal into a n+1 
multiplet with intensity ratios following Pascal's triangle. It has to be noted that coupling 
between nuclei that are chemically equivalent, or in other words with the same chemical shift, 
has no effect on the NMR spectra. At the same way, couplings between nuclei that are distant 
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(usually more than 3 bonds apart for protons in flexible molecules) are usually too small to cause 
observable splittings.  
In particular, the NMR used to analyze modified chitosans and alginates structures was a DRX 
600 Bruker NMR spectrometer (Figure A.I.25).  
 
 
Figure A.I.25. Picture of the Bruker 600 MHz NMR spectrometer. 
In general, nuclear magnetic resonance spectroscopy can be used not only to study the structure 
of molecules but also the interaction of various molecules, the kinetics or dynamics of molecules 
and the composition of mixtures of biological or synthetic solutions or composites. NMR’s 
advantage is the unique ability of a nuclear spectrometer to allow both the non-destructive and 
the quantitative study of molecules in solution and in solid state, as well as to enable the study of 
biological fluids. 
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Conclusions 
Nowadays, nano-bio-technology is emerging as promising strategy to improve biodistribution 
of bioactive substances such as nutrients, drugs, therapeutics as well as tracers for diagnostics by 
means of engineered NCs which have to respect several specifications in terms of safety, loading 
capability, average size, monodispersion, multifunctionality and cost optimization depending on 
the kind of market.  
Therefore, in this work we developed NCs made of completely biocompatible and 
biodegradable materials (vegetal oil, egg lecithin, polysaccharides like chitosan, heparin and 
sodim alginate) with final objective to build up NCs with no side effects by their own.  
Moreover, we developed NCs with up-gradable complexity, in order to be able to engineer NCs 
suitable not only in terms of properties but also in terms of cost, depending on the final market 
specifications. To do that we started from the optimization of primary emulsions (in terms of size 
and PDI) made of soy-bean oil stabilized by a layer of chitosan (secondary emulsion) and then 
we used the layer by layer technique to build up more and more complex nanocapsules. From 
one side the oil core guaranties high loading capability of lipophilic bioactive molecules which 
are the most powerful ones but difficult to distribut into the body and from the other side layer-
by-layer is recognized as the most controlled way to buil up multi-functional polymer shells (e.g. 
tunable thickness, tunable permeability, targeting properties, diagnostics capability, insulation of 
molecules or NPs between layers and so on).  
The most original aspect of this work was to effectively combine the use of oil core and the 
layer by layer technique. Indeed, the layer by layer typically uses solid cores that are much 
monodisperse and stable than nanoemulsions. Instead, we were able to effectively use oil core 
templates by means of some original findings made during the path of the thesis also useful for a 
better exploitation of nanoemulsions as product ready to go on the market by their own.  
We demonstrated that secondary emulsions showing unparalleled long-term stability can be 
produced with a control in size depending on the formulation (down to 100nm), and PDI (≤0.1), 
thanks to the implementation of a novel multi re-dispersion process. In particular, we showed 
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that, in order to get very stable secondary emulsions, a specific concentration is not sufficient, as 
it must be combined with an optimized post-process. Such process was indeed identified as a 
multi-re-dispersion over time by homogenizing at medium pressure (around 700 bar) which had 
to be combined with polymer concentrations typically excluded due to flocculation. Thanks to 
the re-dispersion we were able to uniform the system and obtain ultrastability with no 
flocculation. Such unique stability represents an adding value for nanoemulsions which by their 
own with affordable cost could be exploited in the emerging field of nutraceuticals. Multi-
processed secondary emulsions at high concentrations (> 0.1%) were also proved to satisfy USP 
specifications even after several months, unlike bare emulsions which make these nanoemulsions 
also suitable in pharmacopeia. 
Moreover, we investigated the saturation regime by employing a novel in fluorescence 
approach, with new insights on the evolution of the polymer deposition around primary 
emulsions. Indeed, with this new approach we demonstrated that saturation is a relative concept. 
More precisely, we noticed that there is always equilibrium between polymer on oil surface and 
polymer in solution even at very low polymer concentrations, and only at very high 
concentrations there is a real complete coverage of the emulsion which guaranties ultrastability 
(if not associated to flocculation). However, an optimal concentration corresponding to an almost 
complete coverage and no significant excess of polymer in solution can be identified by the 
proposed approach thanks to the presence of a clear peak in fluorescence.   
For what concerns the preparation of polymer nanocapsules around oil in water nanoemulsions, 
we demonstrated not only the possibility to use secondary emulsions at the saturation 
concentration but also secondary emulsions in their ultrastability region. The latter is more 
advantageous considering that the liquid template is stable for more than one year compared to 
the few weeks of saturated emulsions. Its use was made possible after removal of the excess 
polymer by means of a nanobeads mediated fishing procedure. This procedure was also 
originally developed in during this thesis and it was made possible thanks to the monodispersion 
of the emulsion itself. Therefore, for the first time nanoemulsion can be stored and used like the 
solid ones but with all the well known advantages of oil templates like pre-loading with high 
payloads as well as stabilizing and carrying powerful lipophilic drugs. In addition, no harsh 
conditions are required to remove any solid template therefore the delicacy of the method allows 
the use of natural bio-polymers Moreover, due to the monodispersion and the small size down to 
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100nm these nanocapsules are also suitable for the EPR mechanism. In our opinion 
nanotechnology applied to drug delivery can highly benefit from the use of the proposed method 
offering a real alternative to the preparation of nanocapsules via solid core templating.  
Both in the case of saturated or ultrastable emulsions it was demonstrated by fluorescence 
microscopy the capability to pre-load oil with lipophilic substances. 
As known electrostatic interaction which link single polymer layers of the layer by layer 
nanocapsules can be easily weakened by certain physiological conditions (pH, oxidizing 
conditions). For this reason and also for a future aim to consolidate nanocapsules with shapes 
different from spheres in this thesis was also developed a thioene click chemistry reaction 
between polyelectrolytes modified with N-acethyl cysteine in the case of chitosan and 
allylammine in the case of heparine and sodium alginate. By adapting in an original way 
colorimetric Ellman test it was possible to evaluate cross-linkage efficiency between layers. 
Preliminary results on the stability over time of cross-linked and no cross-linked tri-layers show 
higher stability as expected in the first case.  
Finally, it was also demonstrated capability to build up monodisperse oil core silica shell 
nanocapsules which could be exploited both in drug delivery and in diagnostics with the 
advantage of inorganic materials to be more resistant than polymers to environment conditions 
such as temperature, pH and so on. The synthetic strategy was based on a multi step process 
involving encapsulation of nanodroplets of oil in a bilayer of chitosan and heparin followed by in 
situ synthesis of silica by using TEOS as precursor. Since APTS was chemically linked to 
heparin this allowed formation reaction of TEOS and therefore formation of silica just around oil 
droplets. The inner core which is oil may include a variety of materials like high payloads of 
hydrophobic drugs, as well as fluorescent quantum dots (QDs), magnetic or gold NPs, among 
various other variants for drug delivery and multi-modal imaging. Therefore, we believe this is 
another innovative, low cost and effective way to produce new nanocarriers useful for 
nanomedicine.   
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